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AGENDA 
FRIDAY 24 APRIL 
17.45 1. Welcome
2. One minute’s silence in memory of pharmacists who died since the 2014 AGM
3. Minutes of 2014 AGM 
4. Financial Report and Accounts 2014 
a. Adoption of Audited Statement of Accounts
b. Appointment of Auditors
5. IPU Services Ltd, AGM 
Minutes of 2014 AGM
Financial Statements 2014
a. Adoption of Directors’ Report
b. Adoption of Audited Statement of Accounts
c. Remuneration of Auditors
6. IPU Secretariat Report
7. Group Reports / Open Forum: Introduction and Update
a. Pharmacy Contractors’ Committee Report 
b. Community Pharmacy Committee Report 
c. Employee Pharmacists’ Committee Report 
d. Communications Report 
e. International Pharmacy Matters
8. Open Forum
19.00 End of First Session
SUNDAY 26 APRIL
12.30 9. Report on Motions from 2014 AGM
10. 2015 AGM Motions
11. Open Forum
14.00 Closing of Conference by IPU President, Kathy Maher
2015 AGM IPU AND  
AGM IPU SERVICES LTD
Friday 24 and Sunday 26 April 2015 
(confined to paid up members of the IPU)
Chairperson: Ms Kathy Maher, President
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MESSAGE FROM 
THE PRESIDENT
A s usual, the wide and varied choice of therapeutic 
and business learning and 
development events are 
delivered by esteemed 
speakers and experts. This 
event is such a success due 
to the unending dedication 
of a small team and I thank 
them most sincerely. 
It is appropriate that 
we are in such majestic 
surroundings, considering 
our theme this year is 
‘Reaching Pharmacy’s 
Peak’. Pharmacists are 
very resilient professionals 
and this has been proven 
over the past number 
of years. We have been 
faced with challenge after 
challenge and community 
pharmacists have met 
these challenges and 
overcome them. We 
have had to deal with 
cuts in payments and 
tough economic business 
environments and, as a 
profession, we have stayed 
united and strong. 
In the face of continued 
adversity, we can reach 
pharmacy’s peak. 
We have supported the 
Government’s healthcare 
strategy ‘Future Health: 
A Strategic Framework for 
Reform of the Health Service 
2012-2015’, which sets 
out an integrated model 
of care aiming to treat 
patients at the lowest level 
of complexity. Pharmacists 
are ideally placed to play an 
increased role in healthcare 
I am delighted to welcome you to the Kingdom of Kerry for the 
annual IPU National Pharmacy Conference. The conference 
has gone from strength to strength over the past five years and 
is a fantastic event for pharmacists to attend, participate in, 
network at, and enjoy. 
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and can deliver additional 
services such as a minor 
ailment scheme, new 
medicines service, chronic 
disease management, 
health screening, medicine 
use reviews and a greater 
range of medicines available 
through pharmacy without 
prescription. The public 
has shown their willingness 
to engage with new 
services, with the seasonal 
flu vaccination service 
more than doubling every 
year since introduction. 
Evidence demonstrates 
that pharmacists offer 
positive patient outcomes, 
patient satisfaction and 
efficiency when treating 
minor ailments. In other 
countries, when access to 
primary care was limited 
and under pressure, 
governments created 
additional capacity by 
expanding the range of 
services available from 
pharmacists. The IPU 
has been unstinting in its 
efforts to promote the 
community pharmacy 
sector to all relevant 
stakeholders, but now is the 
time for this government 
to create this capacity 
in Ireland. Irish patients 
deserve equal access to 
timely, safe and efficient 
treatment close to their 
home.
The IPU continues to 
seek out new services to 
offer members which will 
benefit your business and 
professional activities. As 
you know, Health Market 
Research (hmR) is a new 
business intelligence 
service launched by the 
IPU. This will help you 
learn how your business 
is performing, and it will 
help you make informed 
business decisions. 
Pharmacy Watch – the 
name of this unique 
new service – will allow 
participating pharmacies 
to see trends or changes 
in products as well as 
transaction values across 
the sector and within their 
own businesses. The service 
will provide participants 
with access to accurate and 
up-to-date information to 
assist them in running their 
business more efficiently 
and in benchmarking 
performance against the 
local and national pharmacy 
market. The data will be 
completely anonymised 
and aggregated and the 
reports will not allow 
individual pharmacies to 
be identified. This will be a 
game changer in pharmacy 
businesses. To the extent 
that this venture can deliver 
revenue to the IPU, those 
funds will be distributed for 
the benefit of participants 
and members.
The IPU belongs to its 
members. The IPU is 
YOUR voice. We continue 
to regularly communicate 
with members through 
the newsletters, monthly 
General Memoranda, 
text service and social 
media and now the new 
website has launched, 
which has a wealth of 
information to help you in 
every aspect of your role. 
I would encourage you to 
engage with the IPU and 
keep us informed of areas 
of concern that we can 
address on your behalf. 
Your representatives on the 
IPU’s committees continue 
to apply themselves with 
genuine dedication and 
unity of purpose for the 
benefit of the profession. 
I would like to thank 
the excellent staff in 
Butterfield House. 
They are tireless in their 
commitment, dedication 
and enthusiasm for you, 
the IPU’s members.
On your behalf, I 
would like to take this 
opportunity to thank 
our Secretary General, 
Darragh O’Loughlin, for 
his immense work and 
unrelenting dedication to 
the IPU and its members 
and the community 
pharmacy profession and 
for his support, advice and 
guidance to me in my role 
as President. 
Kathy Maher MPSI
Daragh Connolly 
Vice-President, IPU
Bernard Duggan 
Honorary Treasurer, IPU
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APPENDICES
I A list of Submissions made during the year.  
Most are available on www.ipu.ie.
 2014
• Draft Clinical Guidelines for Opioid Substitution Treatment – HSE – May 2014
• Consultation on White Paper on Universal Health Insurance – DoH – May 2014
• Draft Guidance on the Delivery of POMs from a RPB – PSI – Jun 2014
• Presentation to Joint Oireachtas Committee on Health and Children – Jul 2014
• Draft Guidance on Data Protection for Pharmacists – PSI – Jul 2014
• Policy Framework on Temporary Absence – PSI – Jul 2014
• Pharmacy Inspection Policy – PSI – Aug 2014
• Minor Ailment Scheme – DoH – Aug 2014
• Department of Health Statement of Strategy 2015-2017 – Oct 2014
 2015
• Consultation on Guide for Retail Sale of Herbal Medicinal Products – HPRA – Jan 2015 
• Private Health Insurance Consultation – DoH – Jan 2015
• Draft Guidance for Pharmacists on Extemporaneous Dispensing – PSI – Feb 2015
• Transposition of Falsified Medicines Directive (Common Logo) – DoH – Feb 2015
• Presentation to Joint Oireachtas Committee on Health and Children – Mar 2015
• Expanding the Role of Community Pharmacists for the Benefit of the Healthcare System 
– Fianna Fáil – March 2015
II Some key letters and responses received throughout the year:
- PSI Matters
- Department of Health Communications
- PCRS
- HSE
- Health Products Regulatory Authority (HPRA)
- Health Insurance Companies
- Other Matters
III A list of Press Releases issued to the National Media during the year  
on various issues
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President:  Kathy Maher
Vice-President: Daragh Connolly
Hon Treasurer: Bernard Duggan
Regional Representatives (8)
Sean Reilly – Dublin
Stephen Nolan – North East
Conan Burke – North West
Gerry Guinan – South
Daragh Connolly – South East
Peter McElwee – Midland
Joanne Hynes – West
Carmel Collins – Mid-West 
Community Employee Group (3)
Bernard Duggan
David Carroll
Caitriona O’Riordan
Past President
Rory O’Donnell 
Co-options
Ann Marie Horan
John MacNamara
 
NB: Up to five members may be co-opted by the Executive Committee
EXECUTIVE COMMITTEE
2014–2016
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FINANCIAL STATEMENTS
1. Irish Pharmacy 
Union
Financial Reports and 
Accounts for Year Ended  
31 December 2014
In accordance with the 
Constitution of the IPU, 
the Executive Committee 
submits the audited 
accounts for consideration 
by members.
The full details of the 
Accounts have been 
circulated to members with 
the Annual Report of the 
IPU Executive Committee.
If the Accounts are 
approved by the meeting 
after their presentation, 
members will be asked 
to formally adopt the 
Accounts for the year 
ended 31 December 2014 
and agree the election of 
Auditors. In this context, 
the following motions will 
be put to the meeting: 
a. “That the Executive 
Committee Report and 
Audited Statement of 
Accounts of the Irish 
Pharmacy Union for the 
year ended 31 December 
2014 as submitted to this 
meeting, be and are  
hereby adopted.”
b. “That this meeting agrees 
to the election of Baker 
Tilly Ryan Glennon for a 
further year as Auditors 
for the IPU and IPU 
Services Ltd.”
2. IPU Services 
Limited
Financial Reports and 
Accounts for Year Ended 
31 December 2014
At this Annual General 
Meeting of IPU Services 
Ltd, members are asked to 
consider the Report of the 
Directors and the Auditors’ 
Report on the Accounts 
for the Year Ended 31 
December 2014.
The accounts and financial 
reports have been 
circulated to all members.
If the Accounts are 
approved, members will be 
asked to resolve: 
“That the Directors’ Report 
and Audited Statement 
of Accounts for the year 
ended 31 December  
2014 as submitted to  
this meeting, be and are 
hereby adopted.”
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REPORT OF THE 41ST 
ANNUAL GENERAL 
MEETING OF THE IRISH 
PHARMACY UNION  
AND IPU SERVICES LTD
SLIEVE RUSSELL HOTEL,  
BALLYCONNELL, CO. CAVAN
1. The President 
welcomed the 
attendance to the 
41st Annual General 
Meeting of the Irish 
Pharmacy Union.
2. On the proposal of the 
President all present 
stood in silence in 
memory of deceased 
members and family 
members who had died 
since the 2013 AGM. 
3. Minutes of  
2013 AGM
 The report of the 
40th Annual General 
Meeting was taken 
as read. The report 
is available on the 
members’ section 
of www.ipu.ie. The 
report was proposed 
by Daragh Connolly, 
seconded by 
Bernard Duggan and 
unanimously approved 
by the meeting.
4. Financial Reports  
and Accounts 2013
a. John Gleeson 
(Honorary Treasurer) 
presented the IPU’s 
Financial Report. 
He drew members’ 
attention to Page 33 of 
the Annual Report and 
proceeded to explain 
changes in income and 
expenditure in 2013.  
• The total income 
for the year was 
€4,849,799 
compared to 
€4,766,582 in 2012, 
which represented 
a 1.7% increase in 
overall income for 
the year. This was 
largely due to the 
increase in revenue 
generated from 
the sale of the IPU 
Product File to non-
members and the 
substantial increase in 
course income, which 
included revenue 
from IPU Academy.
Friday 9 May - AGM Reports
Present:  The President, Mr Rory O’Donnell and 38 members.
In Attendance: Mr Darragh O’Loughlin, Mr Jim Curran, Ms Wendy McGlashan,  
 Ms Roisin Molloy and Mrs Patrice O’Connor.
Apologies: Apologies were received from eight members 
 
A full report of the 2014 AGM is available from the IPU offices.
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• The reduction in 
levy income was due 
to the levy rebates, 
which were issued 
prior to the 2013 
Conference.
• Other areas showing 
an increase in income 
included AGM 
Sponsorship and Bank 
deposit interest.
• There had been 
a reduction in 
income from both 
Yearbook and 
Review advertising, 
due mainly to the 
continuing economic 
conditions.
• The total expenditure 
for the year was 
€4,378,181 
compared to 
€3,783,133 in 2012, 
which represented 
a 15% increase. The 
increased expenditure 
occurred as a result 
of:
– Salaries, which now 
included course 
assessors. 
– Printing & 
Stationery due to 
additional mailings 
during the year, 
which were now 
being produced in-
house, rather than 
outsourced.
– Travel & Meetings.
– IT: the IPU has 
invested in a new 
Membership 
and Accounts 
management 
system.
– IPU Academy: the 
IPU launched the 
hugely successful 
IPU Academy in 
January 2013 as a 
CPD provider for 
pharmacists. 
– Membership 
Services & Support. 
 This completed the 
Treasurer’s report and 
questions were then 
invited from the floor.
 Jack Shanahan queried 
the substantial increase 
in the Pensions budget 
for 2014. The Treasurer 
said he would revert 
when the figure 
had been checked. 
The reasons for the 
budgeted decrease in 
members’ expenses and 
the increase in legal 
expenses were also 
clarified.
 Following the 
presentation, the 
following motion 
approving the accounts 
was proposed by 
Michael Tierney, 
seconded by John 
MacNamara and carried 
unanimously: 
“That the Executive 
Committee Report and 
Audited Statement of 
Accounts for the Irish 
Pharmacy Union for the 
year ended 31 December 
2013 as submitted to 
this meeting be and are 
hereby adopted.”
b. The following motion 
was proposed by Jack 
Shanahan, seconded by 
Bernard Duggan and 
carried:
“That this meeting agrees 
to the election of Baker 
Tilly Ryan Glennon for a 
further year as auditors 
for the IPU and IPU 
Services Ltd.”
5. IPU Services Ltd 
AGM
The accounts were 
presented by the 
Treasurer and on the 
proposal of Daragh 
Connolly seconded by 
Ann Marie Horan it was 
resolved:
“That the Directors’ 
Report and Audited 
Statement of Accounts 
for the year ended 
31 December 2013 
as submitted to this 
meeting, be and are 
hereby adopted.”
This motion was carried.
The minutes of the 
2013 AGM of IPU 
Services Ltd were taken 
as read. Their adoption 
was proposed by Jack 
Shanahan, seconded by 
Dermot Twomey and 
unanimously approved 
by the meeting.
6. IPU Secretariat 
Report
The IPU Secretariat 
Report was circulated 
to members by post in 
advance of the meeting 
and a more detailed 
report was published on 
the members’ section of 
www.ipu.ie. 
7. Group Reports
a. Pharmacy Contractors 
Committee (PCC) 
Report
This report was 
introduced by Mr Brian 
Walsh, Chairman of the 
Pharmacy Contractors’ 
Committee.
The report was 
circulated to members 
in advance of the 
meeting and a more 
detailed report was 
published on the 
members’ section of 
www.ipu.ie. 
b. Community Pharmacy 
Committee (CPC) 
Report
This report was 
presented by Ms Louise 
Begley, Chairperson 
of the Community 
Pharmacy Committee.
The report was 
circulated to members 
in advance of the 
meeting and a more 
detailed report was 
published on the 
members’ section of 
www.ipu.ie.  
c. Community Employee 
(EPC) Report 
This report was 
delivered by Ms 
Sarah Magner, 
Chairperson of the 
Employee Pharmacists’ 
Committee. 
The report was 
circulated to members 
in advance of the 
meeting and a more 
detailed report was 
published on the 
members’ section of 
www.ipu.ie.  
d. Communications 
Report 
This report was available 
on the members’ 
section of www.ipu.ie 
and was taken as read. 
e. International  
Pharmacy Matters 
This report was available 
on the members’ 
section of www.ipu.ie 
and was taken as read. 
REPORT OF THE 41ST ANNUAL GENERAL MEETING  CONTINUED
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8. President’s Address
The President’s Address 
is included with the full 
report of the meeting. 
9. Open Forum
The President was asked 
for feedback from the 
Department of Health 
regarding the rollout of 
new services through 
pharmacy. He said that 
several meetings have 
taken place with the 
Department of Health, 
including Minister 
White and they are 
interested in more 
services being provided 
through pharmacy. 
However, rollout is 
a bit further away 
than hoped for. The 
Secretary General said 
that the IPU hosted 
a Seminar in January 
2014 and brought 
a former Health 
Minister from Canada 
and a Deputy Chief 
Pharmacist from the 
Scottish Government 
to present real 
information about the 
benefits that accrued 
in their health services 
from introducing 
additional pharmacy 
services. He spoke 
with senior officials in 
the DoH afterwards 
and they were very 
interested in the data 
that was presented. 
However, the DoH 
is going through a 
transition and most of 
their energy appears 
to be on working 
within budget rather 
than discussing things 
which require new 
expenditure. 
Padraic Staunton raised 
the systematic non-
payment of expensive 
medicine and late 
payments for nearly 
everything. He gave 
an example of a claim 
for EU prescriptions, 
dispensed in January 
and submitted on time, 
which had been paid 
in April. The Secretary 
General said that the 
IPU will take advice on 
the best way to proceed 
and that the IPU will 
continue to arduously 
pursue the PCRS to get 
members paid in full, 
on time. The IPU had 
an 82% success rate 
in getting outstanding 
money from the PCRS 
and would not stop until 
100% was achieved. 
Marie McConn asked 
if there had been any 
move from the PSI 
on having the number 
of Anapens held in 
pharmacies for flu 
vaccinations reduced 
from six, or if there was 
any move on getting 
Anapen 500 mcg on 
the market. Pamela 
Logan, Director of 
Pharmacy Services, 
said that the delay in 
getting Anapens 500 
mcg was down to the 
manufacturer and she 
was unsure what the 
issue was although 
there had been a delay 
in getting a licence from 
the IMB. The number 
of Anapens did reduce 
if a pharmacist was 
not going to vaccinate 
two people within 20 
minutes of each other. 
Tim Doody asked why 
there was reticence 
from the PSI in tackling 
the proposed dispensing 
service by courier being 
offered by a recently 
opened pharmacy. 
The Secretary General 
said that he had been 
in contact with the 
PSI Registrar who had 
maintained that the 
pharmacist in question 
did not have clearance 
for a free courier 
service, as reported in 
the national media. The 
Secretary General said 
that the IPU will hold 
the PSI to account on 
this issue so that they 
are doing what they are 
set up to do, which is 
regulating the practice 
of pharmacy in the 
interests of patient 
safety and public 
welfare.
Dan Burns asked why 
the IPU had gone with 
the ANF rather than 
similar enterprises. The 
President said that the 
IPU had gone with ANF 
because the model 
suited the IPU and 
its members. It would 
provide up-to-date 
information, which had 
not been available to 
the IPU heretofore and 
give the IPU a stronger 
negotiating position. 
The Secretary General 
gave the background to 
the ANF model, which 
had been established 
by the Portuguese 
Pharmacy Federation 
five years previously. 
Pierce Healy asked how 
the 10 day return policy 
had been arrived at 
when the IMB wording 
had been “a reasonable 
time period”. The SG 
said that the European 
Commission issued 
Good Distribution 
Practice guidelines 
some years ago and had 
issued new guidelines in 
2014, which referred to 
wholesale distribution 
of medicines. In the 
guidelines that came 
from Europe, which 
have to be adopted 
by national regulators, 
it said that there was 
to be a time limit “for 
example, 10 days”. 
The IMB chose to 
adopt the most rigid 
interpretation of 
the 10 days that was 
expressed in the EU 
Commission GDP 
Guidelines. The IPU 
had pushed for a less 
rigorous interpretation 
and succeeded in 
persuading the IMB 
to introduce an 
“exceptions policy” 
so that medicines 
that have been in 
a pharmacy for 
longer than 10 days 
can, in exceptional 
circumstances, on a 
case-by-case basis, 
be returned. The 
wholesalers have 
assured the IPU that 
they will adopt a 
reasonable approach. 
The IMB has asked 
to be kept informed 
of how the system is 
working as they are 
anxious to ensure that 
pharmacists are not 
put at a disadvantage 
for holding expensive 
medicines in stock for 
individual patients.
In response to a query, 
the meeting was told 
that stoma products are 
governed only by the 
terms and conditions 
of supply rather than 
the GDP guidelines, as 
medical devices are not 
regulated in the same 
way as medicines. A 
new Medical Devices 
Directive is making 
its way through the 
European Commission
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REPORT OF THE 41ST ANNUAL GENERAL MEETING  CONTINUED
The meeting commenced 
with a short briefing on the 
role of the Irish Institute 
of Pharmacy (IIOP) by 
its Executive Director, Dr 
Catriona Bradley. 
Marie Hogan asked how 
the IIOP was funded. Dr 
Bradley said it was dually 
funded by the PSI and 
Department of Health to 
the tune of €1.1M over a 
four year period; €600K 
from the DoH and €500K 
from the PSI. 
Diarmuid O’Donovan 
asked if the IIOP had any 
involvement in the training 
of undergraduate pharmacy 
students. Dr Bradley said 
that the role of the IIOP 
was for post-graduate 
and ongoing professional 
development. 
10.Report on Motions 
from 2013 AGM
The report on motions 
from the 40th Annual 
General Meeting was 
taken as read. 
11. 2014 AGM 
Motions 
The following motions 
were proposed in 
accordance with Article 
30 of the Constitution. 
All motions were 
debated and considered 
by the meeting and 
then passed.
a. Proposed:  
Brian Walsh 
Seconded:  
Grainne O’Leary
“That this AGM calls 
on the Minister for 
Health to extend the 
professional role of 
pharmacists in Ireland, 
in line with experience 
in other countries, to 
allow all patients have 
access to healthcare in 
their community and to 
ensure that pharmacists 
are appropriately 
remunerated for any new 
service that they provide 
on behalf of the State”.
In proposing this motion 
Brian Walsh stated that 
all of us here have known 
for years that pharmacy-
based services can improve 
patient health outcomes 
and at the same time they 
can reduce the State’s 
spending on healthcare. 
By making savings, key 
resources can then be put 
into other areas of the 
healthcare sector for the 
benefit of everyone. 
The IPU made a Pre-
Budget Submission last 
year, which you may 
have seen. Many of the 
proposed services outlined 
in the submission are 
already available in other 
countries such as the minor 
ailments scheme in the 
UK and monitored dosage 
systems scheme operating 
in Denmark and Finland. 
Experience in these 
countries shows us that 
pharmacy-based services 
do lead to considerable 
improvements in patients’ 
health and do result in 
considerable savings to 
healthcare budgets. This is 
what we have been telling 
the officials in the HSE 
and the Department of 
Health in Ireland for some 
time now. 
The ability of pharmacists 
in Ireland to deliver these 
key services is beyond 
doubt. The introduction 
of the flu vaccination 
service and reclassification 
of Emergency Hormonal 
Contraception has shown 
that pharmacy can deliver 
services that patients want 
and use. And they can 
Sunday 11 May - AGM Motions
Present:  The President, Mr Rory O’Donnell and 49 members.
In Attendance: Mr Darragh O’Loughlin, Ms Wendy McGlashan, Ms Roisin Molloy  
 and Mrs Patrice O’Connor.
Apologies: Apologies were received from eight members 
Liz Kerr asked if the 
IPU would be making 
a submission on the 
proposed Universal 
Health Insurance 
(UHI). The Secretary 
General informed 
the meeting that an 
in-house meeting 
was scheduled for the 
week following the 
AGM to discuss and 
a submission would 
be submitted in due 
course.
Keith O’Hourihane said 
that there was a serious 
issue in Cork with regard to 
getting patients approved 
for LTI, especially when 
moving from a medical card 
to LTI. He would forward 
further details to the  
IPU office. 
Padraic Staunton said 
that there was a policy, 
particularly in the Western 
Health Board, of issuing 
medical cards to persons 
who did not justify it, 
on the basis that it was 
saving money for the 
Health Board on the LTI 
Scheme thereby denying 
pharmacists of income. 
He gave examples of 
inconsistencies in other 
areas also and agreed that 
details would be emailed to 
the IPU. The President said 
there was some way to go 
before the dual eligibility 
process was streamlined. 
Particular issues should 
be emailed to Jill Lyons or 
Aoife Garrigan at the IPU.
The President then 
adjourned the AGM until 
Sunday 11 May at 12.30pm.
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be delivered in a cost-
effective way. 
The number of flu 
vaccinations, for instance, 
has increased in community 
pharmacy year on year. 
The focus of our healthcare 
system must be towards 
the creation of a patient-
focused health service 
delivered at the lowest 
level of complexity. We all 
currently play a vital role 
in ensuring patient safety 
and wellbeing. But we are 
underused. Our days spent 
doing paperwork when we 
could be doing more. 
We are willing and able 
to do more for patients. 
We want to engage on a 
change agenda and we 
want to expand our role  
for the benefit of all 
patients in Ireland. 
This motion was carried 
unanimously.
b. Proposed:  
Marie McConn 
Seconded:  
John Gleeson
“That the IPU calls on 
the Minister to review 
the Medical Card 
Prescription Levy and 
to amend its operation; 
firstly by reducing the 
ceiling for over 70s 
to €15; secondly by 
exempting all people 
who are registered 
as homeless with the 
HSE and / or Local 
Authorities and thirdly 
by exempting some 
psychiatric medicines, 
especially Antipsychotic / 
Neuroleptic agents.”
In proposing this motion 
Marie McConn stated that 
prescription charges are 
the bane of my life; I dislike 
them. Initially they were at 
50 cent per item with a cap 
of €10, people were OK 
with it and it really didn’t 
create huge problems for 
the vast majority. Then 
we thought they would 
be abolished. Then they 
increased to €1.50 with a 
cap of €15 and now they 
are €2.50 with a cap of 
€25 and that is too much. 
€25 is too much out of a 
non-contributory OAP. It 
is very easy for someone 
over 70 to use 10 items 
per month. Think about it. 
Two blood pressure tablets, 
one diuretic, a proton 
pump inhibitor, a painkiller, 
something for osteoporosis, 
a calcium supplement, low 
dose aspirin, a statin, eye 
drops – it can run up quite 
quickly.
In reality they are not going 
to be abolished any time 
soon. So what to do? When 
they were introduced, the 
IPU called for exemptions 
for residents of care 
facilities, for homeless 
people, for registered 
Methadone clients and 
people in palliative care or 
having frequent changes 
in medicines. I have been 
thinking about these areas 
and I think they need to be 
widened. So, I propose that 
they should be capped at 
€15 for over-70s. I think 
that is enough to ask them 
to pay. People who have 
registered as homeless with 
the HSE or local authority 
should be exempt. In 
Limerick, HSE and local 
authorities and Dept of 
Social Protection have 
an office where people 
go when they become, or 
are, homeless. This office 
has access to the PASS 
computer system, which 
is a countrywide system, 
through which they can 
find hostel or emergency 
accommodation for 
clients. Then they work 
with them to support 
them through the process 
with the end-goal of 
finding them permanent 
accommodation. Many of 
these clients have mental 
health, alcohol or other 
drug addiction issues. They 
are in severe difficulty and 
most of them can’t or won’t 
pay prescription charges. 
My third category is 
antipsychotic/neuroleptic 
agents. We have all 
seen prescriptions for a 
benzodiazepine, a sleeping 
tablet and an antipsychotic. 
The patient tells you he 
will take the first two 
and he’ll call back for the 
antipsychotic; the one 
thing that might help him. 
He prefers the agents 
that have a quick effect 
rather than the one that 
might give some longer 
term benefit. I know that 
some elderly people take 
these in low doses for 
anxiety disorders, but 
that’s a comparatively low 
usage and anyway I want 
their charges capped. 
This measure would be a 
practical benefit for the 
homeless and for many 
people with addiction issues 
as well.
That is why I am proposing 
the motion that the IPU 
calls on the Minister to 
review the Medical Card 
Prescription Levy and to 
amend its operation; firstly 
by reducing the ceiling for 
over 70s to €15; secondly 
by exempting all people 
who are registered as 
homeless with the HSE and 
/ or Local Authorities and 
thirdly by exempting some 
psychiatric medicines, 
especially Antipsychotic / 
Neuroleptic agents.”
The following amendment 
was proposed by Daragh 
Connolly and seconded by 
Joe Britton.
“That this AGM calls 
on the Minister to 
abolish the medical card 
prescription levy; and 
pending its abolition that 
its operation be reviewed 
firstly by reducing the 
ceiling for over 70s 
to €15; secondly by 
exempting all people who 
are:
a. registered as homeless 
with the HSE and/or 
Local Authorities;
b. persons with 
intellectual disabilities;
c. persons in residential 
care facilities;
 and, thirdly, 
by exempting 
some psychiatric 
medicines, especially 
Antipsychotic/
Neuroleptic agents.”
The motion, as amended, 
was proposed by Marie 
McConn, seconded by Paul 
Fahey and carried with one 
abstention.
c. Proposed: 
Louise Begley 
Seconded: 
Aidan Walsh
“That this AGM calls 
on the IMB to reclassify 
appropriate prescription-
only medicines in order 
to improve the public’s 
access to medicines from 
their pharmacist”.
In proposing this motion 
Louise Begley stated that 
Healthcare in Ireland is 
going through a period of 
significant change – an 
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ever increasing ageing 
population, evolving health 
structures, greater private 
sector involvement in the 
health arena, a growing 
incidence of chronic 
diseases, ever increasing 
public expectations of 
the health service and 
the development of 
new treatments. The 
financial challenge to the 
State to manage this is 
compounded further given 
the current state of the 
public finances and the 
requirement to control 
healthcare expenditure. 
Patients are also feeling 
economic challenges as 
they try to access cost-
effective healthcare in the 
current stagnant economy.
Patients are no longer 
passive recipients of 
healthcare and advice. 
Greater health literacy 
and greater access to 
information, combined 
with increased individual 
interest in personal health 
and personal choice, 
is leading to more and 
more patients actively 
looking after themselves. 
In addition, public 
awareness has increased 
the importance of certain 
lifestyle factors, such as 
avoidance of smoking and 
keeping a well-balanced 
diet, in maintaining health 
and preventing illness. 
Irish patients see health 
education and advice from 
the pharmacist as key ways 
to help them take care 
of their health and minor 
ailments. 
In this context, self-
care can be seen as the 
most common form of 
healthcare. As pressure 
grows on the Irish 
healthcare system, self-
care will be seen as a 
means of controlling and 
rationalising healthcare and 
medication costs. Research 
in Australia showed that 
if minor ailments such 
as coughs, colds and 
others were dealt with in 
community pharmacies, it 
would free up one thousand 
full time GPs to treat more 
serious health problems. 
If we are to successfully 
confront the demands on 
our health system as the 
population ages, we need 
to ensure that our citizens 
stay fit and healthy for as 
long as possible. In both 
health and fiscal terms, 
prevention is better than 
cure.  
 
Self-care can be defined 
as the care taken by 
individuals of their own 
health and well-being 
at the lowest level of 
complexity with advice 
from a healthcare 
professional. It is important 
to note that self-care is 
not ‘no care’. Although, 
by definition, self-care 
can take place without the 
need to visit a healthcare 
professional, effective 
and safe self-care is best 
undertaken with the benefit 
of professional advice. 
Pharmacists have the skills 
and training to ensure that 
patients have an open 
source of professional 
expertise in self-care 
matters. 
Non-prescription 
medicines are an important 
part of healthcare and, 
from the point of view 
of patient safety, must 
be treated in the same 
way as prescription-only 
medicines. They are 
not, and should not, be 
perceived as ordinary 
commodities. Taken 
inappropriately, non-
prescription medicines 
can present a serious 
threat and imply severe 
risks for patients. There 
can be no doubt therefore 
that a responsible public 
health policy needs to 
understand and appreciate 
the potential risks posed 
by non-prescription 
medicines. 
The pharmacist has a key 
role in providing advice 
on appropriate self-
medication, including 
the provision of product 
information, advice 
on product selection, 
advice on side effects 
and interactions and 
crucially, advice on 
the appropriateness of 
beginning or continuing 
self-care; this is sometimes 
referred to as the ‘sign-
posting’ function of the 
pharmacist – advising 
patients to seek specialist 
treatment in cases 
where self-care may be 
ineffective or inappropriate. 
The best way to help ensure 
patient safety for non-
prescription medicines is to 
ensure they are dispensed 
under a pharmacist’s 
supervision within a 
pharmacy. 
For self-care to be fully 
effective, the range of 
medicines made available 
to patients should be 
expanded. The IMB set up 
a Consultative Panel to 
review the classification 
of medicines, following a 
public consultation in July 
2011; the IPU presented to 
the Panel in Feb 2013. In 
Oct 2013, the IMB Board 
fully endorsed the report 
from the Consultative 
Panel and the IMB says 
it is now implementing a 
more proactive process 
for reclassifying medicines 
from prescription-only 
to non-prescription, also 
known as ‘switching’. We 
welcome the decision by 
the IMB to take a proactive 
approach to increased self-
care through switching; 
indeed, the IPU has called 
for this for a number of 
years. Following recent 
switches, for example all 
and levonorgestrel, the 
IPU has produced sales 
protocols and educational 
tools to assist pharmacists 
in the appropriate supply 
of these medicines to 
patients.
I therefore call on 
the IMB to reclassify 
appropriate prescription-
only medicines in order to 
improve the public’s access 
to medicines from their 
pharmacist.
The following amendment 
was proposed by Joe 
Britton and seconded by 
Conor Phelan.
“That this AGM calls 
on the IMB to reclassify 
appropriate prescription-
only medicines, in a 
timely fashion, in order 
to improve the public’s 
access to medicines from 
their pharmacist”.
The motion, as amended, 
was proposed by Louise 
Begley, seconded by 
Sean Kelly and carried 
unanimously.
d. Proposed:  
Jack Shanahan 
Seconded:  
Sean Reilly
“That this AGM calls on 
the Pharmacy Regulator 
to restrict the use of 
unannounced inspections 
to exceptional 
circumstances only.”
In proposing this motion 
Jack Shanahan stated 
that this is basically an 
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extension of an editorial I 
wrote a few months ago. 
The bottom line is that 
there is now a growing 
concern that the inspection 
process in pharmacies is 
fundamentally flawed and it 
opens up a genuine risk to 
the public. Part of the issue 
falls around the process of 
unannounced inspections 
and the substantial risk that 
it may place on dispensing 
medicines to the public. 
Most pharmacists find the 
inspection process quite 
stressful, yet they are 
expected to continue to 
provide a regular dispensing 
service during the routine 
PSI inspection process. In 
many cases, you are talking 
about a single pharmacist 
practice. One of the golden 
rules for safe dispensing is 
to minimise distractions. 
There is no greater 
distraction than somebody 
standing beside you that 
can potentially bring you up 
before a Fitness to Practise 
and have you struck off 
or put you through twelve 
to twenty-four months 
of hell. By definition, that 
is stress. It is distracting, 
whether you like it or 
not and that really is the 
key part of where I am 
coming from in relation 
to this motion. You can 
think of all the scenarios 
you want – you’ve opened 
the safe and she asks you 
to count the OxyContin 
and, suddenly, there 
are only 84 Oxycontin 
instead of 87. Those three 
Oxycontin are, potentially, 
a court case, They are 
potentially a Fitness to 
Practise and all that entails 
and here comes in Mrs 
Murphy with her regular 
prescription – “the bus is 
waiting, I need by ten items 
NOW – and you’re there 
looking after Mrs Murphy 
and you’re dispensing 
her methotrexate and, 
suddenly, you realise that 
they are awfully big looking 
methotrexate and you 
realise that it’s metformin 
you have in your hand. 
That’s the kind of level 
that this thing is at and it’s 
all very well for the PSI 
to say that the inspectors 
are paying due care and 
attention to safeguarding 
the dispensing process. 
By definition, their very 
existence, standing in 
that dispensary or even 
outside the dispensary is 
a distraction. Bearing that 
in mind, there is one way 
that you can, potentially, 
mitigate this risk and that 
is by having somebody 
else doing the dispensing 
process while the 
pharmacist that is dealing 
with the inspector pays 
her full care and attention 
dealing with the inspection 
process and that is why we 
need to have announced 
inspections so that 
pharmacists can arrange 
for another pharmacist, or 
maybe a pharmaceutical 
assistance, to come in and 
to carry on the dispensing 
while the pharmacist is 
dealing with the inspection.
The following amendment 
was proposed by Jack 
Shanahan and seconded by 
Sean Reilly.
“That this AGM calls 
on the Council of the 
Pharmaceutical Society 
of Ireland to allot a 
place to a representative 
of the Irish Pharmacy 
Union on a committee 
being established 
to review inspection 
and enforcement 
procedures.”
The motion, as amended, 
was proposed by Daragh 
Connolly, seconded by 
Joe Britton and carried 
unanimously.
e. Proposed: 
Roy Hogan 
Seconded: 
Michael Tierney
“That this AGM calls 
on the PSI to publish 
costs and timescales 
associated with 
Committees of Inquiry 
and Mediation and 
furthermore calls on 
the PSI to publish 
criteria used by the 
Preliminary Proceedings 
Committee to decide 
whether to recommend 
that a complaint should 
be forwarded to a 
Committee of Inquiry or 
Mediation.” 
In proposing this motion 
Roy Hogan stated that 
on the point of inspection 
and enforcement the PSI’s 
remit is to protect the 
public and safeguard their 
interests. To that end, the 
PSI does, rightly, have a 
role in inspections. But, 
given that power they 
must use it appropriately 
and treat people with 
the openness, honesty 
and integrity that they 
deserve. Pharmacists are 
working hard and doing 
their best and, of course, 
there are pharmacists 
that will end up in conflict 
with the PSI through 
errors, indiscretions and 
I would like to consider 
then what happens once 
a pharmacist is brought 
to the Preliminary 
Proceedings Committee, 
to consider what happens 
to the pharmacist at that 
point. The PSI has a range 
of options open to them 
under Section 40 of the 
Act. Option A allows for 
mediation and option B 
is twofold and allows for 
the Professional Conduct 
Committee to come on 
board. To my knowledge, 
the mediation process 
has only been used once 
so, essentially, everyone 
ends up in front of the 
Preliminary Proceedings 
Committee then going 
forward to the Professional 
Conduct Committee. 
To my mind, the most 
favourable outcome is 
that the issue is addressed 
as speedily and easily as 
possible to deliver the 
required result to protect 
the public. Mediation 
activity takes three 
months and doesn’t involve 
unnecessary hardship 
on the pharmacist. The 
Professional Conduct 
Committee, to my 
knowledge, ranges from 
fifteen months to twenty-
four months plus in terms 
of being back and forth 
to various hearings in 
Fenian Street in a process 
akin to court proceedings 
and, indeed, a number of 
pharmacists have ended 
up in front of the District 
Court on more than one 
occasion revisiting the 
same offences or related 
offences. Often these 
protracted and painful 
experiences really serve 
no purpose except in 
exceptional circumstances. 
I see no reason why the 
great majority of cases 
should not be addressed 
through mediation. It 
achieves the most speedy 
outcome; it should be 
open, fair and transparent 
and it should deliver the 
public health interest in 
addressing the challenge 
as speedily as possible. 
Except in exceptional 
circumstances, I see  
no reason to justify 
running up legal costs. 
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With that in mind I would 
like to propose “That 
this AGM calls on the 
PSI to publish costs and 
timescales associated with 
Committees of Inquiry and 
Mediation and furthermore 
calls on the PSI to publish 
criteria used by the 
Preliminary Proceedings 
Committee to decide 
whether to recommend 
that a complaint should be 
forwarded to a Committee 
of Inquiry or Mediation.” 
This motion was carried 
unanimously.
f. Proposed: 
Michael Tierney 
Seconded: 
Roy Hogan
“That this AGM calls 
on the PSI to reduce 
fees to pharmacists and 
pharmacies to bring the 
fees into line with those 
of other jurisdictions.” 
In proposing this motion 
Michael Tierney stated that 
the current registration 
fee is €400 €570 on first 
registration). For a building 
it’s €2,250 (€3,500 
on first registration). I 
am calling on the PSI 
to bring these costs 
more into line with other 
jurisdictions. In Northern 
Ireland registration is 
approximately €372, 
€330 in the UK, New 
Zealand €326, Australia 
€248. Building registration 
is €2,250 here, €190 
in Northern Ireland, UK 
€273, New Zealand 
around €680 plus tax 
and in Australia €407. 
Huge differences. Over 
the border, registration of 
the building is eleven times 
cheaper than down here. 
The Government action 
plan states “licensing bodies 
and authorities need to 
examine and seek to reduce 
licensing fees in the sectors 
where fees are considered 
to be most onerous. Fees 
in this category include 
the annual registration 
fees for pharmacies and 
pharmacists.” Whilst we 
heard yesterday that 
they are going to make a 
derisory 5% reduction in 
those, we are calling for 
a substantial reduction. 
A GP pays an annual 
registration fee of €510 
for himself and pays 
nothing for his building. 
The PSI in its last set of 
accounts had a surplus 
of €2M and a reserve of 
nearly €11M. There are 36 
staff – one for every 50 
pharmacies in the country 
so a clear direction from 
the Minister’s office would 
have fees reduced and I 
am calling on the IPU to 
step up its campaign to get 
those fees reduced.
This motion was carried 
unanimously.
12.Open Forum
James Collins asked 
if there was any 
move regarding the 
situation whereby a 
pharmacist adjudged an 
undischarged bankrupt 
by the court, by default 
cannot register as 
a pharmacist. The 
Secretary General said 
that it was an issue that 
the IPU had consistently 
raised with the PSI 
and Department of 
Health. There was 
no disagreement, in 
principle, that the 
Pharmacy Act be 
amended to remove 
an archaic and onerous 
clause. Alex White has 
spoken publicly on the 
issue in the Oireachtas 
and he had committed 
in the Oireachtas to 
amending that part of 
the Pharmacy Act in 
conjunction with other 
amendments that 
are being considered. 
The IPU will keep the 
pressure on to have the 
amendment put in place.
Marie McConn asked 
for an update on 
rumours that there 
had been resignations 
from the Council of the 
PSI. The SG said that 
he believed that the 
rumours were fact and 
that the matter would 
be made public when 
the resignations had 
gone to the Minister. 
Joe Britton said that he 
was having problems 
getting remuneration 
from the PCRS for 
anticoagulants. The 
SG said there was 
an issue with the 
approval process and 
that a meeting was 
due with the PCRS. 
He asked Joe to send 
the specifics of his 
problems to Jill Lyons 
at the IPU. Brian Walsh 
undertook to call Joe 
the following week to 
discuss the issue.
Pamela Logan drew the 
meeting’s attention to 
an item on NOACs, 
which had been 
published in the  
IPU Review.
The President thanked 
the organisers of the 
Conference, IPU staff, 
Committee members 
and colleagues for their 
support during his two-year 
Presidency. He wished the 
incoming President, Kathy 
Maher, all the best for the 
next two years and officially 
passed the chain of office 
to the new President of the 
IPU.
Kathy Maher briefly 
addressed the meeting 
(included with the full 
report of the meeting) 
and then closed the 41st 
Annual General Meeting of 
the Irish Pharmacy Union. 
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2014 AGM MOTIONS  
AND REPORT ON 
ACTION TAKEN
The following motions, 
proposed in accordance 
with Article 30 of the 
Constitution, were brought 
before the 2014 AGM for 
consideration:
1. Proposed:  
Brian Walsh
 Seconded: 
Grainne O’Leary
“That this AGM calls 
on the Minister for 
Health to extend the 
professional role of 
pharmacists in Ireland, 
in line with experience 
in other countries, to 
allow all patients have 
access to healthcare in 
their community and to 
ensure that pharmacists 
are appropriately 
remunerated for any new 
service that they provide 
on behalf of the State”.
Action: 
In July 2014, we made a 
submission to the Joint 
Oireachtas Committee 
on Health and Children 
to outline the merits of 
extending the role of the 
pharmacist and proposed 
the introduction of a Minor 
Ailment Scheme. This 
proposal was reiterated as 
part of a suggested ‘To-Do 
List’ for the new Minister 
for Health.
In October 2014, we 
made a submission to the 
Department of Health on 
its Statement of Strategy 
2015-2017, in which 
we highlighted various 
ways in which the role of 
the pharmacist could be 
extended; proposing the 
introduction of a number 
of services including a 
Minor Ailments Scheme, 
New Medicines Service 
and extended vaccinations 
services. All of these 
services would support the 
Department in promoting 
and achieving a healthier 
Ireland, in line with the 
goals of the Department as 
set out in Healthy Ireland.
In November 2014, we met 
with MfH Leo Varadkar. We 
highlighted the success of 
the flu vaccination service 
in pharmacies as evidence 
of the benefits of extending 
the role of the pharmacist 
and proposed that the 
service be extended to 
cover other vaccines, such 
as pneumococcal and 
shingles. We also set out in 
great detail the gains that 
could be made from further 
extending the role of the 
pharmacist and specific 
additional services were 
discussed in detail with the 
Minister.
In January 2015, we held 
our Annual Seminar, 
at which a number of 
eminent speakers attended, 
including Professor 
Colin Bradley, Head of 
Department of General 
Practice, University 
College Cork. Professor 
Bradley declared that 
pharmacists hold the key 
to relieving mounting 
pressures in GP surgeries 
and called for the role 
of the pharmacist to be 
expanded. 
In March 2015, we met 
with John Hennessy, HSE 
Director of Primary Care, 
who had attended the 
IPU Annual Seminar, in 
order to impress upon him 
the benefits of extending 
pharmacy-based services, 
which can offer better 
patient outcomes at a 
lower cost. Mr Hennessy 
declared that the 
infrastructure of more than 
1700 pharmacies across 
the country represented 
a significant opportunity. 
Mr Hennessy expressed a 
genuine interest in working 
with the IPU to put a pilot 
of the New Medicines 
Service and the Minor 
Ailment Scheme together. 
Lastly, in a presentation 
to the Oireachtas Joint 
Committee on Health and 
Children on the issue of 
medicine prices in March 
2015, we stated that the 
objective of any review of 
expenditure on medicines 
must be to maximise 
value for money and to 
ensure best possible health 
outcomes for patients. We 
emphasised that patient 
care is fundamental to 
an efficient and effective 
healthcare system, stating 
that years of short-sighted 
cuts in pharmacy payments 
have undermined the 
profession’s capacity to 
deliver the badly-needed 
pharmacy-based services, 
which have been shown 
elsewhere to improve 
patient health outcomes 
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and, simultaneously, reduce 
spending on healthcare and 
concluding that it is time 
now for the government 
to engage with the IPU 
on a positive agenda 
for change, to deliver 
convenient, accessible and 
cost-effective healthcare 
through a currently 
under-resourced and 
under-utilised pharmacy 
profession.
2. Proposed:  
Marie McConn 
Seconded: 
Paul Fahey
“That this AGM calls 
on the Minister to 
abolish the medical card 
prescription levy; and 
pending its abolition that 
its operation be reviewed 
firstly by reducing the 
ceiling for over 70s 
to €15; secondly by 
exempting all people who 
are:
a. registered as homeless 
with the HSE and / or 
Local Authorities;
b. persons with 
intellectual disabilities;
c. persons in residential 
care facilities; and, 
thirdly, by exempting 
some psychiatric 
medicines, especially 
Antipsychotic / 
Neuroleptic agents.”
Action:
In May 2014, we issued a 
press release setting out 
our concerns regarding 
the adverse impact 
on medicine usage of 
the budget hike in the 
prescription levy from 
€1.50 to €2.50. We 
conducted a survey, which 
demonstrated that 38% 
of medical card patients 
“think twice” about filling 
prescriptions because 
they will have to pay a 
levy of €2.50 for each 
medicine prescribed. It 
was highlighted that this 
was causing some patients 
to “ration” their use of 
medicines, with potentially 
harmful consequences 
and we again called on 
the Government to, 
at a minimum, exempt 
vulnerable groups such as 
homeless people and those 
with intellectual disabilities.
In July, we again raised the 
issue of the prescription 
levy. In a ‘To-Do List’ aimed 
at the newly appointed 
Minister we identified 
four changes which 
could have a significant 
impact on the delivery of 
healthcare in this country, 
which included exempting 
vulnerable groups from 
paying the medical card 
prescription levy. 
Following the publication 
of the Budget in October 
2014, we issued a press-
release expressing concern 
and disappointment at the 
Government’s failure to 
adequately address the 
medical card prescription 
levy in Budget 2015 and 
in particular the failure to 
exempt vulnerable groups 
from the obligation to  
pay it.
3. Proposed: 
Louise Begley 
Seconded: 
Aidan Walsh
“That this AGM calls 
on the IMB to reclassify 
appropriate prescription-
only medicines, in a 
timely fashion, in order 
to improve the public’s 
access to medicines from 
their pharmacist”.
Action:
The HPRA published the 
first list of substances 
suitable for POM to P 
switching in July 2014. It 
had been their intention 
to publish a second list in 
November 2014. However, 
due to the poor response 
by the industry to the first 
list, the HPRA decided 
that, for the next group of 
substances identified, it 
was best to initially directly 
engage with the marketing 
authorisation holders to 
establish their interest 
in reclassification of the 
relevant products and 
consequently progress the 
application submissions. 
This will avoid creating an 
impression publicly that 
these products are to be 
imminently reclassified, 
when the reality is that in 
order for the HPRA to 
be able to achieve this, 
they have to wait for 
the submissions which 
also have to be of an 
appropriate standard. 
The HPRA has begun 
discussions with a 
number of the marketing 
authorisation holders and 
will consider the best the 
means of communicating 
any product 
reclassifications that may 
arise from this, when they 
have a clearer picture of 
what is achievable.
We held a seminar in 
January 2015 on The Role 
of the Pharmacist in Self-
Care – A Prescription 
for Success. The purpose 
of the seminar was 
to demonstrate the 
importance of Self-Care 
and how pharmacists 
can play a greater role 
in this area, utilising 
their accessibility and 
professional capabilities to 
benefit the health system 
and the public by helping 
people to make informed 
choices about self-care, 
providing and interpreting 
information and supporting 
safe and appropriate self-
medication. The speaker 
from New Zealand spoke 
of the success of their 
innovative POM to P 
switching strategy. 
4. Proposed:  
Jack Shanahan 
Seconded:  
Sean Reilly
“That this AGM calls 
on the Council of the 
Pharmaceutical Society 
of Ireland to allot a 
place to a representative 
of the Irish Pharmacy 
Union on the committee 
being established 
to review inspection 
and enforcement 
procedures.”
Action:
We wrote to the PSI in 
June 2014, welcoming 
their decision to have a 
strategic review of their 
inspection policy. We 
nominated a member of 
CPC to sit on the Expert 
Group to provide technical 
advice and assist in the 
development of a new PSI 
inspection policy. 
The PSI Council did not 
support this nomination 
as it felt that the most 
appropriate manner 
to select the three 
pharmacists to the Expert 
Group would be on the 
basis of applications 
submitted to an Expression 
of Interest process. 
Michael Tierney was 
subsequently appointed to 
the Expert Group. 
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5. Proposed: 
Roy Hogan 
Seconded: 
Michael Tierney
“That this AGM calls 
on the PSI to publish 
costs and timescales 
associated with 
Committees of Inquiry 
and Mediation and 
furthermore calls on 
the PSI to publish 
criteria used by the 
Preliminary Proceedings 
Committee to decide 
whether to recommend 
that a complaint should 
be forwarded to a 
Committee of Inquiry or 
Mediation.” 
Action:
We raised these issues 
with the PSI at a meeting 
in July 2014. The PSI 
confirmed that mediation 
guidelines were in place. 
The IPU proposed that 
mediation be moved, as 
part of the amendments 
to the Pharmacy Act, to 
sit before consideration of 
the complaint by the PPC. 
In relation to publication of 
costs and timescales, the 
PSI said that this varied 
considerably from case 
to case. The PSI said that 
they intended to produce 
a guide to the complaints 
process for pharmacists; 
they currently only have a 
guide for complainants.
Further to submissions 
made by the IPU, the PSI 
updated their guidance on 
eligibility for recognition as 
a tutor pharmacist following 
District Court convictions 
or FTP sanctions. In 
general, the convicted/
sanctioned pharmacist will 
not be eligible to be a tutor 
for a period of two years; 
previous guidelines had 
not stated the period of 
ineligibility. We asked the 
PSI to consider a similar 
exercise in relation to the 
publication of convictions 
or sanctions on the PSI 
website. 
At our meeting with the 
PSI in March 2015, the PSI 
confirmed that they are in 
the process of developing 
a Sanctions Policy and a 
Publications Policy, both of 
which will be considered by 
Council at its May meeting. 
The latter policy will deal 
with how long findings and 
outcomes remain on the 
PSI website.  
We met with the PSI in 
March 2015 to discuss 
how the Supreme Court 
ruling on the Corbally vs 
Medical Council case will 
affect future FTP cases. 
The Supreme Court upheld 
the High Court decision 
from November 2014 
which ruled that, in relation 
to single errors, such an 
error must be characterised 
as serious before it 
will amount to poor 
professional performance. 
6. Proposed: 
Roy Hogan 
Seconded:  
Michael Tierney
“That this AGM calls 
on the PSI to reduce 
fees to pharmacists and 
pharmacies to bring the 
fees into line with those 
of other jurisdictions.” 
Action:
We made a submission 
to the PSI on its Draft 
Pharmaceutical Society 
of Ireland (Fees) Rules 
2014 in July 2014. This 
was followed by a meeting 
with the PSI in July 2014 
in which we raised this 
issue. The PSI clarified that 
their €12 million reserves 
included: €6 million in 
fees paid in advance; €2.5 
million pension funds; €2.5 
million in legal reserves; 
and funds from the sale 
of Shrewsbury Road 
which were required to 
be reserved for pharmacy 
practice development. 
Consequently, their actual 
reserves were closer to  
€2 million. 
The PSI only received 
13 submissions for their 
Fees Consultation, which 
led them to believe that 
most pharmacists were 
satisfied with the fee level. 
They felt that it was not 
fair to compare the PSI to 
Northern Ireland (where 
the Department holds the 
inspection function) or the 
UK (due to economies of 
scale). 
The PSI clarified that they 
had reduced fees by 10% 
in 2010 and the further 
5% reduction proposed 
for 2015 was all they could 
facilitate at this time as it 
cost €7 million to run the 
PSI. They said that the 
fees are constantly being 
reviewed.
During our July 2014 oral 
presentation to the Joint 
Oireachtas Committee 
on Health and Children, 
we mentioned a number 
of regulatory issues of 
concern to our members, 
such as PSI registration 
fees, FTP and bankruptcy 
provisions in the Pharmacy 
Act.
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IPU SECRETARIAT 
REPORT
IPU Committees – the 
Community Pharmacy 
Committee, Employee 
Pharmacists’ Committee 
and Pharmacy Contractors’ 
Committee. During the 
last year, the Executive 
commissioned Grant 
Thornton to conduct 
an internal audit and 
governance review of the 
IPU in order to provide 
assurance on the adequacy 
and effectiveness of the 
internal financial controls 
currently in place, to 
review the existing 
Governance Framework 
against best practice and 
to make recommendations 
for improvements as 
appropriate. During the 
audit no material deviations 
from financial procedures 
or material errors were 
noted. The auditors did, 
however, make some 
recommendations to 
further strengthen the 
internal financial control 
framework and support 
the monitoring activities 
already performed by the 
Finance Sub-Committee. 
The audit also found 
that a solid governance 
framework, consisting of 
the various committees and 
supporting documentation 
of the IPU, was in place 
to achieve the objectives 
of the IPU and ensure 
good governance. They 
identified opportunities 
to enhance the IPU 
governance framework 
and to align it more closely 
with best practice. All the 
recommendations have 
been acted upon by the 
Executive Committee.
The members of the IPU’s 
committees have worked 
hard all year to support 
the community pharmacy 
profession. There are 
comprehensive reports 
herein which illustrate the 
wide range of activities that 
the IPU engages in ensures 
the IPU’s continued 
relevance and importance 
to practising pharmacists. 
The IPU exists only to 
serve the interests of its 
members. The pooling of 
members’ ideas, efforts 
and resources, matched 
with the enthusiasm of 
the pharmacists who give 
generously of their time 
and enthusiasm ensures 
that all pharmacists benefit 
from IPU services in 
their practices and their 
businesses and also ensures 
that we are here to support, 
advise and assist individual 
members whenever you 
need us. 
1. Introduction 
While 2014 was a good 
year for the Irish economy, 
with our economic 
growth now the highest 
in the Eurozone and 
our unemployment rate 
below the EU average, 
unfortunately for us 
the overall economic 
improvement has not been 
reflected in the fortunes of 
pharmacy businesses. The 
personal debt overhang in 
the economy is suppressing 
consumer spending and 
reference pricing and falling 
medicine prices continue 
to erode already weak 
pharmacy revenues.
The Executive Committee 
oversees the management 
of the IPU and the 
work of the three main 
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2. Membership & Pharmacy Ownership (as at 09 March 2015)
(1) Membership of the IPU
 Community Proprietors 881
 Industry & Wholesale 5
 Community Employees 1275 *
 Hospital 2
 Army, Academic & Admin 2
 Associate Members 6 
 TOTAL 2171
 
(2) Number of Community Pharmacies
 Pharmacist Owned:
 Single shops 689
 Chains 675
  1364
 
 Non-Pharmacist Owned:
 Single shops 67
 Chains 178 
  245  (1609)
 
(3) Total Number of Chains (2 and over)    
 PHARMACIST NON- 
  PHARMACIST
 Two pharmacies 114  7 242
 Three 35  0 105
 Four  15  1 60
 Five 5  1 30
 Six 7  2 54
 Seven 2   7
 Eight 4   32
 Nine 1   9
 Ten 1   10
 Eleven 1   11
 Thirteen 1   13
 Fifteen 1   15
 Sixteen 1   16
 Eighteen 1   18
 Twenty 1   20
 Twenty-Eight 1   28
 Twenty-Nine  1   29
 Sixty-Five 1   65
 Seventy-Eight 1   78
  (675)  (178) (853)
*Notes on Employee Membership
• 584 are Supervising 
Pharmacists availing of  
the free membership for 
additional pharmacies
• 5 are Supervising Pharmacists 
in non-pharmacist owned 
pharmacies and are covered by 
the sub paid by the pharmacy.
• 70 are availing of the  
free membership. 
• 9 are joint pharmacy owners 
who pay a CE sub.
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3. IPU Academy
The IPU Academy has 
gone from strength 
to strength in 2014, 
providing members with 
access to high quality 
learning opportunities and 
offering them support and 
assistance in complying 
with obligations under 
the regime of mandatory 
Continuing Professional 
Development.
4. Product File Unit
The IPU Product File 
is managed by Fiona 
Hannigan and her team: 
Ger Gahan, Yemi Soile, 
Eilish Barrett and Ciara 
Browne. As well as 
supplying price updates 
and product information 
for members, they provide 
the following services and 
advice: 
• Product sourcing
• General queries on the 
IPU Product File
• GMS pricing issues
• Medicine Shortages
• Discontinued Lists
The IPU also provides a 
Drug Interaction File and 
information files on drug 
use in Pregnancy and 
Breastfeeding, produced 
by the School of Pharmacy 
in Trinity College Dublin. 
These are based on the 
ATC classification system 
and are designed to 
warn pharmacists of the 
possibility of an interaction. 
IPU Product File  
Update 2014
• Reference Pricing/ 
Generic Substitution. 
• There were 40 
molecules deemed 
interchangeable during 
2014 and of these 30 
were reference priced.
• Meetings with system 
vendors to discuss any 
issues arising from 
the implementation 
of Reference Pricing/
Generic Substitution.
• Standardisation of 
fields on IPU Product 
File ongoing.
• Changes made to IPU 
Product File structure 
and outputs.
• IPU Product File link to 
HPRA Website. 
• IPU Product File 
updated to distinguish 
PA/PPA/DRP and EU 
products.
• HPRA File tested 
for mapping to IPU 
Product File.
• Sample fields sent to 
vendors for testing.
• It is hoped to go live 
with the link April 
2015.
5. Administration 
Unit
The Administration Unit 
has three staff members:
• Patrice O’Connor 
looks after membership 
support and assists 
in the day-to-day 
running of the office; 
• Ciara Enright, who 
works part-time as 
the IPU’s accountant, 
is Secretary to the 
Finance Committee. 
She maintains books 
of account and 
advises members on a 
range of taxation and 
accountancy issues. 
• Roisín Molloy is 
responsible for all 
aspects of membership 
and the management 
of the Secretary 
General’s office. 
6. Contractual and 
other Related 
Issues 
Catherine Day joined the 
IPU in September 2014, 
replacing Jill Lyons as 
Contract Manager and 
Secretary to the Pharmacy 
Contractors’ Committee 
(PCC). 
The PCC Secretary plays 
a key role in developing 
and promoting PCC 
initiatives and in the 
resolution of problems 
with the Health Service 
Executive, Primary Care 
Reimbursement Service 
and the Department of 
Health. Throughout 2014, 
the Secretary worked with 
the HSE and the Elton 
John AIDS Foundation 
on the continued success 
of the Needle Exchange 
Programme through 
Community Pharmacy. 
The Secretary met with the 
HSE PCRS on a regular 
basis as part of an IPU 
delegation assigned to on 
progress the Pharmacy 
Interface Project. The 
Secretary also met with 
the PCRS as part of the 
Joint Consultative Group 
on a number of occasions 
to highlight administrative 
issues faced by pharmacists 
in respect of the various 
community drug schemes 
and propose and discuss 
solutions to those issues. 
The Contract Unit spent 
much of the year liaising 
with the HSE PCRS in 
an effort to resolve the 
numerous contractual 
queries and payment 
issues that arose. We 
successfully resolved a 
significant number of 
individual members’ queries 
throughout 2014/2015. 
We successfully pursued 
unpaid methadone 
grants and needle 
exchange retainers, 
secured payment for valid 
claims under the various 
schemes and responded 
to queries relating to 
the contract, handbook, 
circulars, legislation, 
reimbursable medicines 
and fees. We worked on 
making information on 
the HSE contract and 
reimbursement more 
accessible to members by 
reorganising the content 
of the HSE contracts 
section of the IPU 
website and preparing a 
booklet containing clearer 
categorisation for the 
medicines within the core 
lists for the Long Term 
Illness Scheme, both of 
which will be available to 
members in the coming 
months. 
In addition to the above, 
Aoife Garrigan, the 
Contract Administrator is 
responsible for compiling 
information on raids on 
pharmacies and notifying 
members of trends. She 
also uses this information 
to highlight vulnerabilities 
in pharmacies which have 
been identified following 
robberies or raids that have 
occurred. The Contract 
Administrator is also 
responsible for notifying 
members of forged and 
stolen prescriptions in 
circulation. She took a 
significant number of 
calls relating to these the 
past year from the HSE, 
from prescribers and from 
members, further to which 
she notified members via 
the IPU newsletter. 
IPU SECRETARIAT REPORT  CONTINUED
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7. Policy and  
Public Affairs 
Jim Curran, as Director 
of Communications and 
Strategy, oversees the 
IPU’s internal and external 
communications and is 
responsible for developing 
the IPU’s strategy. His 
responsibilities include 
promoting the interests 
of the IPU and the 
membership through 
effective communications 
with members, media, 
agencies and other parties 
that influence the sector. 
He is also responsible for 
overseeing events, business 
development and policy 
research Jim oversaw the 
introduction of the new 
strategy statement for the 
IPU, which will cover the 
period from 2013-2016. 
Jim is an editorial associate 
of the IPU Review and 
is also Secretary to the 
Executive Committee. He 
also represents the IPU on 
external committees.
8. Media and 
Communications
Jim Curran oversees this 
area. Wendy McGlashan 
is Admin Secretary to the 
Executive Committee. 
She organises the annual 
Pharmacy Seminar and 
is responsible for IPU 
publications, including 
the production of the 
Annual Report, IPU 
Review, IPU News (the 
weekly e-newsletter) and 
co-production of the IPU 
Yearbook.
Aoibheann Ní Shúilleabháin 
is responsible for organising 
the annual IPU National 
Pharmacy Conference. She 
manages the IPU website 
and social media channels 
and co-ordinates IPU 
advertising campaigns. She 
works on the co-ordination 
of communications activities 
and assists with national and 
regional media coverage for 
the IPU and public opinion 
research. She is an editorial 
associate of the IPU Review.
Communications
• Market Research: The 
IPU undertook market 
research amongst the 
general public. 
• Advertising Campaigns: 
The IPU continues to 
promote the ‘Ask Your 
Pharmacist First’ message 
with national radio and 
television ad campaigns. 
The IPU TV advertising 
campaign ran from 13 
October 2014 for four 
weeks. Feedback on 
the ad campaign has 
been extremely positive, 
with hundreds of views 
on the IPU’s YouTube 
channel also. There 
was media coverage 
in the Irish Times and 
Evening Herald on the ad 
campaign. Two ads were 
developed and ran on 
RTE, TV3, 3E, Channel 
4, E4 and SKY Media 
package. The ads also ran 
on Video on Demand. 
Highlights included the 
ads being shown during 
the RTÉ One Six-One 
and Nine News, the 
GAA All Stars, Tonight 
with Vincent Browne, 
and shows such as Xposé, 
Fair City, Eastenders 
and The Graham 
Norton Show. ‘Ask 
Your Pharmacist First’ 
patient leaflets were 
also sent to pharmacies 
to complement the 
campaign.
• A Christmas Radio ad 
campaign ran for one 
week, commencing on 8 
December, on national 
and regional radio 
stations. The ad focused 
on the retail aspect of 
pharmacies, and posters 
were sent to pharmacies 
to complement the radio 
ad.
• Communications 
with Members: 
Communications with 
members continue to 
improve, with the IPU 
website, IPU News (the 
weekly e-newsletter) 
and the IPU’s social 
media channels all 
seeing an increase in 
uptake from members. 
Regular communications 
are provided to keep 
members up-to-date 
with vital, current 
information to run an 
efficient pharmacy. 
Members are also 
updated, on a quarterly 
basis, on issues addressed 
by the IPU on their 
behalf and progress 
made. 
• Publications: The IPU 
Review, Yearbook and 
weekly e-newsletter are 
all produced in-house 
rather than through 
external contractors for 
efficiency reasons.
• Annual Review: The 
Annual Review of the 
sector is part of an 
ongoing annual series 
that authoritatively tracks 
changes in community 
pharmacy. It is essential 
research and a reference 
that enables us, as a 
representative body, 
to promote members’ 
interests based on 
credible facts that are 
measured consistently 
over time. The 2014 
Review was carried out 
by Fitzgerald Power 
and is available on the 
members’ section of the 
website.
IPU National Pharmacy 
Conference
The annual IPU National 
Pharmacy Conference has 
been a great success since 
the inaugural event in 2011. 
Since then, the conference 
has grown and expanded 
to facilitate the needs of 
members. The conference 
is a great opportunity for 
members to come together 
in an educational and 
social environment. Over 
the weekend, pharmacists 
have the opportunity to 
build on their Continuing 
Professional Development 
(CPD) and receive 
updates on the work of 
the IPU at the AGM. The 
President’s Dinner is also 
held over the weekend 
of the conference. The 
conference provides 
valuable networking 
opportunities for 
pharmacists. 
9. Pharmacy Services
The Director of Pharmacy 
Services, Pamela 
Logan, co-ordinates 
all Professional, IT and 
Training matters within 
the IPU. Pamela acts as 
Secretary to CPC and 
details of issues covered 
by this Committee can be 
found in the CPC report. 
She works with relevant 
departments and agencies, 
both nationally and 
internationally, to promote 
the role of the pharmacist. 
Pamela also represents the 
IPU at PGEU and FIP. Liz 
Hoctor is the Professional 
Development and Learning 
Manager and has been 
instrumental in the setting 
up of IPU Academy to 
support members in 
their engagement with 
continuing professional 
development. Liz also 
oversees IPU NET, our 
online web-based platform 
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designed to support 
members in the delivery 
of new pharmacy services. 
Alan Reilly is our new 
ICT Program Manager, 
responsible for developing 
IPU IT strategy.
10.Training & HR 
Department 
Susan McManus, Training 
& HR Manager, organises 
and co-ordinates a 
selection of training 
courses for pharmacy 
staff. Janice Burke assists 
Susan in this department. 
124 Pharmacy Technicians 
graduated in March 2015. 
There are 185 students at 
present partaking in Year 1 
and 175 students in Year 2 
of the course. In addition, 
166 students completed 
the Medicine Counter 
Assistant’s (MCA) Course 
in 2014 in Dublin, Cork, 
Galway, Kilkenny, Limerick, 
Tralee, Tullamore and 
Waterford. 95 students 
completed the Interact 
course and 19 completed 
the Interact Plus course. 
The Dublin and Dun 
Laoghaire Education and 
Training Board, DDLETB 
Pharmacy Sales Traineeship 
course was administered in 
Baldoyle, Cork and Kerry 
and to Senior Colleges in 
Dun Laoghaire, Dublin; 
Monaghan Institute; 
Limerick College of Further 
Education and St John’s 
College, Cork. Susan also 
acts as Secretary to the 
Employee Pharmacists’ 
Committee (EPC), co-
produces the IPU Yearbook 
and Diary and Wall-Planner 
and advises members on 
Human Resource issues. 
The Training Department 
in conjunction with the 
Business Development 
Department rolled out the 
Diploma in Leadership and 
Management in February 
2013, a second cohort 
started in October 2013 
and a third cohort in 
October 2014, enrolling 
25 candidates. This is a 
highly interactive course 
spanning 24 months, 
utilising various teaching 
methods, including 
classroom workshops, on-
the-job projects, individual 
and group exercises, case 
study work groups, learner 
forums and individual 
presentations. The ‘face-
to-face’ element of this 
course is delivered by 
Susan Madden, RTCL. 
Other recent additions to 
the Training Department’s 
platform include the 
Pharmacy Retail Sales 
course, 10 completed 
in 2014. This course 
was originally launched 
in October 2013 and 
has been developed and 
tailored specifically to 
assist pharmacy staff in 
developing their retail 
sales skills and know-
how. Delivered over eight 
weeks and is suitable for 
the seasoned employee 
wanting to refresh their 
skills or the new employee 
needing a structure in their 
approach to the retail sales 
process. The 
Medicines in Care 
Homes training pack 
has been designed to 
assist pharmacists in 
providing training on the 
management of medication 
to care staff working in 
residential care settings; 14 
packs were purchased in 
2014. 
In October 2014, we 
launched the Medicine 
Counter Assistant’s 
(MCA) Refresher Course. 
We recognised that all 
pharmacy staff should 
be afforded continuing 
profession development 
(CPD). This one-day 
course is specifically 
tailored to assist medicine 
counter assistants to 
revise and update their 
knowledge. Enrolment is 
open to medicine counter 
assistants who have been 
certified on the Medicine 
Counter Assistant’s (MCA) 
Course or the IPU Interact 
Course for over two years, 
12 completed in 2014 in 
Dublin. 
Another addition to the 
IPU Training Department’s 
platform is the IPU 
Supervisory Development 
Course.  This course is an 
interactive workshop, which 
will be delivered over two 
days, one month apart.  
Day one will specifically 
focus on the development 
of the Supervisor in skills 
such as communication and 
delegation.  Day two will 
focus on the skills needed 
by the Supervisor to 
maximise the performance 
of the individual team 
member. This course 
has been developed for 
practising or aspiring 
supervisors or managers 
as an introduction to the 
Diploma in Leadership and 
Management.  
11. Business Services
The Business Development 
Manager, Darren Kelly, is 
responsible for business 
services and advice to 
members. Along with 
Jim Curran, Director 
of Communication and 
Strategy, we are now 
represented on a number 
of strategic retail forums 
that have enabled us to 
provide a platform for a 
structured engagement 
between the retail sector 
and relevant government 
departments and agencies 
on areas such as crime 
prevention, upward only 
rent issues and town centre 
issues. In September 
2014, we launched our 
third cohort of students on 
the IPU/ILM Diploma in 
Leadership & Management 
training programme. This 
course was developed to 
help pharmacy owners, 
managers and supervisors 
could gain the knowledge 
required to help them 
manage their pharmacies. 
We also ran a number of 
training workshops on 
Crime Prevention and 
Sales & Merchandising. 
A number of affinity 
schemes have been 
negotiated for members 
on a range of products 
and services and details 
can be found on www.
ipu.ie. Members are kept 
up-to-date with current 
legislation through notices 
in the IPU Review, 
Yearbook, E-Newsletter 
and General Memoranda. 
Darren operates the 
IPU Retail Review 
Consultancy Service, which 
is available to members at 
a discounted rate. Over 
100 pharmacies have 
availed of this service to 
date. Darren will come to 
your pharmacy for a full 
day retail review, develop 
a plan and implement the 
plan over the course of the 
day. The feedback from 
members who have availed 
of this service has been 
very positive. Details of 
this service can be found 
on www.ipu.ie and in the 
IPU Review. Members 
can contact the Business 
Department for advice 
and information on the 
Business Helpline 01 406 
1558.
Darren also oversees the 
general maintenance and 
upkeep of Butterfield 
House. 
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12.External 
Consultants
Gordon MRM (PR 
Consultants); Coolamber 
(IT Consultants); John 
Behan (Industrial Relations 
Advisor) and Sean McHugh 
(Industrial Relations 
Advisor); provide advice 
and support to the IPU as 
requested on an ongoing 
basis. Leaf Environmental 
has been retained as 
consultants to the IPU 
on matters regarding 
environmental and waste 
management issues.
13. Main Committee 
Meetings
The number of committee 
meetings is shown in the 
table above.   
 
14. IPU Publications
The following are sent to 
members, on a regular 
basis:
• IPU Review
• IPU Weekly 
E-Newsletter
• General Memoranda
• Price Index List 
Updates
• IPU Product File by 
email and on Disk and 
CD
• Yearbook & Diary
• Wall Planner 
• Quarterly Business 
Trends Surveys
• Training Course 
Updates
15.Pensions and 
Insurance 
AIC Glennon Ltd, 
Pharmacy Insurance 
Ireland and Liberty Asset 
Management provide 
insurance and pension 
services for members.
16.Submissions
The following submissions 
were made during the year. 
Most are available on  
www.ipu.ie.
2014
• Draft Clinical Guidelines 
for Opioid Substitution 
Treatment 
HSE – May 2014
• Consultation on White 
Paper on Universal 
Health Insurance  
DoH – May 2014
• Draft Guidance on  
the Delivery of  
POMs from a RPB  
PSI – June 2014
• Presentation to Joint 
Oireachtas Committee 
on Health and Children 
July 2014
• Draft Guidance on 
Data Protection for 
Pharmacists  
PSI – July 2014
• Policy Framework on 
Temporary Absence  
PSI – July 2014
• Pharmacy  
Inspection Policy  
PSI – August 2014
• Minor Ailment Scheme 
DoH – August 2014
• Department of  
Health Statement  
of Strategy  
2015-2017  
October 2014
2015
• Consultation on  
Guide for Retail Sale 
of Herbal Medicinal 
Products  
HPRA – January 2015
• Private Health  
Insurance  
Consultation  
DoH – January 2015
• Draft Guidance 
for Pharmacists on 
Extemporaneous 
Dispensing  
PSI – February 2015
• Transposition of Falsified 
Medicines Directive 
(Common Logo)  
DoH – February 2015
• Presentation to Joint 
Oireachtas Committee 
on Health and Children 
March 2015
• Expanding the Role of 
Community Pharmacists 
for the Benefit of the 
Healthcare System 
Fianna Fáil – March 2015
17. IPU Review
The IPU Review is produced 
in-house by Jim Curran, 
Wendy McGlashan 
and Aoibheann Ní 
Shúilleabháin. 
18.Conclusion
The business environment 
for pharmacy is constantly 
changing and getting 
increasingly difficult. 
Pharmacies need better 
and faster information 
to run their businesses 
effectively and profitably. 
In order to ensure our 
members have access 
to the best business 
intelligence available, the 
IPU launched Health 
Market Research (hmR) 
to collate anonymised data 
from pharmacists’ systems, 
aggregate the information 
and deliver best-in-class 
benchmarking and trend 
reports to participating 
members. I would 
encourage all of you to 
participate, as the benefits 
to all of us increase with the 
number of participants and 
the purpose of the project 
is solely to benefit IPU 
members. 
I am lucky to work with 
a great team Butterfield 
House, who are fully united 
in their determination to 
represent and serve the 
community pharmacy 
profession to the best 
of their ability. We will 
continue to innovate in 
order to effectively assist 
our members in ever-
changing circumstances, 
while working ceaselessly 
to represent, advocate for 
and defend the community 
pharmacy sector and 
the valuable work that 
pharmacists do. We are 
grateful for your ongoing 
support, without which we 
could not function, and we 
are always keen to receive 
our members’ feedback, 
either directly or via your 
committee members.
Darragh J. O’Loughlin
Secretary General
Total Number of Committee Meetings    
  2014 2013 2012 2011 2010
Executive Committee  7 5 7 6 6
Community Pharmacy Committee  4 4 4 4 5
Pharmacy Contractors’ Committee  2 3 6 5 8
Finance Sub Committee   6 5 6 7 7
All Committee Meetings  0 0 1 0 0
Employee Pharmacists’ Committee 5 4 4 4 4
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PHARMACY 
CONTRACTORS’
COMMITTEE (PCC)
REPORT 2014-2015
Over the past year the PCC’s energies have been 
focused on progressing 
developments in the 
Pharmacy Interface 
Project, dealing with the 
decisions of the HSE 
PCRS along with many 
other urgent issues which 
have arisen during the year.
The main items on the 
Committee’s agenda  
since the last AGM:
Policy Matters
• Monitoring the 
Reference Pricing and 
Generic Substitution 
regime;
• Liaising with our  
legal advisers on the 
FEMPI Appeal;
• Meetings with Ministers 
on extended new services;
• Advocating for a 
pharmacy-based Minor 
Ailments Scheme;
• Advocating for payment 
for multiple dispensings 
for non-GMS patients.
HSE Contract 
Matters
• Monitoring the success 
and implementation of 
the Needle Exchange 
Programme with  
the HSE; 
• Participating in the  
Joint Consultative  
Group with the HSE; 
• Issuing the first PCRS 
Claims Survey, to collate 
statistics and other 
information on the most 
problematic Community 
Drugs Schemes in terms 
of claims and payment; 
• Liaising with the HSE to 
ensure that there is more 
transparency and fairness 
in their dealings with 
pharmacists; 
• Advocating for the 
streamlining of the Long 
Term Illness Scheme; 
• Liaising with the HSE 
and pharmacists around 
the issuing of the 15 
Automatically Approved 
LTI Lists;
• Ensuring the continued 
operation of the 
Incomplete Claims 
Protocol with the HSE; 
• Liaising with the HSE 
PCRS and pharmacists 
to ensure that the 
Incomplete Claims 
Protocol operates 
correctly;
• Monitoring the claiming 
and payment for New 
Oral Anticoagulants;
• Advocating for 
improvements in the 
New Oral Anticoagulant 
Approval System;
• Advocating for Claims 
Listings to be available in 
PDF and Excel Format;
• Monitoring all 
Community Drugs 
Schemes and all 
pharmacy payments;
• Liaising with the HSE 
and DoH to resolve 
issues around the 
Community Pharmacy 
Contractors’ Agreement 
and Pharmacy Contract;
• Working for resolution 
on ongoing HSE PCRS 
Administration issues;
 and
• Working with individual 
members in resolving 
problems with payments.
 
The Pharmacy Contractors’ Committee, under the Chairmanship 
of Brian Walsh, took office in March 2014. Brian Walsh was elected 
as Chairman and Grainne O’Leary elected Vice-Chairperson. The 
Committee held two meetings in 2014 and has had one meeting to 
date in 2015 and two further meetings are scheduled for this year.
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Policy Matters
Reference Pricing & 
Generic Substitution
In May 14, we issued a 
survey to members seeking 
their feedback on the 
implementation of the 
new reference pricing 
and generic substitution 
regime. The results were 
published in July 14. 
Appeal re FEMPI 
Legislation
The PCC continues to 
liaise with our legal advisers, 
Beauchamps Solicitors, on 
progressing our Supreme 
Court appeal against the 
FEMPI decision. Our legal 
team has prepared and filed 
legal submissions, and will 
continue to seek an early 
hearing date in the Court. 
PCRS Claims Survey
The first PCRS Claims 
survey was launched by 
the PCC in November 
2014 to collate statistics 
on the most problematic 
Community Drugs 
Schemes in terms of claims 
and payment. The response 
rate was very high, with 
one in four pharmacy 
contractors responding to 
the survey.
HSE Contract 
Matters
NEX Programme
Throughout 2014 the 
PCC worked with the 
HSE and the Elton John 
AIDS Foundation (EJAF) 
on the Needle Exchange 
Programme. The pilot 
has now recruited the 
maximum number of 
participating pharmacies. 
The feedback from 
pharmacists and service 
users has been very 
positive. A report assessing 
the success of the NEX 
programme commissioned 
by the EJAF will be 
launched in the coming 
months and drafts seen to 
date reflect the positive 
contribution of pharmacists 
to the programme. The 
Contract Manager is a 
member of the Review 
Steering Group.
The Pharmacy  
Interface Project
The PCC has been 
consulting with delegates 
from the IPU on the 
improvement of the 
current pharmacy interface 
with the PCRS. The 
issues raised were used 
to formulate our agenda 
for the Joint Consultative 
Group Meeting in February 
of this year.
Joint Consultative Group
The PCC has met with 
the HSE as part of the 
Joint Consultative Group 
(JCG) twice since the last 
AGM. The PCC continues 
to advocate for greater 
transparency and fairness 
for pharmacists in their 
dealings with the HSE 
PCRS. The following issues 
were on the JCG Agenda 
since the last AGM:
• Long Term Illness Scheme 
The PCC continues 
to advocate for the 
streamlining of the 
LTI approvals process. 
In July 2014, at the 
request of the IPU, 
the HSE PCRS issued 
Automatically Approved 
List of Medicines for 
the 15 LTI’s. The HSE 
PCRS has also agreed to 
issue a list of medicines 
that will not be approved 
under the scheme, and 
a list of medicines that 
may be approved, but 
only if hospital initiated. 
The PCC is hopeful that 
this has/will bring much 
needed clarity to the LTI 
Scheme.
• New Oral Anticoagulants 
With regard to the 
difficulties with claiming 
and payment for the 
dispensing of New 
Oral Anticoagulants, 
the PCC has tirelessly 
advocated for clarity 
and increased efficiency 
around the NOAC 
approval system. Shortly, 
it will be possible for the 
consultant prescriber to 
issue an approval letter to 
the majority of patients 
contemporaneously 
with their prescription. 
Visibility with regard 
to patient approval 
will also be available 
to pharmacists via the 
dispensary system. 
The PCC is hopeful 
that this will reduce 
the delays for patients 
obtaining approval and 
the difficulties faced by 
pharmacists on foot of 
these delays. 
• The Incomplete  
Claims Protocol 
The PCC negotiated 
the Incomplete Claims 
Protocol with the JCG to 
ensure that pharmacists 
get paid for all medicines 
dispensed in good 
faith to medical card 
patients. This protocol 
will continue in 2015 
and continue to be 
monitored by the IPU 
and HSE at the JCG. 
This continues to be a 
very successful outcome 
to a long running 
problem for members. 
In 2014 a small number 
of pharmacies received 
a letter regarding their 
Incomplete Claims 
percentage. We are 
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continuing to liaise with 
the HSE PCRS on behalf 
of these pharmacies.
• Claims Listings 
The PCC has 
continuously sought 
claims listings in formats 
that facilitate easier 
reconciliation between 
claims lodged and 
payments received. The 
PCRS has now agreed 
that it will shortly be 
providing claims listings 
(archived and current) in 
PDF format.
Adherence to CPC 
Agreement & 
Pharmacy Contract 
The PCC continued to 
monitor the HSE/DoH 
adherence to conditions 
of the Pharmacy Contract 
and the Contracts 
Department followed up on 
and successfully resolved 
a significant number of 
individual members’ queries 
throughout 2014/2015. 
We have successfully 
pursued unpaid methadone 
grants and needle exchange 
retainers, secured payment 
for valid claims under 
the various schemes and 
responded to queries 
relating to the contract, 
handbook, circulars, 
legislation, reimbursable 
medicines and fees.
Conclusion
This is a summary of some 
of the major issues dealt 
with throughout the year. 
However, the Contract 
Manager and Contract 
Administrator intervened 
in many other matters 
on a daily basis including 
individual issues for 
members.
Progress can be slow and 
discussions take time. 
There are often difficult 
issues to resolve but, at all 
times, the PCC continues 
to pursue issues on 
behalf of members until, 
ultimately, a resolution is 
found.
Brian Walsh,
Chairman, PCC
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CPC is split into three  
sub-groups:
• Professional Development 
Steering Group 
Anna Kelly, Elizabeth 
Lang, Sarah Magner, 
Sheila O’Loughlin,  
Mark Sajda
• Business Steering Group 
Roy Hogan, Michael 
Tierney, David Gormley, 
John O’Connell,  
Aidan Walsh 
• IT Steering Group 
Jack Shanahan, Mary 
Barry, Ultan Molloy. 
Sean Reilly (Exec) and 
Michael Walsh (PCC) 
have been co-opted  
onto ITSG.
CPC has met four times 
since the May 2014 AGM 
(May, August, November 
and February), dealing with 
a wide variety of issues. At 
the May meeting, CPC 
produced a new strategy 
for 2014-16. The following 
is a summary of the key 
issues dealt with over the 
last 12 months under the 
headings outlined in the 
strategy. 
Professional Issues
Promote the Role of the 
Pharmacist in Government 
and HSE Strategy 
In July, we made an oral 
presentation to the Joint 
Oireachtas Committee on 
Health and Children on 
the expanding role of the 
pharmacist, outlining how 
pharmacists could better 
contribute to primary 
healthcare services. 
Specific mention was made 
of the Minor Ailment 
Scheme, Medicines Use 
Review Service and New 
Medicines Service. Our 
written presentation 
also mentioned Health 
Checks, Health 
Promotions, Extended 
Vaccinations, Chronic 
Disease Management, 
Anticoagulation Service, 
MDS and DUMP.
In September, for our 
pre-budget-2015 
submission, we proposed 
the establishment of 
a pharmacy-based 
Minor Ailment Scheme 
that would allow GMS 
patients to access non-
prescription medicines 
from their pharmacist and 
we described how such a 
scheme could work on a 
budget-neutral basis. We 
met with Minister Varadkar 
in November to discuss this 
proposal further.
With the reclassification 
of ellaOne to non-
prescription, we wrote to 
the Department and HSE 
in February, asking that 
pharmacists be allowed 
to supply emergency 
hormonal contraception to 
medical card patients on a 
Minor Ailment Scheme.  
The Community Pharmacy Committee (CPC) is chaired by 
Louise Begley with Aidan Walsh as Vice-Chair. CPC’s mission 
statement is CPC – working to serve and support community 
pharmacists in their practices and to promote and expand their 
role as pharmacists by continually developing professional, ethical, 
business and technological ideals and standards.
COMMUNITY  
PHARMACY COMMITTEE 
(CPC) ANNUAL REPORT 
2014-2015
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We made a submission 
to the HSE on their draft 
Clinical Guidelines for 
Opioid Substitution in May 
and made submissions to 
the Department of Health 
on their Statement of 
Strategy in October and on 
Private Health Insurance in 
January.
Work with Relevant 
Stakeholders to further 
improve Accessibility 
of Medicines through 
Switches from POM to 
Pharmacist/Pharmacy 
Only
The HPRA published the 
first list of substances for 
switching in July 2014. It 
had been their intention 
to publish a second list in 
November 2014. However, 
due to the poor response 
by the industry to the first 
list, the HPRA decided 
that, for the next group of 
substances identified, it 
was best to initially directly 
engage with the marketing 
authorisation holders to 
establish their interest 
in reclassification of the 
relevant products and 
consequently progress the 
application submissions. 
This will avoid creating an 
impression publicly that 
these products are to be 
imminently reclassified, 
when the reality is that in 
order for the HPRA to 
be able to achieve this, 
they have to wait for the 
submissions which also have 
to be of an appropriate 
standard. The HPRA has 
begun discussions with a 
number of the marketing 
authorisation holders and 
will consider the best the 
means of communicating 
any product 
reclassifications that may 
arise from this, when they 
have a clearer picture of 
what is achievable.
In early 2014, the IPU 
gave a demonstration of 
IPU NET to the HPRA, 
illustrating how IPU NET 
supports pharmacists in 
both the delivering and 
recording of services 
to patients. The HPRA 
suggested that IPU 
NET would be a valuable 
tool to demonstrate 
the continuing safe and 
appropriate supply of 
domperidone-containing 
medicines in pharmacy. 
Johnson & Johnson kindly 
provided a grant to support 
the development of the 
Domperidone module on 
IPU NET. The IPU NET 
Domperidone module was 
launched in December 
2014.
We held a seminar in 
January 2015 on The Role 
of the Pharmacist in Self-
Care – A Prescription for 
Success.  The purpose 
of the seminar was 
to demonstrate the 
importance of Self-Care 
and how pharmacists 
can play a greater role 
in this area, utilising 
their accessibility and 
professional capabilities to 
benefit the health system 
and the public by helping 
people to make informed 
choices about self-care, 
providing and interpreting 
information and supporting 
safe and appropriate self-
medication. 
Further develop the  
Health Screening Role  
for Pharmacists
We continue to work with 
the Irish Heart Foundation 
to deliver Cardiovascular 
Risk Assessment Training for 
Pharmacists. This excellent 
course, which has been 
attended by over 300 
pharmacists to date, gives 
pharmacists the knowledge 
and skills to facilitate 
setting up a pharmacy 
health screening service. 
Details of future courses 
can be found on the IPU 
website.
There was an extremely 
positive response to the 
Operation Transformation 
Know Your Numbers 
campaign at the beginning 
of the year. 670 
pharmacies signed up to 
the campaign and the IPU 
and pharmacies received 
great media coverage from 
the event. The Operation 
Transformation team 
was extremely pleased 
with the success of the 
campaign, calling it ‘one of 
the most important days in 
Operation Transformation 
history’. An Operation 
Transformation module was 
developed for IPU NET, 
which provided real time 
analysis of data recorded 
by pharmacies and BMI 
measurements indicated 
that of those measured, 
39% were in the overweight 
range and 23% in the obese 
range.
Further to the publication 
by the PSI of Guidance 
on the Provision of Testing 
Services in Pharmacies, 
we updated our health 
screening SOP templates 
and IPU NET module to 
reflect the new guidance.   
Pursue the Implementation 
of Medicine Use Reviews in 
Community Pharmacy 
The IPU and Pfizer ran a 
pilot adherence service 
in selected pharmacies 
from January to August 
2014 to demonstrate 
the value of pharmacists 
in ensuring that patients 
adhere to their medicines. 
The pilot demonstrated the 
potential of pharmacists 
to improve patients’ 
health outcomes through 
ensuring a consistent 
supply of medicines for the 
patient and the early and 
proactive identification 
by pharmacists of any 
potential factors which 
may affect patient 
adherence such as 
tolerability, side-effects, 
or patients’ understanding 
of their medicines. Patient 
adherence was doubled 
over the course of the 
study.
Extend the Pharmacy 
Vaccination Service to 
include other Vaccines  
and High Tech Injectables 
We updated all the SOPs 
and guidance on the 
IPU website to facilitate 
pharmacists delivering a 
pharmacy flu vaccination 
service in 2014/15. In the 
2014/15 season, according 
to IPU NET statistics, 22% 
of people vaccinated in 
pharmacy had never been 
vaccinated before and 94% 
of those were in an at-risk 
group.
We met with Astra Zeneca 
in August 2014 to discuss 
their intra-nasal flu vaccine 
for children and agreed to 
collaborate in lobbying for 
children to be included in 
the vaccination cohorts for 
2015/16.
In our meeting with the 
Minister for Health in 
November, we proposed 
that vaccination be 
extended to cover 
pneumococcal and shingles 
vaccines.    
We met with a number 
of pharma companies to 
discuss developing a high 
tech sub-cut injection 
training service whereby 
pharmacists would train 
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their patients in self-
injecting high tech sub-
cut medicines; this role is 
currently carried out by 
nurses in the community. 
At the August meeting, 
CPC agreed that we 
would work with Hibernian 
Healthcare on the delivery 
of a national sub-cut 
service. The service will be 
rolled out gradually across 
the country; details will be 
provided shortly.    
Develop an Anticoagulation 
Service through 
Community Pharmacy
Dermot Twomey is working 
with the HSE to further 
expand his pharmacy 
anticoagulation service 
to other community 
pharmacies. 
Assist Members in dealing 
with PSI/HSE/HPRA/
DAFM Inspections and 
Fitness to Practise Issues
We assisted a number 
of members in dealing 
with complaints made to 
the PSI or investigations 
instigated following PSI 
inspections and helped 
members prepare for 
FTP hearings and District 
Court appearances. We 
updated the Self-Audit 
Tool to reflect feedback 
from PSI inspections. We 
produced a range of SOP 
templates which members 
can download from the IPU 
website and personalise for 
their pharmacy. 
Further to submissions 
made by the IPU, the PSI 
updated their guidance on 
eligibility for recognition as 
a tutor pharmacist following 
District Court convictions 
or FTP sanctions. In 
general, the convicted/
sanctioned pharmacist 
will not be eligible to be a 
tutor for a period of two 
years; previous guidelines 
had not stated the period 
of ineligibility. We have 
asked the PSI to consider a 
similar exercise in relation 
to the publication of 
convictions or sanctions on 
the PSI website. We met 
with the PSI in March to 
discuss how the Supreme 
Court ruling on the 
Corbally case will affect 
future FTP cases.
We met with the 
Department of Agriculture, 
Food and the Marine 
(DAFM) in June 2014 
to discuss a number of 
issues in relation to DAFM 
veterinary medicines 
inspections. We are liaising 
with PGEU and HPRA 
in relation to the new EU 
veterinary regulations. We 
made a submission to the 
HPRA on Herbal Medicinal 
Products in January.
We made a number of 
submissions to the PSI 
throughout the year on 
Draft Guidance on the 
Delivery of POMs; Draft PSI 
Fees 2014; Draft Guidance 
on Data Protection for 
Pharmacists; Temporary 
Absence; Pharmacy 
Inspection Policy; and 
Extemporaneous Dispensing. 
The submissions can be 
viewed on the IPU website. 
We sent all pharmacies a 
guide to Data Protection in 
March. 
We wrote a number of 
letters to the PSI over 
the year in relation to 
the Sims Clinic, PSI 
Committee Expenses, 
Nursing Home Guidance, 
Extemporaneous 
Preparations, PSI 
Inspection Policy and 
Wholesaler Deliveries. The 
letters can be viewed on 
the IPU website. 
Lobby for Amendments to 
the Pharmacy Act 2007
During our July oral 
presentation to the Joint 
Oireachtas Committee on 
Health and Children, we 
mentioned a number of 
regulatory issues of concern 
to our members, such as 
PSI registration fees, FTP 
and bankruptcy provisions 
in the Pharmacy Act.
We met with the PSI in 
July 2014 and March 2015 
and agreed that we would 
collaborate to ensure the 
necessary amendments to 
the Pharmacy Act were 
made. We also agreed that 
it was vital that there was 
a Chief Pharmacist in the 
Department of Health; 
consequently, we wrote to 
and met with DoH on this 
issue
Liaise with DoH 
and HPRA on the 
Transposition of EU 
Directives into Irish 
Legislation
We met with the 
Department of Health 
to discuss the Medical 
Devices Directive and 
Falsified Medicines 
Directive. We keep 
a watching brief on 
transposition of Directives, 
through liaison with DoH, 
through the Medication 
Safety Forum and through 
meetings with the HPRA.
We made a submission to 
the DoH in February on 
regulations to transpose 
the Falsified Medicines 
Directive (internet 
pharmacy) and have made 
comments to DoH in 
relation to cross-border 
recognition of prescriptions 
legislation.       
Build relationships with 
Pharma, Schools of 
Pharmacy, Irish Institute 
of Pharmacy and Patient 
Groups to assist in the 
provision of CPD
We had meetings with 
Nutricia (May), Eireceutica 
(May), MSD (May), 
Boehringer (June), Leo 
Pharma (June), Pfizer 
(June), IPHA (July), J&J 
(Aug), Astra Zeneca (Aug), 
Merck Serono (Oct), 
Sanofi Pasteur MSD (Jan), 
HRA Pharma (Jan) and 
Pfizer (Mar) to discuss a 
range of issues of mutual 
concern.   
Ultan Molloy represented 
CPC on the UCC Advisory 
Board which developed a 
course on health literacy. 
The course was launched in 
March.  
Liz Hoctor represents the 
IPU on the IIoP Steering 
Group. Anna Kelly  
assisted IIoP in piloting  
the ePortfolio. 
In collaboration with 
MSD, we broadcasted 
a national webinar on 
Fertility in October 
on the IPU Academy 
learning management 
system (LMS). This 
webinar complemented 
the live learning topic, 
Management of Infertility, 
in the IPU Academy 
Autumn Programme. 174 
members participated in 
the live webinar and made 
significant contributions 
via the text box to a lively 
question and answer 
session. Feedback was very 
positive for this event. A 
recorded version of the 
webinar is available on the 
IPU Academy LMS.
We were heavily involved 
in the development of 
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the HSE website www.
undertheweather.ie 
to support antibiotic 
awareness. The feedback 
on the website, which has 
received over 100,000 
hits, has been very positive.
We collaborated with the 
National Adult Literacy 
Agency (NALA) to develop 
a live learning topic Health 
Literacy is the Best Medicine 
which was delivered in four 
locations nationwide as 
part of the IPU Academy 
Autumn 2014 Programme. 
In conjunction with NALA 
and MSD, we launched 
a health literacy audit for 
pharmacies in March. 
Pharmacies who complete 
the online audit will receive 
a Crystal Clear Mark to 
identify their pharmacy 
as being health-literacy-
friendly. 
Continue to Market IPU 
Academy to Members 
The IPU Academy Autumn 
2014 Programme was 
delivered over an eight 
week period, commencing 
in 2014. During that time, 
79 courses were delivered 
by a team of 26 tutors 
in 22 venues nationwide. 
The IPU Academy 
Autumn 2014 Programme 
recorded a total of 3,000 
attendances, with 1,079 
individual pharmacists 
attending events. 
IT Issues
Maintain the IPU Product 
File as the Definitive File 
on the Irish Market for 
Medicines and Medical 
Devices
Matching links to the 
HPRA website to facilitate 
access to SPCs and PILS 
is complete. Test files 
have been provided to the 
system vendors and it is 
hoped to go live with the 
link in April 2015. 
The PCRS now provides 
lists of automatically 
approved medicines for LTI 
patients in a format that can 
be easily distributed with the 
IPU Product File. Work is 
continuing to issue LTI files 
to the system vendors. 
We are liaising with a 
company to investigate an 
alternative source for the 
Drug Interactions File. The 
next development focus 
for the IPU Product File 
team will be live updates 
and security of the IPU 
Product File. 
We met with the vendors in 
January 2015 to discuss all 
upcoming IPU Product File 
developments.  
Work with HIQA on 
the eHealth Standards 
Advisory Group (eSAG) 
to develop eHealth 
Interoperability Standards
The Chair of the IT Steering 
Group, Jack Shanahan, 
continues to represent the 
IPU on HIQA’s eHealth 
Standards Advisory Group. 
The IPU has been invited 
to participate in two other 
HIQA subgroups: 
• The CDA ePrescribing 
specification, a draft 
specification for the 
clinical document 
architecture (CDA) 
to the support the 
electronic transfer of 
prescriptions in Ireland.
• Data model for a national 
electronic medicinal 
product reference 
catalogue, i.e. an 
electronic dictionary of 
medications available 
for prescribing and 
dispensing within a 
jurisdiction.
Work with the DoH/HSE 
on the Implementation of 
their ICT strategy
We met with the DoH 
eHealth/ICT Lead to 
discuss implementation 
of the DoH’s eHealth 
Strategy published in 
December 2013. The 
implementation of this 
strategy will be the 
function of the HSE and 
eHealth Ireland. eHealth 
Ireland will shortly publish 
its Health ICT Strategy 
which is expected to detail 
infrastructure development 
requirements, proposed 
national solutions (including 
electronic prescribing) 
and the implementation 
plan for issuing Individual 
Health Identifiers (IHI) and 
Health Service Provider 
Identifiers (HSPI). We 
have been invited to 
participate in the HSE’s 
ICT Reform Programme 
and attended an industry 
briefing on Enabling 
Healthcare Reform through 
Strategic ICT and eHealth 
in November 2014. We 
met with Healthlink 
to explore a possible 
partnership between 
the two organisations in 
developing a National 
Primary Care ePrescribing 
Solution and met with the 
ICT Programme Manager 
for the HSE CIO’s Office 
about driving the project 
forward.  
 
Investigate the 
Development of a Hub to 
facilitate e-prescribing
We met with the Health 
Innovation Hub (HIH) and 
UCC to discuss the HIH 
Electronic Prescription 
Service (EPS) project 
piloted in the Blackpool 
area of Cork in 2013, as 
well as future EPS projects. 
The HIH is running 
another EPS project and 
the proposal for an EPS 
solution by McLernons 
has been chosen by the 
HIH to trial later this year; 
the proposal is based on 
a “pull” solution using 2D 
barcoding and a central hub 
hosted in a participating 
healthcare centre. The trial 
will take place in Mallow, 
Cork, in an area serviced 
by 20 GPs and 11-12 
pharmacies. We have been 
invited to be part of the 
project team to represent 
community pharmacy and 
we attended an information 
evening in February 2015. 
Work with the Vendors 
on Standardisation of 
Dispensary Systems 
with the aim of getting 
Independent Certification 
to comply with Pharmacy 
Regulations
We have formed a 
Dispensary Software 
Review Group to review the 
standardised Dispensary 
System Specification. 
We held a workshop in 
October 2014 to work 
through the document. 
We met with the system 
vendors in January 2015 
to discuss the specification 
and an action plan will be 
developed.  
Continue to work with 
Wholesalers and Vendors 
to roll out the Pharmacy 
Broadband Ordering 
System, ensuring PIMS 
Compliance and Inclusion 
of Pricing Information
We met with each of the 
stakeholders to discuss 
progress of the project. We 
facilitated a meeting with 
the Pharmacy Broadband 
Ordering System (PBOS) 
Technical Team to discuss 
the progress of the PBOS 
implementation by each 
stakeholder, lessons 
learned in the process 
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and a possible review of 
the Pharmacy Internet 
Messaging Standard 
(PIMS). The meeting put 
focus on completing the 
project and stimulated 
activity from participating 
stakeholders. Each of 
the wholesalers is at an 
advanced stage of rollout 
with active participation 
from the system vendors. 
The IPU continues 
to facilitate technical 
meetings to support the 
project.
Work with PCRS on 
the Pharmacy Interface 
Project, with priority given 
to Integration of IPU NET 
with the PCRS Vaccination 
Recording Website
At the JCG in June 
2014, the HSE tabled an 
updated version of their 
Pharmacy Interface Project 
Proposal document. 
The IPU members of 
the Pharmacy Interface 
Review Group met in 
July for an initial review 
of the proposal. There 
have been a number of 
meetings between the IPU 
and the PCRS to discuss 
items for the Pharmacy 
Interface Project. The 
PCRS has developed a 
working draft towards 
a Pharmacy Interface 
Project Memorandum 
of Agreement (MoA). 
The IPU negotiated the 
project items with the 
PCRS and categorised the 
agreed project items into 
deliverable phases. 
Work with the HPRA 
to develop a Simplified 
Reporting System 
for ADRs, preferably 
automated through 
Dispensary Systems
We met with the HPRA 
in July 2014 to discuss 
a simplified approach 
to ADR reporting from 
pharmacy dispensary 
software systems. A 
functional specification was 
then drafted for review by 
the ITSG.  The specification 
has been provided to 
all system vendors in 
January 2015 – the 
vendors provided technical 
feedback on the functional 
specification, as well as 
resource requirements, 
and the IPU continues to 
work with the HPRA in 
delivering the module.
Continue to foster Good 
Relationships with Vendors 
We met with each of 
the vendors to discuss 
support issues and product 
plans. Helix Health and 
Touchstore are happy to 
have IPU representation 
on their user focus groups; 
McLernons does not 
want IPU representation 
on their focus groups. 
We met with the system 
vendors in January 2015 to 
discuss IPU Product File 
developments and various 
projects. It was agreed to 
meet again in April and 
every quarter thereafter 
to maintain relationships 
between the IPU and the 
vendors. 
Liaise with IPHA/APMI/
DoH on Medicines 
Authentication as part of 
the Falsified Medicines 
Directive
The Falsified Medicines 
Directive lays out 
the principles for an 
EU-wide medicines 
authentication system, 
to prevent counterfeit 
medicines entering the 
supply chain. The IPU is 
heavily involved in the 
European Stakeholder 
Model through our 
membership of PGEU. We 
intend working with Irish 
stakeholders to develop a 
national hub to facilitate 
authentication in Irish 
pharmacies. The system 
must be implemented 
by 2017 but significant 
work will be required 
between now and then. 
We held a symposium on 
medicines authentication 
in November where 
key stakeholders heard 
presentations from 
potential providers of the 
national hub. 
Business Issues
Business Policy 
The Business Department 
works closely with a 
number of different 
organisations and 
national business groups 
addressing business 
issues affecting retail 
pharmacy. We are part of 
the Retail Consultation 
Forum along with other 
business representative 
organisations such as 
Retail Ireland, ISME and 
RGDATA. We attended 
and made representations 
at meetings which were 
held at Government 
buildings. The Forum was 
established by Government 
to provide a platform for 
a structured engagement 
between the retail sector 
and relevant government 
departments and agencies. 
The Forum agreed a 
pre-budget submission 
addressing retail issues, 
which was forwarded to 
Government. 
The quarterly business 
trends survey to monitor 
members’ views and 
experiences from a 
business perspective has 
proven to be a valuable 
source of information on 
the current issues affecting 
the pharmacy sector. 
We issued a number of 
press releases highlighting 
business issues.
We are involved in the 
National Strategic Retail 
Forum with An Garda 
Síochána and other 
retailers. We hope to 
ensure that a Crime 
Prevention and Reduction 
approach is taken to deal 
with the issue of shoplifting. 
We also hope to foster and 
sustain, at a strategic level, 
positive communication 
channels between An 
Garda Síochána and the 
Retail Community. 
We met with the National 
Consumer Agency in 
August and October 
2014 to discuss issues 
arising from their survey 
and possible areas for 
collaboration in the future. 
We are involved in a 
campaign, with a number 
of national business 
organisations to promote 
Senator Fergal Quinn’s Bill 
on repealing Upward Only 
Rent Reviews.
Business Review 
Consultancy
The Business Review 
Consultancy was developed 
by the Business Steering 
Group to assist members 
in getting the most from 
their front of pharmacy. 
Darren Kelly, Business 
Development Manager, 
goes to the member’s 
pharmacy and gives 
one day of his time and 
expertise for a small fee. 
Our Business Review 
Consultancy has been 
extremely busy this year 
with over 25 pharmacies 
reviewed to date. The 
feedback from members 
and their staff has been 
very positive. 
35ANNUAL REPORT OF IPU EXECUTIVE COMMITTEE 2015
CPC ANNUAL REPORT 2014-2015  CONTINUED
Business Training 
We continue to develop 
new training initiatives 
for members and their 
staff to help them in 
their day to day business. 
We launched our third 
Diploma in Leadership 
& Management which 
started in September. 
We held a Crime 
Prevention Workshop in 
October. This workshop 
dealt with legislation 
and how members can 
prevent theft from their 
pharmacy. We ran a Sales 
& Merchandising training 
programme in March. This 
workshop was attended by 
pharmacy staff/owners. 
The workshop gave an 
overview of the basics 
of retail selling and how 
effective merchandising 
can help to maximise sales 
in pharmacies.
Business Briefings
We held 11 Business 
Briefings around the 
country in June and July 
2014. Over 150 members 
and staff attended these 
briefings. Members 
were given an economic 
overview of the sector by 
Economist, Jim Power. 
At the briefings, we also 
launched the new IPU /
ANF initiative, hmR 
Ireland.
Business Seminar 
We were involved with 
the inaugural Pharmacy 
Summit which took place 
in November 2014. 
The Summit was aimed 
specifically at business 
issues affecting pharmacies. 
Over 150 members and 
pharmacy staff attended 
the event.
IPU Review Articles
There have been many 
business articles published 
in the IPU Review; 
articles on areas such as 
merchandising, security, 
planning, customer service, 
tax and business regulations 
have been published to 
help members in their 
businesses.
Review of Pharmacy 
Sector/Business 
Information Development
Fitzgerald Power was 
commissioned to examine 
the community pharmacy 
sector and report on the 
principal factors shaping 
future sustainability. The 
research included a survey 
of community pharmacists, 
in-depth financial case 
studies, interviews with 
pharmacy sector experts 
and a study of national 
and international reports, 
research projects and 
statistics.
Benchmarking
A significant number of 
members have signed up 
to participate with Health 
Market Research (hmR) 
Ireland in an initiative we 
launched in association 
with our partners, the 
Portuguese National 
Pharmacy Association 
(ANF), to introduce a 
state-of-the-art business 
intelligence service, which 
will allow participating 
members to see trends or 
changes in product mix as 
well as transaction values 
across the sector, and 
within their own businesses. 
Roadshows to promote 
the initiative were held in 
eleven venues around the 
country, where there was 
an overwhelmingly positive 
response to the initiative.
Business Presentation  
to UCC
The Business Development 
Manager made a 
presentation to fourth year 
pharmacy students in UCC 
on Business Development 
and how the IPU can help 
pharmacists in the retail 
business world.
Louise Begley,
Chairperson, CPC
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EMPLOYEE
PHARMACISTS’
COMMITTEE (EPC)
REPORT 2014-2015
Currently there are 1,275 community employee members of 
the IPU, which comprises 
59% of the full membership. 
The EPC met four times 
since the 2014 AGM 
(June, September and 
November 2014 and 
January 2015). The 
EPC continues to have 
active representation on 
other IPU Committees, 
with an allocation 
of three employee 
representatives on the 
Executive Committee 
and four representatives 
on the Community 
Pharmacy Committee. 
This representation 
guarantees that the views 
of employee pharmacists 
are voiced and heard on 
the other Committees 
of the IPU, therefore, 
empowering employee 
input into decisions and 
in the development and 
implementation of IPU 
policies. 
Communications
At the September 
2014 EPC meeting, 
the Committee agreed 
to develop a ‘Checklist 
for Locums’. The 
main objective of the 
checklist was to afford 
employee members with 
a comprehensive list of 
what is expected of them 
prior to doing a locum 
and or working in a new or 
unfamiliar pharmacy. 
The EPC continues to 
encourage fourth year 
students and pharmacy 
interns to become involved 
with the IPU. To date, 50 
fourth year students and 
pharmacy interns are in 
receipt of the IPU weekly 
employee E-newsletter. 
Events
At the November 2014 
EPC meeting, the 
Committee agreed to hold 
a Seminar for pharmacy 
interns early in 2015. 
The main objectives of 
the Seminar were to 
inform the attendees 
on the benefits of IPU 
membership, endorse the 
Diploma in Leadership and 
Management that the IPU 
is currently running and 
to provide a platform that 
is informative, topical and 
enjoyable. 
The Employee Pharmacists’ Committee (EPC) represents 
the interests of community pharmacy employee members of 
the IPU. The EPC is chaired by Elizabeth Lang with Sheila 
O’Loughlin as Vice-Chairperson. The mission statement of 
the EPC is: “To promote the professional and economic interests 
of employee pharmacists and constructively engage with other 
Committees of the IPU and other stakeholders through the 
Employee Pharmacists’ Committee.” 
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The one-day Seminar 
was held in the Royal 
College of Surgeons 
(RCSI) on Saturday, 
14 February. The two 
morning sessions entitled 
‘How will you manage?’ 
focused on Leadership 
and Management and 
were delivered by Susan 
Madden, Principal, SE 
College. The presentation 
conveyed that leadership 
and management are core 
skills for a pharmacist in 
today’s world, particularly 
the modern pharmacy and 
business environment. As a 
pharmacist, you won’t just 
be a health professional; 
you will be both a leader 
and manager of a team 
of people within the 
workplace. 
The afternoon sessions, 
delivered Bernard Duggan, 
centred on effective and 
appropriate communication 
within Clinical Issues, 
COPD and Diabetes. 
Attendees were split into 
groups in order to work 
on case studies, which 
increased engagement 
and provided an open 
learning experience. These 
sessions highlighted that 
improved communication 
skills will enhance patient 
support, improve their 
outcomes and promote the 
pharmacist’s professional 
expertise, thus benefiting 
both patient and 
pharmacist.
The day was judged a 
success, with 15 interns in 
attendance and 10 signing-
up to IPU membership, 
which will be progressed 
when they qualify. 
Although the attendance 
was disappointingly 
low, there was a great 
atmosphere with much 
interaction in both the 
morning and afternoon 
sessions. 
Increase and Retain 
IPU Membership 
Throughout the year 
the EPC endeavoured 
to encourage non-
members to sign up to IPU 
membership. In order to 
assist in retaining current 
members, the EPC has 
secured a slot at the IPU 
National Conference 
2015, at 10.00am on 
Sunday 26 April, for a 
CPD session on Leadership 
and Management. This 
CPD session is aimed at 
endorsing the Diploma in 
Leadership & Management 
that the IPU is currently 
running its third cohort and 
to provide an introduction 
to the topic. 
On the Saturday of the 
Conference, the EPC 
will be hosting a lunch to 
enable employee members 
to meet and chat face-
to-face with Committee 
members. 
Representation  
and Services
The EPC will continue 
to pursue its objectives 
with intent and to actively 
represent the interests 
of employee members. It 
will also ensure that the 
IPU continues to provide 
services and support 
to employee members 
within the community 
pharmacy sector. The 
coming years will be trying 
for community pharmacy; 
therefore, it is vital that 
employee pharmacists have 
a representative body which 
supports on their behalf. The 
EPC will continue to be this 
body and it recommends 
the involvement of more 
employees on both a 
regional and national 
platform within the IPU 
in order to strengthen 
the resolve of employee 
pharmacists both in the 
IPU and throughout the 
profession.
In 2010, the EPC initiated 
a structured mediation 
service for the resolution 
of disputes between 
employees and employers. 
We believe the service can 
be beneficial to all parties in 
that it may help to achieve 
an early resolution of a 
dispute at a local level and, 
at the same time, avoid 
unnecessary legal costs, 
save time and maintain a 
good working relationship. 
To date, the EPC continues 
to remind members in the 
weekly E-newsletter and 
General Memoranda that 
this service is still available.
Conclusion
The EPC urges employee 
members to use their 
membership to the full 
and keep themselves 
well-versed by reading the 
IPU weekly E-newsletter, 
General Memoranda, 
IPU Review and other 
information presented by 
the IPU. In June 2010, 
all IPU members were 
assigned an @ipumail.
ie email account and the 
EPC continually reminds 
employee members who 
have not activated their 
account to do so without 
delay. The EPC would 
also recommend that 
employee members check 
the ‘Employee Pharmacists’ 
section of www.ipu.ie on a 
regular basis. 
I would like to thank all the 
members of the EPC for all 
their work over the last year 
and the staff of the IPU, in 
particular Darragh, Roisin, 
Pamela, Catherine and 
Darren for their support 
and advice on all matters. 
I would in particular like to 
thank the Secretary to the 
EPC, Susan McManus, 
for her hard work and 
dedication to the EPC 
and the President, Kathy 
Maher, for her direction 
and assistance throughout 
the year.
Elizabeth Lang,
Chairperson, EPC
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COMMUNICATIONS 
REPORT
Awide range of commun-ications tools including newsletters, 
email, text alerts, social 
media and the IPU 
Review are used to keep 
members up-to-date on 
ongoing and urgent issues. 
Press releases are issued 
regularly, promoting the 
role of the pharmacist and 
highlighting pharmacists’ 
concerns to the media. 
Communications with 
the public is strengthened 
with advertising campaigns 
throughout the year. 
The Communications Team 
all invest a great deal of 
time, effort and resources 
in working with the media 
to brief journalists on 
issues affecting community 
pharmacy.  
Media Relations
There has been a 
substantial amount of 
media coverage since 
the last AGM. Regular 
press releases are issued 
by the IPU, promoting 
the role of pharmacists, 
raising concerns affecting 
community pharmacists 
and advocating on behalf of 
patients. We receive regular 
coverage in the national 
media, including RTÉ 
One’s Morning Edition and 
TV3’s The 5.30, as well as 
current affairs programmes 
such as Drivetime, The 
Last Word, The Right 
Hook and Newstalk’s 
Lunchtime Show. Many 
of these are available to 
watch on the IPU YouTube 
Channel, showing the 
strength of spokespersons 
representing the IPU. 
The national newspapers, 
including the Irish Times, 
Irish Independent, Irish 
Examiner and Herald 
also carry regular articles 
and interviews with IPU 
representatives. We also 
receive significant coverage 
from the medical journals 
and provincial media 
with IPU spokespersons 
regularly appearing on local 
radio and quoted in local 
media.
Some of the key issues that 
arose during the last year 
were:
• The Impact of 
Medicine Shortages on 
Pharmacists and Patients
• Calls for the Expanded 
Role of Pharmacists 
• IPU Crime Survey
• Calls to Unwind the 
FEMPI Act
• Pharmacist’s Advice  
There were many press 
releases issued over 
the past year with 
pharmacists offering 
advice on a range of 
issues. Pharmacists were 
in the media advising on 
men’s health, the “dos 
and don’ts” of giving 
medicine to young 
children, antibiotic 
awareness, advice 
on colds and flu, the 
importance of medicines 
warnings on labels, the 
dangers of mixing alcohol 
and medicines and much 
more.
• Pharmacy Business 
In the last 12 months, 
press releases have been 
issued with a focus on 
the pharmacy business. 
With the support of 
statistics from the 
quarterly pharmacy 
business trends surveys, 
the Annual Review of the 
Sector and the Attitudes 
to Pharmacy Survey 
the IPU can highlight 
key challenges that are 
affecting pharmacies, 
including reducing sales 
and footfall, increasing 
The Communications Team includes Jim Curran, Aoibheann  
Ní Shúilleabháin, Wendy McGlashan and external advisors and 
has an important role in communicating key messages to the 
media, the public, stakeholders and members.
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costs and the impact 
on the sector from 
reference pricing. 
Press releases also for 
called a reduction in 
business costs and the 
introduction of initiatives 
to assist the pharmacy 
retail sector. A major 
end-of-year survey 
highlighted the extent 
and impact of crime in 
pharmacies.
• Advocating for Patients 
The IPU issues press 
releases advocating 
on behalf of patients 
of pharmacies. For 
example, we called 
for more medicines 
to be made available 
without prescription and 
expressed outrage at the 
withdrawal of medical 
cards for certain patients. 
The IPU renewed its 
call to exempt certain 
patient cohorts from 
the prescription levy. 
In January 2015, we 
held a seminar for key 
stakeholders with the 
theme ‘Pharmacists 
role in Self-Care-A 
Prescription for Success’. 
There was considerable 
media interest in the 
event.
A list of all the press 
releases issued is available 
on page //.
We thank IPU 
Spokespersons, who do 
great work throughout the 
year, for taking time out 
from their pharmacies to 
be interviewed and brief 
journalists. 
Advertising  
Campaign – ‘Ask  
Your Pharmacist First’
The IPU continues to 
promote the ‘Ask Your 
Pharmacist First’ message 
with national radio and 
poster ad campaigns 
and in October 2014, 
we introduced television 
advertisements to the 
advertising campaign.
The IPU TV advertising 
campaign ran from 
13 October for four 
weeks. Feedback on the 
ad campaign has been 
extremely positive, with 
hundreds of views on the 
IPU’s YouTube channel 
also. There was media 
coverage in the Irish Times 
and Evening Herald on the 
ad campaign. Two ads were 
developed and ran on RTE, 
TV3, 3E, Channel 4, E4 
and SKY Media package. 
The ads also ran on Video 
on Demand. Highlights 
included during the RTÉ 
One Six-One and Nine 
News, the GAA All Stars, 
Tonight with Vincent Browne, 
and shows such as Xposé, 
Fair City, Eastenders and 
The Graham Norton Show.
A Christmas Radio ad 
campaign ran for one 
week, commencing on 8 
December, on national and 
regional radio stations. The 
ad focused on the retail 
aspect of pharmacies, 
and posters were sent to 
pharmacies to complement 
the radio ad.
Operation 
Transformation
On 10 January 2015, 
pharmacies around the 
country got involved 
with the Operation 
Transformation ‘Know 
Your Numbers’ campaign 
to offer BMI and 
Waist Circumference 
measurements to patients. 
There was an extremely 
positive response to 
the campaign, with 670 
pharmacies signed up 
to offer the services to 
members of the public. 
This was a great 
opportunity to promote the 
role of the pharmacist and 
there was a large amount of 
media coverage from the 
campaign, both in the lead 
up to the campaign and 
after the campaign. Media 
coverage included the 
Operation Transformation 
television programme, 
which highlighted the 
campaign before it 
commenced and the 
coverage from the seven 
key locations, including 
an interview with Kathy 
Maher. There was also 
coverage on RTÉ Radio 
One’s The John Murray 
Show, including an interview 
with Kathy discussing the 
statistics from IPU NET, 
and 2FM’s The Nicky Byrne 
Show. The Irish Examiner 
also covered the IPU NET 
statistics and numerous 
other national and regional 
papers covered pharmacies’ 
involvement in the 
campaign.
IPU members also carried 
out the measurements 
as part of a ‘Know Your 
Numbers’ campaign for 
RTÉ staff at the end of 
January and at the Centra 
conference in Killarney at 
the beginning of February. 
Communications  
to Members
Communications to 
members continue to 
develop and uptake 
continues to increase. 
Usage of the IPU 
website is growing, as 
well as time spent on the 
website. The IPU Review 
and monthly General 
Memorandum are vital 
resources of information 
for members. The open 
rate of IPU News, the 
weekly e-newsletter, is 
also increasing with more 
members accessing their 
IPUMail regularly. Social 
media is another tool 
for communicating with 
both members and the 
public, and the number of 
followers on our Facebook 
and Twitter accounts are 
growing each week. We also 
use SMS to get information 
to members quickly on 
important updates and 
deadlines. 
Political Engagement
A delegation from the 
IPU met with the Minister 
for Health in November 
2014 to outline our 
concerns in relation to 
the administration of the 
LTI Scheme; PSI fees and 
enforcement, Bankruptcy 
and medicine shortages 
among other issues. We 
also called for an expanded 
role for pharmacists and for 
the repeal of the FEMPI 
Act. IPU delegations met 
with the Joint Oireachtas 
Committee on Health 
and Children in July 2014 
to discuss expanding the 
role of pharmacists and in 
March 2015 to discuss the 
price of medicines. 
COMMUNICATIONS REPORT  CONTINUED
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INTERNATIONAL 
REPRESENTATION
1.  PGEU Report 
The Pharmaceutical Group 
of the European Union 
(PGEU) is the European 
association representing 
community pharmacists 
in 34 European countries 
including EU Member 
States, EEA countries and 
EU applicant countries. 
Overall, PGEU represents 
over 400,000 community 
pharmacists in Europe 
through their professional 
bodies and pharmacists’ 
associations. PGEU’s 
objective is to promote 
the role of pharmacists as 
key players in healthcare 
systems throughout 
Europe and to ensure that 
the views of the pharmacy 
profession are taken 
into account in the EU 
decision-making process. 
The IPU is represented 
at PGEU by Darragh 
O’Loughlin, Head of 
Delegation and current 
PGEU President, Rory 
O’Donnell and Pamela 
Logan. We have been very 
active within PGEU over 
the past year, ensuring that 
community pharmacy is 
considered in a wide variety 
of EU Directives. 70% of 
legislation in Ireland comes 
from EU Directives so it is 
vital that lobbying is done 
at this level rather than 
waiting for transposition 
into Irish legislation. 
Over the past year, PGEU 
has been involved in a large 
number of Directives and 
Regulations. The following 
have now been completed 
at EU level and have either 
been transposed or are 
in the process of being 
transposed into national 
legislation:
• Cross Border Healthcare 
and Patient Rights’ 
Directive – Recognition 
of Prescriptions
• Falsified Medicines 
Directive - Internet
• Good Distribution 
Practice Guidelines
The following Directives 
and Regulations are still 
ongoing:
• Falsified Medicines 
Directive – Medicines 
Authentication
• Data Protection 
Regulation
• Medical Devices 
Regulation
• Veterinary Medicines 
Regulation
• European  
Professional Card
• Trans-Atlantic Trade  
and Investment 
Partnership (TTIP)
Falsified Medicines 
Directive – Medicines 
Authentication
The European Commission 
(EC) continues to 
negotiate the Delegated 
Acts with the Member 
State Expert Group. It 
seems likely that adoption 
of the Delegated Acts 
will be delayed, possibly 
until the summer. The EU 
Hub is complete and has 
now been connected to 
the German SecurPharm 
project. The Hub and the 
European Stakeholder 
Model (ESM) approach 
were presented to the EC 
and national experts in 
September.
The European Medicines 
Verification Organisation 
(EMVO) is the stakeholder 
organisation set up to 
manage the European 
Hub and the National 
Blueprint Systems. Initially 
the EMVO will be owned 
by five organisations 
which are part of the 
ESM – EFPIA (pharma), 
GIRP (wholesalers), 
PGEU (community 
pharmacy), EAEPC 
(parallel distributors), 
and EGA (generics). 
Membership is also open 
to representatives of 
the hospital and self-
medication sectors. Full 
membership of the EMVO 
is limited to organisations 
which represent at least 
16 EEA countries and at 
least 25% of the market 
share of the sector they 
represent; however, other 
stakeholders can become 
affiliate members.
The ESM will implement 
an Advanced Blueprint 
Strategy. This is the 
selection of a small group 
of IT suppliers who will 
be given ESM approval, 
together with template 
contracts and technical 
specifications, to assist 
Member States setting up 
their National Medicines 
Verification Organisation 
(NMVO). National 
stakeholders will be free to 
choose among the different 
Blueprint providers. They 
may also pursue a separate 
national system if they 
wish. 
Data Protection Regulation
The Commission is 
proposing a significant 
reform of data protection 
legislation. For the first 
time, data concerning 
health is defined and the 
processing of personal 
data concerning health 
is specifically regulated. 
PGEU produced a position 
paper and suggested two 
amendments that were 
carried by the Plenary. 
PGEU has co-signed a 
letter with CPME (medical 
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practitioners) and CED 
(dentists) seeking to have 
access to the Electronic 
Health Record for all health 
professions, not just GPs 
and specialists. PGEU is 
also seeking a revision of 
the criteria to appoint a 
data controller.
The Council of Ministers 
is currently reviewing 
the proposed Regulation 
with the aim of reaching 
a common position. The 
European Parliament (EP) 
introduced the concept of 
pseudo-anonymised data, 
e.g. linking data subjects 
without identifying the 
patients, inclusion of 
which is currently being 
debated. Most recently 
it has emerged that the 
Council wishes to rewrite 
the legislation, removing 
the section on health data 
and relocating it elsewhere 
in the proposed regulation. 
The Commission is pushing 
for a complete agreement 
between Council and the 
EP before the end of the 
year. 
Medical Devices 
Regulation
The Council of Ministers 
is currently reviewing the 
draft Regulation with the 
aim of reaching a common 
position, which will then 
come back to the EP for 
review. PGEU has met 
with the Commission 
to confirm PGEU’s 
position on traceability of 
medical devices which was 
previously rejected. PGEU 
wishes for the traceability 
system to be compatible 
with the current 
authorisation system for 
medicines.  
Veterinary Medicines 
Regulation
The EC is proposing a 
significant reform of 
European legislation 
on veterinary medicinal 
products, replacing a 
number of Directives 
with one Regulation. The 
proposal includes new 
provisions that will have 
an impact on pharmacy 
practices. 
Retail Supply and  
Record Keeping
All retailers including 
pharmacists will need to 
keep a record of every 
purchase or supply of 
veterinary medicinal 
products, both POM and 
non-POM (currently 
not required for CAM). 
Retailers will also need to 
carry out a detailed audit of 
stock once a year. Vets can 
only supply antimicrobial 
products for animals under 
their care and only for 
the amount required for 
the treatment concerned. 
Only retailers specifically 
authorised to do so by 
national law may supply 
anabolic, anti-infectious, 
anti-parasitic, anti-
inflammatory, hormonal 
or psychotropic veterinary 
medicinal products. It had 
originally been proposed 
to separate prescribing 
and dispensing but this 
is beyond EC power and 
would have resulted in a 
radical change in most 
Member States. 
Internet Supply
It is proposed to allow 
retailers who are authorised 
to supply veterinary 
medicinal products under 
national law to offer such 
services by internet within 
the EU. Unlike the pharma 
legislation, the proposal 
would allow the cross-
border internet selling of 
veterinary prescription 
medicinal products despite 
national restrictions on 
that matter. Such websites 
must display a common 
logo (it is likely that this 
will be a different common 
logo than that required for 
human medicines under 
the Falsified Medicines 
Directive) and other safety 
features. The design of the 
logo will be adopted by 
Implementing Act.
Prescriptions
The proposal establishes 
a standard prescription 
for veterinary medicinal 
products that must be 
recognisable throughout 
the EU/EEA. 
European  
Professional Card
The European Professional 
Card is a feature of the 
Professional Qualifications 
Directive. It is not really a 
card but an e-certificate 
to exchange between 
regulators to assist in the 
process of recognition of 
professional qualifications 
between Member States. 
Pharmacists will be 
included. Implementing 
legislation is expected to be 
published mid-March.  
TTIP
TTIP (Transatlantic 
Trade and Investment 
Partnership) is a trade 
agreement currently being 
negotiated between the 
EU and the USA. As well 
as focusing on custom 
tariffs, TTIP will focus 
on regulation, i.e. how 
differing regulations in the 
EU and US may either be 
harmonised or subject to 
mutual recognition with the 
aim of making trade easier. 
One consequence of 
such harmonisation could 
be that Member States 
which have, for example, 
ownership or establishment 
rules could find that US 
pharmacy chains could 
have free market access. 
However, Member States 
can list certain conditions 
to market access, e.g. 
establishment – this is 
called a Reservation; 
consequently, the US 
would not be able, for 
example, to open a 
pharmacy chain in that 
Member State. Two areas 
of particular concern 
to Ireland are sale of 
pharmaceuticals and 
internet pharmacy. We 
already have significant 
medicines shortages due to 
parallel trade within the EU. 
This would be magnified 
were parallel trade to 
be extended to the US. 
Currently, internet supply 
of POMs is prohibited; 
however, if this is not 
subject to a reservation, US 
internet pharmacies could 
supply into Ireland. 
2. Report on FIP 
Congress, Bangkok
The 74th International 
Pharmaceutical Federation 
(FIP) World Congress 
of Pharmacy and 
Pharmaceutical Sciences 
was held in Bangkok 
from 30 August to 4 
September. The event, 
which was co-hosted 
by the Pharmaceutical 
Association of Thailand, 
welcomed over 1,900 
participants from 95 
countries.  
The conference whose 
theme was “Access to 
medicines and pharmacists 
today, better outcomes 
tomorrow” featured 
sessions, symposia, 
workshops, discussions 
and exhibitions focused on 
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global pharmacy practice 
and pharmaceutical 
sciences.  
First woman President  
for FIP
Spanish pharmacist, 
Carmen Peña, was elected 
as President of FIP. She 
is the first woman and the 
first pharmacist from Spain 
to be elected as President 
in the Federation’s 102-
year history. Dr Peña, a 
community pharmacist 
from Madrid, has served 
FIP for over 20 years 
including as a Vice-
president since 2008. She 
is currently President of the 
General Pharmaceutical 
Council of Spain, which 
represents over 65,000 
pharmacists. 
In her election statement, 
Dr Peña drew particular 
attention to the 
importance of the FIP 
Education Initiative, 
which works to transform 
pharmacy education so 
that societal and workforce 
needs around the world 
can be met. “Building a 
pharmaceutical workforce 
that is competent, 
sustainable, accountable 
and respected by society 
and by our colleagues in 
other health professions 
will make our countries’ 
health systems more 
efficient by lowering 
morbidity, mortality 
and cost,” she said. She 
added that pharmacists 
should be active agents 
in shaping healthcare 
policies, including the 
pharmaceutical policies of 
their respective countries, 
and that FIP can provide 
invaluable guidance and 
resources to this end.
Evolution of Models of 
Care in England and 
Scotland
Claire Anderson, Alex 
MacKinnon and Helen 
Gordon spoke about the 
challenges facing health 
and pharmacy in Great 
Britain and how they have 
been addressed. Scotland 
has produced a strategy 
called “Prescription for 
Excellence” which aims 
to ensure that all patients 
receive high quality 
pharmaceutical care 
from clinical pharmacist 
independent prescribers. 
Health services are 
delivered through 
collaborative partnerships 
with the patient, carer, 
GP, pharmacist and other 
relevant health and social 
care professionals so that 
every patient gets the 
best possible outcomes 
from their medicines, 
avoiding waste and harm. 
In England, the Royal 
Pharmaceutical Society 
has published a report of 
the Commission on future 
models of care delivered 
through pharmacy called 
“Now or Never: Shaping 
Pharmacy for the Future”. 
The report concludes 
that pharmacy can offer 
more as care givers to 
help patients manage 
their medicines more 
effectively. Examples 
of proposed services 
include pharmacist-led 
clinics for long-term 
conditions, medicines 
reviews, monitoring 
and dose adjustment of 
anticoagulants, health 
checks, promoting of self 
care and minor ailments 
service.  
Health Needs of 
Vulnerable Patients
Martin Henman from 
TCD, Dublin, spoke 
about improving access 
to quality healthcare for 
patients with mental health 
conditions and patients 
from vulnerable groups. 
Irrespective of the degree 
of intellectual difficulty, 
People with Intellectual 
Difficulty (PWID) have 
difficulty accessing health 
services, find healthcare 
consultations and facilities 
disconcerting, receive less 
healthcare, receive a lower 
quality of care, have poorer 
outcomes for a number 
of conditions, die 15 years 
earlier than people without 
intellectual difficulties 
and  have three times 
the mortality rate of the 
general population. There 
are some practical steps 
that can be taken. The 
pharmacist can advise and 
counsel patients and carers 
about their medicines, 
conduct simple medication 
reviews, discuss any 
administration concerns 
and anticipate patient 
safety issues. Collaborative 
care of PWID is necessary 
for complex patients and 
in particular in evaluating 
potential adverse 
events. Communication 
and establishing a 
relationship are essential 
to the responsible use of 
medicines. 
Reclassifying Medicines 
from POM to P
Natalie Gauld from New 
Zealand spoke of the 
benefits of reclassifying 
medicines from 
prescription-only to non-
prescription: empowers the 
consumer; saves time and 
money for the consumer; 
reduces barriers to access 
to medicines; saves health 
workforce time and 
health funding; and may 
improve the quality of 
use of medicines. When 
medicines are reclassified, 
it is important that 
consumers are provided 
with written information 
to help them make an 
informed decision about 
using the medicine, to back 
up their interaction with 
the pharmacist and to know 
how to use the medicine, 
to help them to know when 
to seek a doctor’s help. The 
information provided will 
depend on the medicine 
and the condition and 
pharmacists should be 
provided with appropriate 
training where considered 
necessary. New Zealand 
has seen a number of 
progressive reclassifications 
since 2009 – 
chloramphenicol eye, 
famciclovir oral, calcipotriol 
dermal, trimethoprim and 
vaccines for influenza, 
meningococcal, pertussis 
and shingles. It is important 
that we continue to 
look for innovative new 
approaches that support 
the desire of people to take 
responsibility and play a 
more active role in their 
own healthcare.   
Electronic Prescribing  
in Estonia
Kristiina Sepp gave on 
overview of electronic 
prescribing in Estonia. 
Electronic prescriptions 
were introduced in 2010. 
The doctor completes the 
prescription, including 
diagnosis, and forwards it 
to a national database. The 
patient presents at their 
chosen pharmacy with their 
ID card (which can also be 
used when purchasing OTC 
medicines). The pharmacist 
retrieves the prescription 
from the database and 
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records what has been 
dispensed. Since the 
introduction of electronic 
prescribing, it is estimated 
that the number of GP 
errors has decreased by 
78% and pharmacist errors 
by 67%. The system is also 
useful in tracking abuse, 
overuse and adherence 
as both the doctor and 
pharmacist can view the 
patient’s history. In a recent 
survey, 83% of pharmacists 
and 92% of doctors said 
that it made their work 
easier. 
Supply Chain Issues
Sherry Peister from the 
Canadian Pharmacists’ 
Association (CPA) 
discussed concerns about 
the global pharmaceutical 
supply chain. Reasons 
for the breakdown in 
supply include increases in 
global demand; increased 
inspections and sharing of 
reporting among national 
regulatory agencies; parallel 
trade (particularly in the 
EU); national stockpiling 
(e.g. Tamiflu); differences in 
quality assurance standards 
between domestic and 
international markets; 
natural disasters affecting 
manufacture; lack of 
economic incentives/
low prices; concentration 
of active pharmaceutical 
ingredient production; 
just-in-time inventories; 
and lack of global/regional 
information on supply. 
An internal summit on 
Medicines Shortages was 
held in Canada in June, 
organised by FIP and CPA. 
Recommendations made 
to address supply issues 
include the establishment 
of publicly accessible 
means of providing drug 
shortage information that is 
timely, complete, focused 
on current shortages and 
their reasons and provides 
details of duration and 
responses; national and 
international forecasts 
for medicine demands 
should be developed to 
enable manufacturers to 
predict supply quantities; 
there should be greater 
harmonisation of 
regulations and standards 
between international 
and domestic markets; 
contingency planning 
should be contained in 
purchasing contracts; a 
list of medically necessary 
medicines should be 
identified at either 
national or international 
level and coordinated 
by the WHO. Finally, it 
was acknowledged that 
no one wins with drug 
shortages; addressing and 
minimising drug shortages 
is everyone’s responsibility 
and all stakeholders need 
to learn more about each 
other’s roles and challenges 
in order to best position 
strategies. 
The 75th World Congress 
of Pharmacy and 
Pharmaceutical Sciences 
will take place in Düsseldorf 
from 29 September to 3 
October 2015. The theme 
of the conference will be 
“Better practice – Science 
based, evidence driven”. 
Pharmacists are encouraged 
to attend this exciting 
conference to meet and 
share experiences with 
pharmacy colleagues from all 
over the world.    
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The following motions, proposed in accordance 
with Article 30 of the Constitution, are brought 
before the meeting for consideration:
2015 AGM MOTIONS
1. Proposed: Brian Walsh
 Seconded: Mike Walsh
“ That this AGM calls on the Minister for Health to ensure 
that the HSE gives adequate notice of at least four weeks 
to the Irish Pharmacy Union and its members before 
implementing changes to the reimbursement prices of 
items which are dispensed under the State schemes.” 
2. Proposed: Mike Walsh
 Seconded: Brian Walsh
“ That this AGM calls on the Minister for Health to 
apply any plans to unwind the FEMPI legislation for 
public sector workers or any class of health professional 
fairly and equitably to pharmacists, who have been 
disproportionately impacted by the legislation.” 
3. Proposed: Sarah Magner
 Seconded: Caitriona O’Riordan
“ That this AGM calls on the Minister for Health and 
HSE to increase the range of vaccinations available in 
community pharmacy.”
4. Proposed: Louise Begley
 Seconded: Elizabeth Lang
“ That this AGM calls on the HSE to make emergency 
hormonal contraception (EHC) available to women with 
medical cards directly from their community pharmacy.”
5. Proposed: Jack Shanahan
 Seconded: Louise Begley
“ That this AGM calls on the Department of Health to 
amend Part 6 of the Pharmacy Act 2007 in response 
to the Supreme Court judgment on Corbally and for the 
Pharmaceutical Society of Ireland, where appropriate, to 
use the various private, non-accusatorial, non-adversarial 
strategies available to them to ensure high professional 
standards.”
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The following submissions 
were made during the year. 
Most are available on  
www.ipu.ie.
2014
• Draft Clinical Guidelines 
for Opioid Substitution 
Treatment 
HSE – May 2014
• Consultation on White 
Paper on Universal 
Health Insurance  
DoH – May 2014
• Draft Guidance on  
the Delivery of  
POMs from a RPB  
PSI – June 2014
• Presentation to Joint 
Oireachtas Committee 
on Health and Children 
July 2014
• Draft Guidance on 
Data Protection for 
Pharmacists  
PSI – July 2014
• Policy Framework on 
Temporary Absence  
PSI – July 2014
• Pharmacy  
Inspection Policy  
PSI – August 2014
• Minor Ailment Scheme 
DoH – August 2014
• Department of  
Health Statement  
of Strategy  
2015-2017  
October 2014
2015
• Consultation on  
Guide for Retail Sale 
of Herbal Medicinal 
Products  
HPRA – January 2015
• Private Health  
Insurance  
Consultation  
DoH – January 2015
• Draft Guidance 
for Pharmacists on 
Extemporaneous 
Dispensing  
PSI – February 2015
• Transposition of Falsified 
Medicines Directive 
(Common Logo)  
DoH – February 2015
• Presentation to Joint 
Oireachtas Committee 
on Health and Children 
March 2015
• Expanding the Role of 
Community Pharmacists 
for the Benefit of the 
Healthcare System 
Fianna Fáil – March 2015
SUBMISSIONS
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SOME KEY LETTERS AND 
RESPONSES RECEIVED 
THROUGHOUT THE YEAR
APPENDIX II
Topics
• PSI MATTERS
– Prescription Levy
– Sims IVF Clinic, 
Clonskeagh
– Wholesale Deliveries  
to RPBs
– Wholesaler’s Key 
holding for Retail 
Pharmacy Businesses
• DEPARTMENT  
OF HEALTH 
– Generic Medicines
– Chief Pharmacist 
Position
– Medical Devices
– FEMPI
– Minor Ailment Scheme
– General
• PCRS
• HSE
• HEALTH PRODUCTS 
REGULATORY 
AUTHORITY (HPRA)
• HEALTH INSURANCE 
COMPANIES
• OTHER MATTERS
PSI MATTERS
Prescription Levy
Director of Pharmacy 
Services to CEO & 
Registrar, PSI 
[23 April 2014]
Re: Prescription Levy
In recent months, we 
have received a significant 
number of queries from 
pharmacists, asking for 
advice on how they should 
deal with GMS patients 
who refuse to pay the 
prescription levy. Whilst 
pharmacists are mindful 
of their duty of care to 
patients under the Code 
of Conduct, I’m sure you 
will agree that pharmacists 
cannot continue to 
supply medicines to 
patients who do not pay 
the prescription levy as 
the HSE automatically 
deducts the levy from 
pharmacy payments. Some 
pharmacists have been left 
out of pocket to the tune 
of hundreds of euro.
Some pharmacists have 
tried to introduce a scheme 
whereby they dispense 
one week’s supply of 
the medicine, reserving 
the remainder for when 
the patient returns with 
the levy. However, this 
has proved difficult to 
enforce with psychiatric 
patients who typically 
receive weekly supplies 
anyway. Pharmacists have 
also reported particular 
problems in collecting the 
levy from carers of patients 
in HSE day care centres; 
usually the HSE carer 
comes to the pharmacy 
to collect the medicine on 
behalf of the patient and 
explains that they have not 
been given the levy by the 
patient. 
It would be most useful 
if you could let us know 
what advice you give to 
pharmacists who contact 
you in relation to the 
situations outlined above. 
I look forward to hearing 
from you. 
CEO & Registrar,  
PSI to Director of  
Pharmacy Services 
[26 June 2014]
Re: Prescription Levy
I write further to your 
letter of 23 April 2014 in 
which you raised the issue 
of payment by patients 
of the prescription levy 
under section 59(1A) of 
the Health (Amendment) 
(No.2) Act 2010.
At a PSI/Department of 
Health meeting on 23 April 
2014, the PSI raised with 
Department officials the 
appropriate interpretation 
and implementation of 
section 59(1A) regarding 
the charging and collection 
of the prescription levy 
by pharmacists in light 
of recent responses to 
parliamentary questions on 
this issue.
The PSI has since written 
to the Department to 
seek formal clarification of 
the position regarding the 
prescription levy in order 
that PSI can clarify its 
guidance to the pharmacy 
profession on the issue.   
On receipt of a response, 
the PSI will update its 
guidance to the profession.
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Sims IVF Clinic, 
Clonskeagh
Director of Pharmacy 
Services to CEO & 
Registrar, PSI
[14 May 2014]
Re: Sims IVF Clinic, 
Clonskeagh
I am writing to you about 
an issue regarding the Sims 
IVF Clinic in Clonskeagh, 
Dublin, which I believe 
has been brought to your 
attention already. 
A number of pharmacies 
around the country have 
informed us that their 
patients have been told 
by the Sims Clinic that 
they must have their IVF 
medicines dispensed at 
a particular pharmacy 
group which has branches 
in George’s Street and 
Dundrum, Dublin. It is 
implied by the Sims Clinic 
that this is for safety 
reasons as this pharmacy 
group is experienced 
in dealing with these 
products; this implies that 
other pharmacies do not 
have such experience. It 
has also been reported 
to us that the Sims Clinic 
requires patients to sign a 
form consenting to having 
their medicines dispensed 
at one of these pharmacies. 
It would seem that the 
arrangement involves the 
Sims Clinic forwarding 
the patient’s prescription 
directly to the pharmacy 
in question, thus making 
it difficult for any patient 
who would prefer to get 
her prescription dispensed 
at her local community 
pharmacy. On one 
occasion reported to us, 
the patient did insist that 
her prescription was sent 
to her directly so she 
could have it dispensed at 
her local pharmacy. She 
consequently received a 
number of phone calls from 
the Sims Clinic’s preferred 
pharmacy, asking why she 
had not come to them to 
collect her medicines.  
It is a principle of our health 
system that the patient 
must always have a right 
to choose the pharmacy 
in which to have their 
medicines dispensed. Yet 
this right would appear to 
be ignored in this instance. 
Whilst I acknowledge 
that the Pharmaceutical 
Society of Ireland (PSI) 
has no authority over the 
Sims Clinic, I believe it is 
appropriate that the PSI 
should closely scrutinise 
the relationship between 
the Sims Clinic and the 
aforementioned pharmacy 
group.
CEO & Registrar,  
PSI to Director of  
Pharmacy Services
[12 June May 2014]
Re: Sims IVF Clinic, 
Clonskeagh
Thank you for your letter of 
14 May 2014 in regard to 
the above.
The letter refers to reports  
received from pharmacies 
around the country which 
suggest that the SIMs 
Clinic, a fertility clinic 
based in Clonskeagh, is 
directing patients to attend 
a particular pharmacy 
group on the basis that 
these pharmacies are 
experienced in dealing with 
the products prescribed. 
The letter references 
specific information you 
have which suggests the 
manner in which this 
direction is taking place 
may be interfering with 
patient choice.
Sections 63 and 64 of 
the Pharmacy Act 2007 
deal with inappropriate 
and improper relationships 
between pharmacists and 
medical practitioners. 
With respect to your 
particular query, I would 
point out that Section 
64(5) of the Pharmacy 
Act 2007 (The Act) 
provides that a registered 
medical practitioner 
shall not recommend 
any pharmacist or retail 
pharmacy business to a 
member of the public 
otherwise than in the 
exercise of his or her 
professional judgment 
as a registered medical 
practitioner. Section 
67(8) further enacts that 
a contravention of this 
section by a registered 
medical practitioner, for 
the purposes of section 
45 of the Medical 
Practitioners Act 1978 
and so much of Part V 
of that Act as relates to 
that section, constitutes 
professional misconduct 
by the registered medical 
practitioner. It is open to 
any patient  to make a 
complaint to the Medical 
Council about referrals or 
the recommendations of 
a general practitioner and 
the Medical Council can 
determine if such referrals 
are appropriate or not.
Notwithstanding this, 
the Inspection and 
Enforcement Unit of the 
PSI is happy to meet with 
the patient/(s) you identify 
in regard to this matter 
where these patients 
are agreeable to such a 
meeting. 
I hope this clarifies the 
issues raised in your letter.
Wholesale Deliveries 
to RPBs
Secretary General to  
CEO & Registrar, PSI
[22 January 2015]
Re: Wholesale  
Deliveries to RPBs
The most recent PSI 
Newsletter, Issue 9 
2014, published last 
month, identified a 
practice whereby certain 
pharmacies permit 
wholesaler delivery drivers 
access to the pharmacy 
premises, outside normal 
opening hours and without 
a pharmacist being present, 
to facilitate the delivery 
of orders. The newsletter 
went on to say that it was 
the opinion of the PSI that 
it was neither lawful nor 
appropriate for wholesaler 
delivery drivers to be key-
holders for pharmacies and 
to have access to areas of 
pharmacy premises where 
medicines, patient records 
and other confidential 
records are stored. 
On foot of the PSI 
statement, we have 
contacted the two main 
wholesalers, United Drug 
and Uniphar. Both are 
extremely concerned about 
this restrictive position and 
have made it quite clear 
that, if implemented, it 
would be impossible for 
them to maintain a twice 
a day delivery service and 
that, as a result, pharmacies 
in rural areas would be 
restricted to a maximum of 
one delivery per day with 
no guarantee of current 
morning delivery times 
being maintained. Such 
an outcome would clearly 
result in a disimproved 
pharmacy service and 
reduced access to 
medicines for patients 
living in rural areas, leading 
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to deterioration in overall 
public welfare and potential 
risks to patient safety.
Wholesaler delivery drivers 
are thoroughly vetted by 
the wholesalers which 
employ them. They are 
entrusted every day with 
substantial quantities 
of medicines, including 
controlled drugs, which 
are safely delivered 
to pharmacies across 
the country for supply 
to patients. In those 
circumstances, it seems 
excessive to impute an 
additional risk in the 
same drivers potentially 
having brief access to 
similar medicines on the 
pharmacy shelf in the short 
time taken to deposit the 
wholesale totes on the 
pharmacy floor. 
As for patient records, 
these are typically 
stored electronically, on 
a password-protected 
computer, in line with data 
protection best practice. 
The driver, even if he were 
minded to do so, could not 
gain access.
We would be happy to 
meet with you to discuss 
this matter further, with 
a view to identifying a 
solution which addresses 
whatever perceived risk 
the PSI is seeking to 
mitigate while, at the same 
time, does not undermine 
the timely access to 
essential medicines which 
is provided nationwide 
by the current wholesale 
service. In the meantime, 
we ask that you suspend 
the implementation of 
this policy as a matter of 
urgency, in order to ensure 
that patients living in rural 
areas continue to receive 
the pharmacy service that 
they deserve.
Secretary General to  
CEO & Registrar, PSI
[3 February 2015]
Re: Wholesale  
Deliveries to RPBs
Since I wrote to you 
last week regarding PSI 
policy on out-of-hours 
wholesaler deliveries, 
the IPU has heard from 
members who report that 
the PSI is insisting these 
pharmacists confirm that 
they have ceased the 
out-of-hours delivery 
of medicines to their 
pharmacies. In my letter 
I asked that you suspend 
the implementation of 
this policy as a matter of 
urgency, until such time as 
we would meet to consider 
a solution which addresses 
whatever perceived risk the 
PSI is seeking to mitigate 
while, at the same time, 
does not undermine the 
timely access to essential 
medicines which is provided 
nationwide by the current 
wholesale service.
It is our understanding that 
one wholesaler holds keys 
for 165 pharmacies, many 
of which serve relatively 
remote rural communities. 
The pharmacists in 
question are extremely 
anxious that their patients 
should continue to receive 
the standard of pharmacy 
service that they currently 
have, and that their 
access to medicines not 
be diminished particularly 
since it is the position of 
the wholesaler that it would 
simply not be possible to 
maintain the current level 
of service if they can only 
make deliveries during 
pharmacies’ opening hours.
The correspondence which 
these pharmacists have 
received from the PSI 
may relate to inspections 
which had already taken 
place before I wrote to 
you last week. Can you 
please confirm that the 
PSI has now suspended 
implementation of this 
flawed policy until a 
practical solution is found 
which prioritises the 
current needs of patients 
above the undefined risks 
which the PSI believes 
exist.
Wholesaler’s Key 
holding for Retail 
Pharmacy Businesses
CEO & Registrar, PSI  
to Secretary General  
[17 February 2015]
Re: Wholesaler’s Key 
holding for Retail 
Pharmacy Businesses
Thank you for your letters 
dated 22nd January and 
3rd February 2015 in 
relation to the recent PSI 
Newsletter article on Key-
holding for Pharmacies.
As outlined in the article, 
the PSI is aware that 
certain pharmacies have 
permitted wholesaler 
delivery drivers to access 
the pharmacy premises 
before or after opening 
hours, without a pharmacist 
being present, in order to 
facilitate the delivery of 
orders.
Section 26(2) of Pharmacy 
Act 2007 makes it an 
offence for a person 
carrying on a retail 
pharmacy business to sell 
and supply a medicine 
other than under the 
supervision of a registered 
pharmacist. References 
in the Act to the term 
‘sale and supply’ include 
references to the keeping 
of the medicinal product. 
In order to comply with 
this requirement, where 
non-pharmacist members 
of pharmacy staff are key 
holders for a pharmacy, 
they should not access the 
pharmacy in the absence of 
a registered pharmacist.
As you are aware, in 
any pharmacy, the 
superintendent pharmacist, 
acting through the 
supervising pharmacist, 
is responsible for the 
management, control 
and safe keeping of all 
medicines, including 
those on a general sales 
list. The superintendent 
pharmacist, acting through 
the supervising pharmacist, 
is also responsible for the 
safekeeping of patient 
records, confidential 
information and other legal 
records kept in pharmacies.
Having regard to the 
foregoing, the PSI 
considers that it is not 
in accordance with the 
Pharmacy Act and that it 
is not appropriate, from 
patient safety, medicines’ 
security or data protection 
perspectives for persons 
not employed by or 
engaged by the pharmacy 
(such as wholesale delivery 
drivers) to be key holders 
of the pharmacy, and 
to have access to areas 
where medicinal products 
(including controlled drugs 
and prescription only 
medicines) and patient 
records are stored.
Since the current 
inspection system under 
the Pharmacy Act 2007 
commenced, the PSI has 
worked with many individual 
pharmacies on a case 
by case basis to address 
this issue, and it has been 
possible to identify and 
implement practical key 
holding and other solutions 
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having regard to the 
individual circumstances 
of the pharmacy without 
impacting on medicines’ 
supply to pharmacies and 
availability to patients. 
The PSI is cognisant 
of potential challenges 
for some pharmacies in 
relation to this matter 
the legal requirements 
previously outlined cannot 
be disregarded. However, 
the PSI will work with 
these pharmacies over the 
coming months to identify 
appropriate solutions
You may also wish to note 
that at a recent HPRA 
conference on wholesale 
distribution in November 
2014, this matter was also 
raised with all wholesalers 
and HPRA, as the 
regulator of pharmaceutical 
wholesalers, advised that 
key holding of pharmacies 
by wholesalers was 
inappropriate. The PSI has 
engaged with the HPRA in 
relation to this matter and 
will continue to do so.
The PSI is happy to engage 
with individual pharmacies 
and with the IPU to discuss 
this matter further.
DEPARTMENT 
OF HEALTH
Generic Medicines
Secretary General to 
Minister for Health
[6 June 2014]
RE: Generic Medicine 
Price Reductions
I am writing to you to 
express, on behalf of 
our members, deep 
dissatisfaction at a recent 
unilateral action of the 
HSE. This has affected all 
of our members who have 
community pharmacy 
contracts with the HSE.
On 1 May and without 
any prior notification to 
the Irish Pharmacy Union 
and/or our members, the 
HSE imposed a further 
unexpected price reduction 
in the reimbursement 
prices for an extensive 
range of generic medicines 
(being generic medicinal 
products not designated as 
interchangeable by the Irish 
Medicines Board).
As you will be aware the 
Health (Pricing and Supply 
of Medical Goods) Act 
2013 provides that, inter 
alia, the HSE must, at 
least 4 weeks prior to 
any changes in reference 
prices (for a relevant 
group of interchangeable 
medicinal products) enter 
into certain consultations 
and provide notification of 
such proposed change to 
community pharmacists 
(see Section 24 of the 
Act).
While, in this case, the 
generic medicinal products 
in question are obviously 
not interchangeable 
medicinal products, 
the consultation and 
notification provisions of 
Section 24 of the Act 
have, in our opinion and 
having taken initial legal 
advice, set and established 
an obligation on the HSE 
to provide such notification 
for all such proposed 
price reductions. This 
was and is certainly the 
belief and understanding 
of our members and they 
are shocked and most 
concerned that the HSE 
would act in such a way 
in complete disregard for 
such obligations and in 
complete disregard of the 
interests of the community 
pharmacists.  Those 
community pharmacists, in 
already extremely difficult 
trading circumstances, 
have now had a further 
price reduction unilaterally 
imposed by the HSE 
without fair or reasonable 
notice.  Many of our 
community pharmacist 
members will have acquired 
and stocked these generic 
medicinal products and 
agreed purchase prices, 
quantities etc. on the 
assumption that the 
HSE would continue to 
reimburse these medicines 
at the established 
reimbursement price. This 
was an entirely legitimate 
expectation on the part of 
our community pharmacist 
members, particularly in 
light of the notification and 
consultation provisions in 
the 2013 Act. The HSE, 
would, in our view, have 
been fully aware of this 
legitimate expectation and 
the fact that many of our 
community pharmacist 
members would have relied 
on it and acted upon it.  
Given such a situation, 
the HSE, in our view, had 
a duty to our community 
pharmacist members to 
provide adequate notice 
of the proposed change in 
the reimbursement price 
of these generic medicinal 
products, particularly 
having regard to the 
provisions of the 2013 Act.
Indeed the provisions 
of the HSE Agreement 
with the Association 
of Pharmaceutical 
Manufacturers in Ireland 
(the “APMI”) expressly also 
provides for consultation 
with the APMI in relation 
to any such proposed 
reduction and, assuming 
such consultation occurred 
prior to 1 May, the HSE 
would have had ample 
time to provide advance 
warning to our members. 
This is particularly the 
case where there was in 
effect an obligation arising 
from the 2013 Act and 
the expectation created 
that any such proposed 
price decreases would be 
subject to consultation 
and notification at least 
4 weeks prior to their 
implementation. To the 
detriment of our members’ 
interests, the HSE ignored 
such obligations and 
imposed the unilateral price 
reduction.
However rather than 
seeking to assert our 
members legal rights to 
seek to review the decision 
of the HSE and/or to seek 
damages, we would be 
prepared to advise them 
not to do so if a clear 
commitment was given by 
the HSE that notification 
and consultation, as 
provided for in the 2013 
Act, will be provided in 
respect of any future 
proposed price reductions.
Were such a commitment 
to be provided to us, we 
would in turn provide 
it to our members and 
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would seek to ensure they 
are fully apprised of this 
development.
Minister for Health to 
Secretary General
[25 August 2014]
RE: Generic Medicine 
Price Reductions
I refer to your letter of 
6 June concerning a 
HSE decision to reduce 
the price of generic 
medicines with effect from 
1 May 2014. The delay in 
responding is regretted.
You will be aware that the 
HSE is responsible for 
decisions in relation to the 
pricing and reimbursement 
of medicinal products 
under the GMS and other 
community drug schemes 
in accordance with the 
provisions of the Health 
(Pricing and Supply of 
Medical Goods) Act
2013 (the 2013 Act).
Section 21(2) of the 2013 
Act sets out the criteria the 
HSE is obliged to take in to 
account when considering 
the proposed relevant price 
for a medicinal product 
to be added to the List 
of Reimbursable Items, 
including:
(g) the terms of any 
agreement in place 
(whether entered into 
before, on or after the 
commencement of 
this section) between 
the Executive and any 
representative body of 
the suppliers of drugs, 
medicines or medicinal 
or surgical appliances 
where the agreement 
relates, whether directly or 
indirectly, to the price of 
the item.
Section 21(3) provides that 
the Executive may review 
and alter the relevant price 
of a listed item to take into 
account any change in any 
of the matters referred 
to in subsection (2) 
subsequent to the last time 
the relevant price was set 
for those purposes.
Section 22 provides that 
the Executive must, not 
later than 14 days after 
making a relevant decision 
under Section 21, notify 
the relevant suppliers 
in writing of its decision 
and the reasons for the 
decision. In this context, 
the HSE must give the 
relevant suppliers 28 days 
to make representations 
to the HSE with respect 
to the proposal and, after 
considering the relevant 
representations, the 
HSE may implement 
the proposals without 
modification.
It should be noted that 
while Section 24(6) 
provides that when the 
HSE sets a reference 
price for a group of 
interchangeable medicines, 
it shall give a minimum 
of 28 days’ notice in 
writing to community 
pharmacy contractors 
prior to the reference 
price taking effect, no such 
requirement is placed on 
the HSE under Section 21 
of the 2013 Act.
In this context, while I 
acknowledge the points 
raised in your letter 
regarding your members’ 
concerns surrounding the 
manner in which the HSE 
implemented recent price 
cuts for generic medicines, 
I would like to make it clear 
that the HSE has and will 
continue to comply fully 
with the provisions of 
the 2013 Act in terms of 
setting relevant prices for 
items included on the List 
of Reimbursable Items and 
the setting of reference 
prices.
I trust that this clarifies the 
matter for you.
Chief Pharmacist 
Position
Secretary General IPU to 
Secretary General, DoH 
[12 June 2014]
Re: Chief Pharmacist 
Position 
I have been asked by the 
Committees of the Irish 
Pharmacy Union (IPU) to 
write to you and express 
our concern at the recent 
decision of the Department 
of Health not to appoint a 
Chief Pharmacist. 
The IPU believes that 
a well-resourced Chief 
Pharmacist is essential 
within the Department, 
particularly given the 
increasing range and 
complexity of strategies, 
regulations and EU 
Directives requiring 
implementation. In fact, 
during your time as 
Registrar and CEO of the 
Pharmaceutical Society 
of Ireland (PSI), you 
advocated, not only for 
a Chief Pharmacist but 
for the appointment of 
a Chief Pharmaceutical 
Officer, leading a team 
of pharmacists, to deliver 
on the pharmacy part of 
the Government’s reform 
agenda.
The Government’s  
Future Health: A Strategic 
Framework for Reform  
of the Health Service 
2012-2015 sets out the 
main healthcare reforms 
that will be introduced in 
the coming years, as key 
building blocks for the 
introduction of Universal 
Health Insurance in 2016. 
The framework document 
describes a very ambitious 
programme for healthcare 
reform. The IPU welcomes 
the proposals to encourage 
treatment at the lowest 
level of complexity that is 
safe, timely and efficient, 
delivered as close to 
home as possible. The IPU 
has long advocated that 
community pharmacists 
have a key role to play 
in delivering treatment 
locally as a key part of a 
wider healthcare network 
and we will continue to 
engage constructively with 
Government, with other 
healthcare professionals 
and with the public to 
ensure the potential of 
pharmacy is realised as part 
of this strategic framework. 
However, it is unclear 
how the true potential of 
pharmacy can be properly 
achieved without a Chief 
Pharmacist to drive this 
strategy. 
Improving patient safety 
and quality assurance 
in healthcare is a stated 
priority for the Department 
and, to achieve this, the 
key stakeholders must 
be facilitated in coming 
together to share their 
expertise and experiences. 
However, there has only 
been one meeting of the 
Medication Safety Forum 
since the departure of the 
previous Chief Pharmacist. 
In addition, notwithstanding 
the excellent work being 
carried out by an over-
stretched Medicines 
Unit, the lack of a Chief 
Pharmacist has led to 
delays in the long-awaited 
revised Misuse of Drugs 
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Regulations and in the 
transposition of the parts 
of the Cross Border 
Healthcare and Patients’ 
Rights Directive which 
facilitate a system for 
recognition of prescriptions 
from other EU Member 
States. There are also 
a number of other 
important Directives on 
the way which require a 
Chief Pharmacist’s input, 
including, for example, 
the Falsified Medicines 
(Medicines Authentication 
and Use of Common 
Internet Logo) Directive 
and the Medical Devices 
Directive. 
During Ireland’s Presidency 
of the EU, then Chief 
Pharmacist Marita 
Kinsella and her colleagues 
performed excellent work 
and your Department built 
an enviable reputation 
for effectiveness. Only 
through the appointment 
of a Chief Pharmacist can 
this hard-won reputation 
be maintained. 
I urge you now 
to reconsider the 
Department’s position and 
seek to engage a Chief 
Pharmaceutical Officer or 
a Chief Pharmacist, with 
an appropriate salary scale 
and contract, as a matter of 
urgency.  
I would welcome the 
opportunity to meet 
with you to discuss this 
important matter further. 
Medical Devices
Secretary General IPU to 
Secretary General, DoH
[16 May 2014]
Re: Community 
Pharmacists’ position on 
the EP position on first 
reading on the Proposal for 
a Regulation on Medical 
Devices and on in vitro 
Medical Devices
I am writing to you 
on behalf of the Irish 
Pharmacy Union (IPU) in 
relation to the European 
Parliament opinion on 
the Medical Devices and 
on the in-vitro Medical 
Devices proposal. The IPU 
has followed with great 
interest the developments 
in relation to this proposal 
and would like to contribute 
to the debate that will be 
held in Council. 
We strongly endorse the 
EP Position on the Medical 
Devices and in vitro 
Medical Devices and we 
would like you to support 
the following positions, 
which have been adopted in 
the EP opinion:
1. To solve the problem 
of borderline products 
(Article 3 and Recital 8 
of the MD Regulation) 
We request you to support 
a proposal that establishes 
that the Commission 
should be able to decide 
how to classify a product 
when there is a problem 
of classification between 
Member States. 
2. To clarify the obligations 
placed on distributors 
(Article 12 paragraph 2 
and 4 of the MD and in 
vitro MD Regulation) 
We ask you to support the 
amendment proposed to 
exclude pharmacists and 
other distributors from 
the obligation to ensure 
that manufacturers have 
complied with their entire 
traceability obligation. 
Also we ask you to support 
a second amendment to 
ensure corrective action 
undertaken by pharmacists 
is within the scope of their 
activities. While we strongly 
support traceability and 
surveillance, it will not be 
possible in practice for 
pharmacists to ensure 
that manufacturers have 
complied with all their 
traceability obligations. 
3. To solve the problems of 
compatibility between 
the traceability systems 
used in the pharmacy 
(Article 24 paragraph 8 
and recital 34 of the MD 
Regulation and Article 22 
paragraph 8 and recital 
27of the in vitro MD 
Regulation)
We ask you to support 
the proposal establishing 
that, when adopting a 
traceability system, the 
Commission must have 
regard for compatibility 
with other traceability 
systems used by the 
stakeholders involved 
with medical devices, 
such as the system for 
pharmaceuticals. We also 
ask you to support an 
amendment proposing to 
include both human and 
machine readable formats 
in Medical Device labels, 
which will facilitate the 
workability of the system.
4. To enhance the vigilance 
of medical devices 
(Article 61 paragraph 3 
of the MD Regulation 
and Article 59 paragraph 
3 of the in vitro MD 
Regulation)
We would like to see 
reinforcement of the 
pharmacist’s role in 
vigilance and we ask you to 
support the amendments 
proposed with this aim.
5. To avoid unnecessary  
waste of resources 
(Article 13 paragraph 1 of 
the MD Regulation)
We ask you to support 
the proposals granting 
pharmacists derogation 
from the requirement 
of two years’ experience 
to manufacture a 
custom made device. 
Pharmacists undergo 
extensive training in 
pharmaceutical preparation 
and technology, including 
extemporaneous 
preparations, during 
their formal education 
followed by application 
of this knowledge during 
the obligatory internship 
which forms part of formal 
pharmacy education. We 
believe therefore that 
the onerous requirement 
for an additional two 
years’ experience is 
disproportionate to any 
perceived benefit.
However, we have a remark 
regarding a provision 
adopted in the Medical 
Devices report but not 
included in the in vitro 
Medical Devices’ report.
The Commission 
proposal establishes a 
set of obligations on 
distributors to improve 
market surveillance. We 
mostly welcome these 
obligations. However 
we were concerned 
about a distributor’s 
requirement to ensure 
that manufacturers have 
complied with all the 
traceability obligations 
(Article 12 – paragraph 
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2 – subparagraph 1 – point 
c). This will not be possible 
for pharmacists as they 
would not have access to 
the relevant information 
or databases. The report 
of the Medical Devices 
regulation covers our 
concerns and excludes 
distributors from this 
obligation (amendment 
108). However the in 
vitro Medical Devices’ 
report has not changed 
the Commission proposal 
and pharmacists remain 
liable for checking that 
the manufacturer has 
complied with all the 
traceability obligations 
linked to in vitro devices. 
The obligations based 
on distributors in both 
Regulations need to be 
consistent and practicable. 
Therefore we ask you 
to consider adopting 
the above mentioned 
amendment (amendment 
108) of the ENVI Medical 
Devices report in the in 
vitro Medical Devices 
report also. We hope you 
can make this point in any 
future negotiation on the 
in vitro Medical Devices 
proposal.
I thank you in advance 
for considering these 
suggestions. Do not 
hesitate to contact me if 
you would like any further 
information or clarification 
of the points raised in this 
letter. 
FEMPI
From Secretary General to 
Minister for Health
[9 March 2015]
Re: Financial Emergency 
Measures in the Public 
Interest (FEMPI) 
Legislation
The Irish Pharmacy Union 
(IPU) notes that the Irish 
Medical Organisation has 
agreed a Memorandum of 
Understanding (MoU) with 
the HSE and Department 
of Health on a new GP 
Contract. The MoU 
encompasses a negotiation 
process for an orderly 
unwinding of the FEMPI 
legislation in its application 
to GPs since 2009. It is 
understood that these 
negotiations will take place 
in line with the Minister 
for Public Expenditure and 
Reform’s plans to open 
negotiations with public 
sector unions on an orderly 
unwinding of the FEMPI 
legislation.
The IPU has previously 
stated that it is time for the 
FEMPI Act 2009 and the 
regulations made under 
it to be repealed or at the 
very least set aside as there 
is little basis for maintaining 
such emergency measures 
now. The Minister for 
Public Expenditure and 
Reform has acknowledged 
that the legality of FEMPI 
legislation, which we have 
challenged, is predicated on 
there being an emergency 
in the State’s finances. 
The emergency has passed 
and yet the legislation, the 
regulations and the cuts 
under them continue in 
force. The IPU welcomes 
the Department of 
Health’s and the HSE’s 
recognition that a process 
for an unwinding of FEMPI 
legislation is necessary. 
The IPU challenged the 
constitutionality of the 
FEMPI legislation and 
regulations and strenuously 
opposed the cuts imposed 
on foot of FEMPI 
regulations for a number 
of reasons, one being that 
they were disproportionate 
in terms of their impact on 
pharmacists compared to 
other health professionals. 
Community pharmacy 
contractors have 
contributed an enormous 
and disproportionate level 
of savings to the exchequer 
in terms of both direct 
and indirect cuts to their 
payments on foot of the 
measures introduced under 
the FEMPI legislation. 
Pharmacists have been 
unfairly impacted in 
terms of loss of income 
in comparison to other 
professionals contracted 
to provide services to 
the HSE, public sector 
employees and other 
groups in receipt of State 
payments. 
Where it is proposed that 
the FEMPI legislation 
may be unwound in 
its application to a 
specific class of health 
professionals, both the 
negotiation process and 
any actions taken in this 
regard must be applied 
equally to other health 
professionals impacted by 
the legislation. There must 
be parity of application 
and of process and the 
unwinding must of course 
be fair, equitable and 
proportionate to each 
profession in terms of the 
cuts suffered by each.  
To give preferential 
treatment to one class of 
health professionals would 
be unjustifiable. I expect 
that you will not do so. 
I therefore request and 
look forward to a meeting 
with you at the earliest 
opportunity to discuss the 
unwinding of the FEMPI 
legislation in its application 
to our members. 
I look forward to hearing 
from you.
Minor Ailment 
Scheme
Secretary General IPU to 
Minister for Health
[15 August 2014]
Re: Improving Access 
to Healthcare through a 
pharmacy-based Minor 
Ailment Scheme
You recently reaffirmed 
the Government’s laudable 
plan to proceed with the 
implementation of universal 
GP care on a staged basis. 
The Irish Pharmacy Union 
(IPU) wholeheartedly 
supports this policy and 
believes that, as a matter of 
principle, access to medical 
care and to healthcare 
generally should be on the 
basis of need and not ability 
to pay. 
In the attached 
document, we propose 
the establishment of a 
pharmacy-based Minor 
Ailment Scheme that 
would allow GMS patients 
to access non-prescription 
medicines from their 
pharmacist, as private 
patients currently do, and 
we describe how such a 
scheme could work on a 
budget-neutral basis.
One of the greatest 
challenges that will need 
to be overcome with the 
roll-out of GP care is 
the shortage of General 
Practitioners. The Irish 
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Medical Organisation has 
estimated that the policy 
could lead to 750,000 
extra GP consultations 
per year while, at the same 
time, the Irish College of 
General Practitioners is 
warning of a GP manpower 
crisis.
In other countries, where 
access to primary care is 
limited due to a shortage 
of GPs, additional capacity 
has been created by 
expanding the range of 
services available from 
pharmacists. The Royal 
College of General 
Practitioners and the 
College of Emergency 
Medicine in the UK have 
estimated that one in seven 
GP consultations and one 
in 12 A & E attendances 
could have been dealt with 
by a visit to a pharmacy. 
By allowing patients with 
minor ailments to be 
treated in a pharmacy, the 
proposed pharmacy-based 
Minor Ailment Scheme 
will free up GPs’ valuable 
time, allowing them to 
deal with the diagnosis and 
treatment of patients with 
more complex or serious 
conditions. 
We hope this innovative 
proposal, which offers 
quicker and easier access 
to treatment for minor 
ailments and which 
mirrors services already 
operating successfully in 
both Northern Ireland 
and Scotland, meets with 
your approval. We would 
be happy to meet with you 
to discuss the proposal 
further.
Secretary General to 
Minister for Health
[19 November 2014]
Re: Supplementary 
Information on Pharmacy-
based Minor Ailment 
Scheme
Thank you for taking the 
time to meet with us 
on November 3rd. We 
welcomed the opportunity 
to discuss our proposal for 
the introduction of a Minor 
Ailment Scheme for GMS 
patients. At the meeting, 
we undertook to provide 
further information on the 
studies and evaluations of 
similar schemes in other 
jurisdictions, which have 
been published in reputable 
journals.
Minor Ailment Schemes 
have been introduced 
across England over the 
past 10 years. The schemes 
were introduced in all 
community pharmacies 
in Scotland in 2006 
and Northern Ireland in 
2009. In 2012, the Welsh 
Government proposed a 
plan to roll the scheme out 
nationally, and that process 
is currently underway. 
To date, the vast majority 
of the studies have focused 
on local Minor Ailment 
Schemes in the UK, though 
there are similar schemes 
in operation in Canada. 
The most recent of these 
studies is the ‘Community 
Pharmacy Management of 
Minor Illness: MINA Study’, 
which was published in 
January 2014 and was 
led by the University of 
Aberdeen in collaboration 
with the NHS and the 
University of East Anglia. 
Their research spanned 
two years and, as well as 
collating and citing data 
from other sources, the 
researchers interviewed 
patients and medical 
professionals and examined 
data on consultations 
for common ailments 
from selected Accident 
& Emergency (A&E) 
departments, general 
practices and pharmacies 
in East Anglia, England and 
Grampian, Scotland. 
The study found that:
• The rate of re-
consultation to a GP or 
other health professional 
following a consultation 
with a pharmacist 
regarding a minor ailment 
was low, varying between 
2.4% and 23.4%;
• The researchers found 
that over the course of 
the study, approximately 
13.2% of all A&E 
consultations and 13.2% 
of GP consultations for 
common ailments could 
have been managed in 
community pharmacies, 
which are similar 
statistics to those found 
in earlier studies;
• The study found that 
outcomes were equally 
good regardless of 
whether patients were 
treated at a pharmacy, 
A&E or GP practice;
• The cost of treating a 
minor ailment in an A&E 
setting was almost five 
times greater than that of 
treating it in a pharmacy 
setting;
• The cost of treating 
a minor ailment in a 
General Practice setting 
was almost three times 
greater than that of 
treating it in a pharmacy 
setting;
• Of the patients 
interviewed, convenience 
was deemed to be the 
main deciding factor 
in determining where a 
patient would seek care 
for a minor ailment and 
distance was in the top 
three in determining 
where the patient would 
go for treatment.
The study concluded:
‘The cohort study 
confirmed equivalence of 
health-related outcomes 
for pharmacy-managed 
patients presenting with 
symptoms similar to those 
in high cost settings. The 
lower costs associated with 
the management of these 
symptoms in pharmacies, 
compared with the other 
settings, provides further 
evidence of the suitability 
of pharmacies to manage 
these conditions’.
The University of Aberdeen 
led an earlier review of the 
Minor Ailment Scheme, 
which they published in the 
British Journal of Medical 
Practice in 2013. The review 
was entitled ‘Are pharmacy-
based minor ailment schemes 
a substitute for other service 
providers?’. The link to the 
review is here: http://bjgp.
org/content/bjgp/63/612/
e472.full.pdf.
• Studies cited found 
that the percentage of 
patients who found a 
complete resolution of 
their symptoms after 
a consultation with a 
pharmacist ranged from 
68% to 94%;
• Studies cited found that 
if the Minor Ailment 
Scheme had not existed 
the number of patients 
that availed of it that 
would have gone to their 
GP first ranged from 47 
to 92%;
• Studies cited showed 
that > 90% of users 
would reuse the scheme.
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The review concluded that:
‘Low re-consultation and 
high symptom-resolution 
rates suggest that minor 
ailments are being dealt 
with appropriately by 
Pharmacy-based Minor 
Ailment Schemes (PMAS). 
PMAS consultations 
are less expensive than 
consultations with GPs. 
This evidence suggests that 
PMASs provide a suitable 
alternative to general 
practice consultations’.
A literature review carried 
out in 2008 by the 
Pharmaceutical Society of 
Ireland for their ‘Pharmacy 
Ireland Working Group 
2020, Interim Report’ 
provided the following 
statistics for England 
(please see interim report 
here: http://www.thepsi.
ie/Libraries/Publications/
Interim_Report_of_the_
Pharmacy_Ireland_2020_
Working_Group.sflb.ashx.
• 51.4 million GP 
consultations a year were 
solely for minor ailments;
• 18% of GPs’ workloads 
or an hour a day for each 
GP is spent on minor 
ailments;
• The total cost of the 
consultations to the 
NHS was £1.8 billion (or 
€2.5 million) and 80% of 
that cost was attributable 
to the GP’s time.
Similar studies have also 
been carried out in Canada. 
An in-depth evaluation was 
carried out by Research 
Power Incorporated, 
a consultancy firm, on 
behalf of the Pharmacy 
Association of Nova Scotia. 
Their report, ‘Evaluation 
of the Provision of Minor 
Ailment Services in the 
Pharmacy Setting’, was 
published in October 
2013 (available on  https://
pans.ns.ca/wp-content/
uploads/2013/11/2013-10-
17-PANS-report_FINAL.
pdf). 
The findings are similar to 
the UK study in terms of 
the high patient satisfaction 
rates and the efficiencies 
generated.
• Participating pharmacies 
experienced good patient 
uptake of the service;
• Almost all of the 
patients completing the 
satisfaction survey (96%) 
indicated that the service 
was beneficial or very 
beneficial;
• 99% of the patients 
surveyed said that they 
would use the service 
again;
• 89% indicated that their 
concern was satisfactorily 
resolved through the 
assessment;
• Almost all patients 
responding to the 
survey (96%) indicated 
that the minor ailment 
assessment and 
prescribing service 
helped them gain access 
to health care sooner;
• Most patients surveyed 
indicated they would 
have either seen their 
GP (57%) or attended a 
walk-in clinic/A&E (29%) 
if the MAS had not been 
available to them.
The success of the seasonal 
flu vaccination service here 
in Ireland demonstrates 
that when additional 
services are communicated 
and promoted effectively 
to the Irish public, they 
respond well to and avail 
of those services. Over 
32,000 flu vaccinations 
have been delivered in the 
Community Pharmacy 
setting since this season’s 
flu vaccination service 
began. The year-on-
year increases in at-risk 
individuals availing of the 
vaccination demonstrate 
that the word is getting out 
there and that pharmacists 
are trusted by the public to 
deliver health services. In 
relation to Minor Ailment 
Schemes specifically, the 
studies demonstrate that 
pharmacists can offer 
positive patient outcomes, 
patient satisfaction and 
efficiency when it comes 
to treating minor ailments, 
as well as diverting patients 
away from GP services and 
hospital A&E departments. 
If any further information is 
required we are more than 
happy to provide it.
General
Secretary General to 
Minister for Health
[18 July 2014]
I write on behalf of the 
President and Executive 
Committee of the Irish 
Pharmacy Union to 
congratulate you on your 
appointment as Minister 
for Health. You take on 
the role at a challenging 
time as the health service 
in Ireland is undergoing a 
period of profound change, 
faced with twin pressures 
of increasing demand and 
diminishing resources. 
The community pharmacy 
profession plays a valuable 
role in primary care and has 
a significant part to play in 
the delivery of healthcare in 
a reformed health service. 
Pharmacists are the most 
accessible healthcare 
profession, due to their 
presence in every town, 
village and community, and 
are therefore in a perfect 
position to deliver a broader 
range of structured, high 
quality, cost-effective 
healthcare services, 
particularly in the area 
of public health, chronic 
disease management 
and optimising the use 
of medicines – services 
which have been shown 
elsewhere to improve 
health outcomes and 
enhance quality of life and, 
ultimately, result in long 
term savings. 
We look forward to working 
constructively with you 
in the development of 
a reformed system of 
primary healthcare which 
meets the objectives of 
the Government’s Future 
Health strategy and delivers 
for patients and the public.
Secretary General to 
Minister of State for 
Primary and Social Care
[21 July 2014]
I write on behalf of the 
President and Executive 
Committee of the Irish 
Pharmacy Union to 
congratulate you on your 
appointment as Minister 
of State for Primary and 
Social Care. You take on 
the role at a challenging 
time as health services in 
Ireland are undergoing a 
period of profound change, 
faced with twin pressures 
of increasing demand and 
diminishing resources. 
The community pharmacy 
profession plays a valuable 
role in primary care and has 
a significant part to play in 
the delivery of healthcare in 
a reformed health service. 
Pharmacists are the most 
accessible healthcare 
profession in both urban 
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and rural areas and their 
presence in every town, 
village and community 
positions them perfectly 
to deliver a broader 
range of structured, high 
quality and cost-effective 
healthcare services, 
particularly in the area 
of public health, chronic 
disease management 
and optimising the use 
of medicines – services 
which have been shown to 
improve health outcomes 
and enhance quality of life 
and, ultimately, result in 
long term savings. 
We look forward to working 
constructively with you 
in the development of 
a reformed system of 
primary healthcare which 
emphasises equity of 
access, which meets 
the objectives of the 
Government’s Future 
Health strategy and which 
delivers for patients and the 
public.
Secretary General IPU to 
Minister for Health
[8 August 2014]
I wish to refer to your 
opinion column in the Irish 
Independent, published on 
Tuesday, August 5th. 
In your column you 
stated your intention to 
reduce medicine prices 
and mark-ups. However, 
there is no mark-up paid 
to pharmacists under the 
community drugs schemes 
reimbursed by the HSE. 
Pharmacists are paid only 
the ingredient cost, without 
mark-up, plus a regressive 
flat fee. Regulations made 
in July 2009 under the 
Financial Emergency 
Measures in the Public 
Interest Act  reduced the 
reimbursement price of 
medicines from 100% of 
invoice cost to 91.8% and, 
at the same time, reduced 
the mark-up which had 
previously been paid on the 
Long Term Illness Scheme 
and the Drugs Payment 
Scheme from 50% to 
20%. In July 2013, further 
regulations made under the 
same Act eliminated the 
20% mark-up completely, 
leaving pharmacists reliant 
on the dispensing fee alone. 
Since its inception, the 
GMS Scheme has never 
attracted a mark-up.
As regards medicine 
prices, these have fallen 
very dramatically in recent 
years and continue to fall. 
The ESRI, in their report 
entitled Pharmaceutical 
Prices, Prescribing Practices 
and Usage of Generics, 
published in June 2013, 
observed that price 
reductions of the order of 
30% per item reimbursed 
have been achieved 
between 2009 and 2013 
and that the GMS price per 
item in 2013 had declined, 
in nominal terms, to levels 
last seen in 2001/2002. 
Since then, the Health 
(Pricing and Supply of 
Medical Goods) Act 2013 
has introduced a system 
of generic substitution 
and reference pricing 
which has further reduced 
generic medicine prices 
very substantially. The 
HSE Chief Pharmacist, 
Shaun Flanagan, told RTÉ 
News on Friday, 1 August, 
that €50m in savings had 
accrued already this year 
and that Ireland is no longer 
paying more than the EU 
average for medicines.
It is also worth noting that 
it is not only the HSE 
which is benefiting from 
medicine price reductions. 
In very challenging 
economic circumstances, 
pharmacists are passing 
on the reductions to their 
patients and the public, 
who are seeing the effect 
at the pharmacy counter 
as the cost of filling their 
prescriptions has fallen and 
continues to fall. 
Director of Pharmacy 
Services to Medicines, 
Controlled Drugs and 
Pharmacy Legislation  
Unit, DoH
[19 November 2014]
Re: Patient Safety Issue 
with Clozapine 
At the last Medication 
Safety Forum meeting, we 
highlighted a patient safety 
issue regarding clozapine. 
This medicine can only be 
dispensed from specialist 
psychiatric clinics. The 
nurses in such clinics then 
ask community pharmacists 
to blister-pack those 
medicines along with other 
medicines that the patient 
receives directly from the 
pharmacy (i.e. the patient 
personally brings the 
clozapine to the pharmacy 
for the pharmacist to 
include in the blister pack). 
This cohort of patients 
would typically have 
difficulty complying with 
their medication regime. 
Similar issues arise with 
HIV medication. During 
recent inspections, the 
Pharmaceutical Society 
of Ireland (PSI) has asked 
pharmacists to cease this 
practice. 
I would like to suggest 
that we put a small group 
together from the IPU, 
PSI, HSE and DoH to 
discuss how we can best 
address this patient safety 
issue.
Secretary General to 
Medicines, Controlled  
Drugs and Pharmacy 
Legislation Unit
[17 February 2015]
Re: Transposition of Article 
85c of the EU Falsified 
Medicines Directive 
(2011/62/EU)
Thank you for your letter 
of 4 February 2015, 
inviting our feedback on 
the Transposition of Article 
85c of the EU Falsified 
Medicines Directive 
(2011/62/EU) regarding 
the internet supply of non-
prescription medicines.
The Commission agreed 
to adopt Implementing 
Acts in order to harmonise 
the functioning of 
the Common Logo. 
Consequently, the 
Commission Implementing 
Regulation (EU) No 
699/2014 was published 
on 24 June 2014 on the 
design of the common 
logo to identify persons 
offering medicinal products 
for sale at a distance 
to the public and the 
technical, electronic and 
cryptographic requirements 
for verification of its 
authenticity. 
The Irish Pharmacy Union 
(IPU) is of the view 
that the Department’s 
proposed European 
Union (Amendment 
of the Pharmacy Act 
2007) Regulations 2015 
and Medicinal Products 
(Prescription and Control 
of Supply) (Amendment) 
Regulations 2015 meet 
the requirements of the 
Implementing Regulation 
and very clearly set out how 
internet supply of non-
prescription medicines will 
be regulated in Ireland.  
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The proposed Medicinal 
Products (Prescription 
and Control of Supply)
(Amendment) Regulations 
2015 place significant 
additional responsibilities 
on the Pharmaceutical 
Society of Ireland (PSI): 
establish and maintain the 
information society service 
(ISS) supply list for (A) 
pharmacies and (B) non-
pharmacies who wish to 
supply non-prescription 
medicinal products to the 
public via the internet; 
renew registrations every 12 
months; collect registration 
fees; establish and maintain 
a website to facilitate 
hyperlinks from individual 
websites to the ISS supply 
list; ensure that medicinal 
products supplied via the 
internet are sourced from 
an authorised supplier; 
ensure that such medicines 
are stored appropriately; 
ensure that appropriate 
records are kept; ensure 
that the supply of such 
medicines is appropriate 
and reasonable; ensure 
that the purchaser is aware 
how the medicinal product 
should be used; and 
inspect premises supplying 
medicines by internet. 
Whilst we have no 
issue with the PSI 
being responsible for 
the establishment and 
maintenance of the ISS 
supply list, we would like 
it noted that pharmacists’ 
and pharmacies’ current 
registration fees ought not 
to be used to fund these 
additional responsibilities 
being placed on the PSI. 
Irish pharmacists and 
Irish pharmacies already 
pay among the highest 
registration fees in Europe; 
we would therefore 
appreciate confirmation 
that these funds will not 
to be used to defray the 
costs of regulating and 
policing non-pharmacy 
establishments, and even 
pharmacy establishments, 
who are engaged in the 
supply of non-prescription 
medicines by internet.      
We would be happy to 
meet with you to discuss 
the issues outlined above in 
more detail.
Secretary General to 
Minister for Health
[9 April 2015]
Re: Notice to Pharmacists 
re Price Reductions on 
Medical Goods
As we approach the 
second anniversary of 
the passing into law of 
the Health (Pricing and 
Supply of Medical Goods) 
Act 2013, it is opportune 
to consider the impact 
of its operation. The Act, 
which inter alia introduced 
a system of generic 
substitution and reference 
pricing and gave the 
Health Service Executive 
greater control over pricing 
of medicines and other 
reimbursable items, has 
led to considerable savings 
for the State but has, 
equally, led to unintended 
negative consequences for 
pharmacists. In addition 
to the ongoing setting of 
reference prices, which 
process has encompassed 
legal minimum notice 
periods to pharmacists, 
two other rounds of 
price changes have been 
implemented without 
notice to pharmacists since 
the commencement of 
the Act and have resulted 
in pharmacists incurring 
significant unforeseen 
financial losses. 
In February of this year, 
the Irish Pharmacy Union 
was informed that changes 
would be introduced to 
the list of reimbursable 
Ostomy products on the 
1st April 2015. Despite 
repeated efforts to secure 
details of the proposed 
changes, neither the IPU 
nor our members received 
any further information 
from the HSE until the 
afternoon of Friday, 27th 
March, less than two 
and a half working days 
before the changes were 
to be implemented. When 
we requested that the 
date of implementation 
be deferred until May 
to enable pharmacists 
to identify the products 
affected and to manage 
their stocks to minimise 
their losses, this was 
refused.  This followed 
a similar situation on 
1st May 2014 when 
price reductions were 
imposed without notice 
to pharmacists on 
generic medicines which 
had not been deemed 
interchangeable under the 
Act.
While it is legitimate that 
the State would seek to 
ensure maximum value for 
its spend on medicines, 
it is neither fair nor 
reasonable for the HSE 
to impose such losses on 
pharmacists, particularly 
when such a situation could 
be minimised or avoided 
by giving adequate notice. 
Pharmacists may, with 
good reason, decide to 
no longer stock expensive 
items for patients to avoid 
such losses in the future, 
which would result in a 
dis-improvement in service 
levels currently enjoyed by 
Irish patients.
We propose that Section 21 
of the Health (Pricing and 
Supply of Medical Goods) 
Act 2013 be amended 
to provide for reasonable 
notice to be given to 
pharmacists in terms of 
all price reductions on 
medical goods. We fail 
to see the distinction 
between reference prices 
being imposed on foot of 
medicines being deemed 
interchangeable, and price 
changes being imposed 
on other items.  Section 
24 of the Act creates, at 
a minimum, a threshold of 
fairness and reasonableness 
in terms of notification to 
pharmacists in advance 
of price changes being 
introduced. On that basis, a 
notice period equivalent to 
that provided for in Section 
24 should be required to 
effect reductions to prices 
on products that fall under 
Section 21. It is clear that 
the significant impact on 
pharmacists caused by un-
notified price reductions on 
medicinal products was not 
considered when the Act 
was drafted and we ask that 
you rectify this anomaly 
urgently.
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PCRS
Secretary General to Mr P 
Burke, HSE, Primary Care 
Reimbursement Service
[9 April 2015]
Re: Letters to Patients 
from PCRS
At the last JCG meeting, 
the IPU raised the serious 
matter of the wording 
and content of letters 
from the PCRS issuing 
to patients and relating to 
pharmacists. There was an 
implication in those letters 
that the pharmacists had 
been remiss in dispensing 
privately to patients when 
the patients were eligible 
under other schemes, 
notwithstanding that the 
GPs, pharmacists and 
patients concerned were 
unaware of that eligibility. 
A further piece of 
correspondence from 
the PCRS to a patient 
has since been brought 
to our attention. The last 
paragraph states:
‘All pharmacies with HSE 
contracts should not be 
charging any mark-up on 
drugs dispensed under the 
Drugs Payment Scheme 
from the 24th July 2013 
onwards, but unfortunately 
there are some pharmacies 
that are still charging the 
mark up and it is affecting 
the client’s payment if the 
drugs are under the co-
payment amount of €144’.
This is an egregious 
misrepresentation 
of the way the DPS 
scheme operates. The 
clear inference from 
the correspondence to 
the patient is that their 
pharmacist has behaved 
improperly and in breach 
of their contract with the 
HSE. This is not the case. 
Misinforming patients 
in this way is injurious 
to the reputation of the 
pharmacist concerned 
and the business of their 
pharmacy. 
As you know, the prices 
charged for medicines 
dispensed below the DPS 
threshold are entirely a 
matter for the pharmacist. 
You accepted this in a 
meeting with the IPU 
and vendors relating to 
reference pricing in June 
2013. The HSE has no 
role in determining what a 
pharmacist charges private 
patients for medicines 
and a DPS-registered 
patient is a private patient 
for the proportion of their 
medicine costs that comes 
below the threshold. 
The IPU has identified a 
pattern of misinformation 
in correspondence 
emanating from the PCRS 
with regard to the charging 
of patients below the DPS 
threshold. This is damaging 
the reputations and 
businesses of our members. 
This must cease as a matter 
of urgency and there 
must be a commitment 
in this regard from you 
to us at our meeting on 
Monday. Members whose 
reputations and businesses 
have already been affected 
will be advised to take 
legal advice with a view 
to vindicating their good 
names. 
HSE
Secretary General to 
National Director of 
Primary Care, HSE
[8 April 2015]
Re:  Minor Ailment 
Scheme and New 
Medicines Service
I would like to thank you 
for meeting with us on the 
10th March. 
We welcome your 
receptiveness to our 
proposals for the expansion 
of the range of services 
provided by pharmacists, 
and for your willingness to 
explore how the proposals 
could be implemented. In 
particular, we are looking 
forward to working with you 
to explore a framework for 
rolling out a Minor Ailment 
Scheme and piloting a New 
Medicines Service with a 
view to a broader rollout. 
We are confident that 
both schemes would be 
of benefit to the HSE 
in terms of creating 
efficiencies and improving 
patient outcomes in 
line with the plans set 
out in Healthy Ireland. 
The resource of 1,700 
community pharmacies 
can provide much needed 
support to other Primary 
Care providers, particularly 
as access to free GP care is 
expanded.
One of the greatest 
challenges that will need 
to be overcome with the 
expansion of free GP care 
is the shortage of General 
Practitioners. The Irish 
Medical Organisation has 
estimated that the policy 
could lead to 750,000 
extra GP consultations 
per year while, at the same 
time, the Irish College of 
General Practitioners has 
warned of a GP manpower 
crisis. By allowing GMS 
patients with minor 
ailments to be treated in 
a pharmacy, the proposed 
pharmacy-based Minor 
Ailment Scheme will free 
up GPs’ valuable time, 
allowing them to deal with 
the additional workload. 
We would like to meet with 
you or your team at the 
earliest opportunity to begin 
the process of taking these 
proposals to the next level. 
We are available to meet on 
either the 27th or 28th of 
April, should that suit.
Secretary General to 
National Director of 
Primary Care, HSE
[9 April 2015]
Re: Price Reductions on 
Ostomy Products
I am writing to you 
to express our deep 
dissatisfaction at the 
manner in which recent 
price reductions were, 
yet again, implemented 
by HSE PCRS without 
reasonable notification 
to our members. 
Implementing such 
changes without notice 
is, in our view, both 
unprofessional and 
discourteous, and creates 
significant difficulties for 
our members. 
In February of this year, 
the Irish Pharmacy Union 
was informed that changes 
would be introduced to 
the list of reimbursable 
Ostomy products on the 
1st April 2015. Despite 
repeated efforts to secure 
the details of the proposed 
changes, neither the IPU 
nor our members received 
any further information 
from the HSE until the 
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afternoon of Friday, 27th 
March, less than two and 
a half working days before 
the changes were to be 
implemented. When we 
requested that the date of 
implementation be deferred 
until May, this was refused. 
On the 1st May 2014 a 
similar situation arose 
when price reductions 
were imposed on generic 
medicinal products, without 
notice to pharmacists.
There is no evidence 
that the HSE gave any 
consideration to the impact 
on pharmacists who, in 
order to ensure adequate 
stocks for their patients, 
purchased these high 
value items at the higher 
price and will now suffer 
significant financial losses 
as a result.
It is neither fair nor 
reasonable for the HSE 
to impose such losses on 
pharmacists, particularly 
when such a situation could 
have been minimised by 
giving adequate notice, 
to allow pharmacists to 
manage their stocks and 
minimise their losses. 
Otherwise, it risks creating 
a situation whereby 
pharmacists seeking to 
avoid such losses in the 
future may, with good 
reason, decide to no longer 
stock expensive items for 
patients.
In the interests of having a 
positive and constructive 
relationship with the HSE 
we request that where price 
reductions are planned, 
the HSE should extend 
our members the courtesy 
of furnishing the IPU with 
a list of relevant price 
changes at least four weeks 
in advance of such changes 
being implemented.
HPRA
Secretary General to 
Director of Veterinary 
Sciences, HPRA
[24 March 2015]
Re: Regulation on 
Veterinary Medicinal 
Products
I am writing to you 
on behalf of the Irish 
Pharmacy Union (IPU), 
the representative body for 
community pharmacists, in 
connection with the reform 
of European legislation 
on veterinary medicinal 
products, as proposed by 
the European Commission.
We welcome the 
Commission’s proposal 
on veterinary medicinal 
products. In particular, we 
welcome the measures 
aimed at tackling antibiotic 
resistance, given the need 
to ensure rational use 
of antimicrobials in the 
veterinary sector. 
 
We note that the 
Commission has included 
a number of proposals 
with the aim of regulating 
the retail dispensing of 
veterinary medicines. 
Whilst we welcome most 
of the proposals, we have 
some concerns that we 
would like to outline to 
you, given that the HPRA 
is participating in the 
expert group drafting the 
Regulation. 
1. Special licence for 
certain medicines 
(Article 109)
 We believe that 
pharmacies and other 
authorised stakeholders 
should be excluded 
from the requirement 
of a specific licence for 
supplying the medicines 
described in Article 
109. It is important 
to highlight that the 
right of pharmacists to 
dispense medication of 
this nature is recognised 
in all European countries. 
It would be absurd if 
pharmacists were able to 
dispense these kinds of 
medication for humans 
under the normal 
pharmacy licence, but 
need a specific licence 
for veterinary products.
2. Retail of veterinary 
medicinal products  
and record keeping 
(Article 107)
 We strongly support the 
idea of further record 
keeping for certain 
veterinary medicinal 
products and, in 
particular, for antibiotics. 
However, we believe that 
keeping records of non-
prescription veterinary 
medical products may 
be disproportionate and 
may not be justified on 
public health grounds, 
particularly for non-food 
producing animals. In this 
case, Member States 
are better positioned 
to decide the extent to 
which non-prescription 
veterinary medicines 
records ought to be kept.
3. Veterinary prescriptions 
(Article 110)
 The right to refuse 
the recognition 
of veterinarian 
prescriptions, when 
justified, should be 
included in the core 
text of the Directive 
rather than in a recital, 
as this is a key issue of 
public health concern.  
This is consistent with 
the policy adopted in 
European legislation. 
In particular, the same 
solution is adopted 
for the recognition of 
human medicines in 
the Directive on the 
application of Patients’ 
Rights in Cross-border 
Healthcare (Directive 
2011/24/EU).
 In addition, when there 
is not an authorised 
veterinary medicine in a 
Member State to treat 
an animal, in exceptional 
circumstances the 
Regulation allows 
the use of alternative 
medicines. For example, 
human medicines may 
be prescribed. We 
believe that the cross 
border recognition of 
veterinarian prescriptions 
in those cases must 
be prohibited. In a 
cross border context, 
the exceptional 
circumstances cannot 
be assessed and the 
prescriptions can be 
abused.
4.Manufacturing 
authorisation exemption 
(Article 91)
 The proposal will exclude 
all retailers from the 
need for a manufacturing 
authorisation to prepare 
veterinary medicines. The 
current Directive only 
excludes pharmacies. 
It follows a practice 
where pharmacists 
prepare, for individual 
animals or a small group 
of animals, medicines 
on demand following 
veterinarian instructions 
or processes established 
in the pharmacopeia. 
Pharmacies have 
the equipment and 
training needed for 
these purposes and 
this situation should be 
maintained.
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5. Internet supply (Recital 
56 and Article 108)
 Member States are 
free to decide the level 
of health protection 
they want to achieve. 
Therefore they should be 
able to decide whether 
the internet selling of 
prescription veterinary 
medicines is allowed 
in their territory. The 
harmonisation of the 
conditions of the supply 
of veterinary medicines 
must not jeopardise 
Member States’ 
competences on health. 
I attach some detail for 
each of the amendments 
we have proposed above. 
We would be happy to 
meet with you, at your 
convenience, to discuss 
these issues in more detail.  
HEALTH 
INSURANCE 
COMPANIES
Director of Pharmacy 
Services to Aviva Health 
Insurance Ireland Ltd, 
GloHealth, Laya and VHI
[7 January 2015]
Re: Pharmacy Vaccination 
and Health Screening
I am writing to you 
on behalf of the Irish 
Pharmacy Union (IPU), 
the representative body for 
community pharmacists, 
in relation to Aviva Health 
reimbursing its members 
for pharmacy influenza 
vaccinations and health 
screening. 
In 2011, pharmacists 
began participating in 
the Seasonal Influenza 
Vaccination Service. In the 
first season, pharmacists 
vaccinated 9,000 patients, 
in the second season they 
vaccinated 18,000 and 
last season they vaccinated 
over 40,000 patients; we 
do not yet have final figures 
for 2014/15. Information 
was collected from Irish 
pharmacists about the 
people they had vaccinated 
and showed that last 
season, 25% of patients 
vaccinated in pharmacies 
had never been vaccinated 
before and, of those, 85% 
were in an at risk group. 
This shows the true value 
of pharmacists being 
involved in vaccination 
as pharmacists see their 
patients with chronic 
diseases every month. 
Research in the USA 
has proven that when 
pharmacists provide 
vaccines, everybody 
benefits – the pharmacist, 
other healthcare 
providers and, most 
of all, the patients and 
the wider community. 
In fact, because of the 
increased awareness within 
communities, the overall 
number of vaccinations has 
been shown to increase. 
The overarching aim for all 
healthcare professionals 
is to increase the vaccine 
uptake in at-risk groups and 
to reduce the morbidity, 
mortality and burden to the 
health service, particularly 
in primary care, associated 
with seasonal influenza.
I’m sure you will agree 
that it is beneficial, not 
just to the patient but to 
you as a health insurer, 
that vaccination uptake 
increases in Ireland, 
especially in the at-risk 
categories. When more 
people are vaccinated, 
fewer people end up in 
hospital with flu-related 
illnesses. We propose that 
Aviva Health considers 
reimbursing its members 
for pharmacy influenza 
vaccinations in order 
to promote increased 
vaccination rates and 
reduce associated illnesses.
Another service being 
offered in community 
pharmacy is health 
screening or health 
checks. This involves the 
pharmacist conducting 
a series of checks on the 
patient, e.g. blood pressure, 
blood glucose, cholesterol, 
BMI, and recommending 
either lifestyle advice or 
referral to the patient’s 
GP. It is important to note 
that the pharmacist does 
not diagnose a particular 
chronic disease; rather 
they identify patients who 
are at risk and provide 
the appropriate advice 
or referral. The aim is to 
reduce the number of 
people developing chronic 
disease in the first place, 
thus reducing costs in 
secondary care, costs 
that are often met by 
health insurers. Over 600 
pharmacies have registered 
to partner with RTE’s 
Operation Transformation 
and to measure patients’ 
BMIs this coming weekend. 
I’m sure Aviva Health 
welcomes such an initiative 
and we propose that 
patients who receive a 
health check or screening 
in their local community 
pharmacy be able to claim 
back the cost of the check 
from Aviva Health.
We are of course happy 
to meet with you, at your 
convenience, to discuss 
these issues in more detail.  
Product & Business 
Development Manager,  
Vhi to Director of  
Pharmacy Services
[26 January 2015]
Thank you for your recent 
letter which John O’Dwyer 
passed on to the business 
and product development 
team regarding pharmacy 
vaccination and health 
screening services.
Firstly, Vhi welcomes any 
initiatives which promote 
and encourage people 
to avail of preventative 
care services such as 
vaccinations, screenings 
and health checks. Vhi 
Healthcare is an active 
participator in various 
preventative healthcare 
initiatives such as our Blue 
September campaigns, our 
free diabetes and colon 
cancer screening and our 
promotion of DEXLIFE 
lifestyle intervention.
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However, for Vhi 
Healthcare, as a health 
insurance company, 
our primary function 
is to provide cover for 
unforeseen illness or injury 
requiring hospital care.
In considering new health 
insurance products or 
new benefits/services 
such as vaccines and 
screening, we must take 
this factor into account, 
especially in the current 
cost conscious market 
whereby many of our 
members face affordability 
issues. Secondly, member 
demand and access to 
both new and current 
benefit/services is also 
taken into consideration. 
To date there has not been 
sufficient demand from 
our membership in order 
to justify extending cover 
for additional vaccination/
screening services over 
and above what is currently 
covered by Vhi Healthcare 
benefits.
We of course continuously 
review the range of services 
we offer our members and 
as such we are more than 
happy to meet with you to 
discuss services which your 
members currently offer 
or are seeking to develop 
in the future. Where 
enhancements are being 
made in the future we will 
consider your request.
Thank you for bringing your 
services to our attention 
and we look forward to 
hearing from you.
OTHER 
MATTERS
Director of Pharmacy 
Services to 
Minister for Health / Head, 
HSE Crisis Pregnancy 
Programme / National 
Director for Health and 
Wellbeing, HSE / Chief 
Executive, Family Planning 
Association
[6 February 2015]
Re: Access to Emergency 
Contraception for Medical 
Card Patients
I am writing to draw your 
attention to an issue which 
could potentially become 
a real concern within the 
next few months, namely 
access to emergency oral 
contraceptives for Medical 
Card Patients. 
Only a few years ago, there 
were three reimbursable 
emergency contraceptives 
available to patients 
under the GMS Scheme: 
Levonelle®, Norlevo® 
and ellaOne®. Norlevo 
was reclassified in 2011 
from prescription only to 
pharmacy sales not subject 
to medical prescription. HRA 
Pharma, the manufacturer 
of this product, asked 
for the GMS code to be 
removed, meaning that 
it could no longer be 
prescribed under the GMS 
scheme. Fortunately, at 
that time, both Levonelle 
and ellaOne were available 
to be prescribed under the 
scheme. 
Consilient Health, the 
new owners of Levonelle, 
recently announced 
that Levonelle will 
henceforth be available 
under the brand name 
Prevenelle®. Prevenelle 
has been reclassified 
from prescription only to 
pharmacy sales not subject 
to medical prescription from 
1st March 2015. It is not 
clear, at the time of writing, 
whether Prevenelle’s 
reimbursable status 
under the GMS Scheme 
will remain following its 
rebranding. 
On 8th January 2015, the 
European Commission 
made the decision to grant 
HRA Pharma’s application 
to change the classification 
status of ellaOne (ulipristal 
acetate) from prescription 
only to sales not subject to 
medical prescription. This 
decision will result in the 
medicine being available 
without prescription 
throughout the EU. HRA 
Pharma has now changed 
the SmPC for ellaOne 
and is in the process of 
producing new packaging. 
They expect non-
prescription presentations 
of ellaOne to be shipped 
to Irish wholesalers in late 
March and distributed to 
pharmacies in April, in time 
for the UK and Ireland 
launch on 20th April 
2015. On that basis, once 
wholesalers and pharmacies 
have used up the current 
stock of the prescription 
only presentation, the only 
version of this medicine 
that will be available to 
patients will be the non-
prescription pack. This 
product, ellaOne, is the 
only product of its kind 
on the market, i.e. 120-
hour emergency oral 
contraception, and at the 
time of writing it is not clear 
whether or not it will remain 
on the reimbursable list.  
We are concerned 
that, in less than two 
months, it could be the 
case that no emergency 
oral contraceptives will 
be available for GPs to 
prescribe under the GMS 
Scheme. This is of huge 
concern to the IPU, 
given the potentially far-
reaching and life-changing 
consequences that an 
unwanted or unplanned 
pregnancy could have for 
affected women.  
We would welcome the 
opportunity, at your 
earliest convenience 
given the urgency of 
the matter, to discuss 
a possible mechanism 
by which pharmacists 
could dispense non-
prescription presentations 
of emergency oral 
contraceptives directly 
to GMS patients under 
the GMS scheme. The 
effectiveness of emergency 
contraception diminishes 
between the time of 
unprotected sex and 
the time of taking them, 
emphasising the value 
of the convenience and 
accessibility of community 
pharmacies. Pharmacists 
have been permitted to 
supply Norlevo to patients 
without prescription 
since 2011 and have thus 
established the safety of 
the service. 
We have written to the 
Minister for Health 
and the HSE National 
Director for Primary 
Care, to outline the 
importance and urgency 
of the matter. We believe 
that the Department of 
Health and HSE should 
work with the IPU to put 
in place a mechanism to 
enable immediate access to 
emergency contraception 
without prescription for 
all patients under their 
existing GMS eligibility. 
We are of course happy to 
meet with you to discuss 
this issue in more detail. 
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PRESS RELEASES ISSUED 
TO THE NATIONAL MEDIA 
DURING THE YEAR ON 
VARIOUS MATTERS
APPENDIX III
2014
21 May  
Irish Pharmacy Flu 
Vaccination Services 
highlighted at Global Level
26 May 
Exam Time – Pharmacists’ 
Advice to Students
28 May 
Competition Authority 
/ IMO Case – IPU 
welcomes Competition 
Authority’s acceptance of 
the rights of representative 
bodies to discuss and 
consult on fees, resources 
and other issues
30 May 
Pharmacists warn that 
mixing Alcohol with 
Medicines can cause 
serious health problems
09 June 
Men encouraged to reduce 
health risks by talking to 
their Pharmacist
16 June 
Pharmacists warn parents 
of health risks when giving 
medicines to children
17 June 
Irish Pharmacist elected 
President of the 
Pharmaceutical Group 
of the European Union – 
representing 400,000 
community pharmacists
18 June 
Pharmacists issue Safety 
Guidelines to Stay Safe in 
the Sun
01 July 
IPU Submission to Joint 
Oireachtas Committee 
on Health and Children: 
Expanding the role of 
pharmacists would free up 
GPs in the roll-out of free 
GP Care – Pharmacists 
call for a joined-up 
approach to the delivery of 
healthcare
06 July 
Health Minister’s To-Do 
List
17 July 
IPU welcomes move 
to increase availability 
of medicines through 
pharmacies without 
prescription: 34 extra 
medicines available to 
patients through their 
pharmacy without 
prescription
24 July 
Pharmacists call for an 
expanded role to reduce 
pressures on GPs as Free 
GP Care rolls out
25 July 
Patients putting themselves 
at risk by ignoring Medicine 
warnings
31 July 
Pharmacists call for action 
on Heart Disease – 
Ireland’s No. 1 Killer
21 August 
Back To School – 
Pharmacists’ Advice on 
Treating Head Lice 
28 August 
Electric Picnic Music 
Festival: Pharmacists issue 
tips to stay healthy at 
Electric Picnic
09 September 
Pharmacists call for urgent 
appointment of a Chief 
Pharmacy Officer – Call 
follows appointment today 
of 3 Deputy Chief Nurses 
in Department.
19 September 
Pre-Budget Submission 
– Irish Pharmacy Union 
– Pharmacists call on the 
Government to introduce 
Pharmacy-Based Minor 
Ailment Scheme (Scheme 
to reduce pressures on 
GP services would be cost 
neutral to the State)
23 September 
World Pharmacists Day 
– 25 September 2014 
– Pharmacists express 
frustration at the lack of 
political will to expand their 
role - “Let us do more like 
our colleagues in Scotland 
or Canada”
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26 September 
World Heart Day – Sunday 
28th September
21 October 
Pharmacists highlight 
medicine shortages putting 
patients at risk – Medicine 
shortages driven by falling 
medicine prices.
03 November 
Pharmacists Meet with 
Minister for Health – New 
figures from IPU confirm 
over 32,000 people received 
flu vaccine from community 
pharmacies already this 
autumn. / Pharmacists 
call on Minister to extend 
vaccination service to include 
other serious infections 
including Shingles and 
Pneumococcal Pneumonia. 
/ Minister informed that 
pharmacists have the ability 
to support our overburdened 
health service.
20 November 
Pharmacists promote 
Self-Care in the use of 
Antibiotics - Pharmacists 
warn antibiotics should only 
be used when prescribed 
and when absolutely 
necessary / Overuse and 
misuse of antibiotics put 
patients’ health at risk
12 December 
Pharmacists issue health 
tips to avoid Colds and Flu 
– Warn that Antibiotics are 
not effective against colds 
and flu.
19 December 
Stay Safe this Christmas 
and New Year - 
Pharmacists Warn of 
the Dangers of Mixing 
Alcohol with Medicines – 
Ask your pharmacist first 
before mixing Alcohol with 
Medicines – Medicines can 
contain alcohol, putting you 
at risk of driving over the 
limit
23 December 
Ask Your Pharmacist 
for advice to assist with 
New Year’s Resolutions 
– Pharmacists encourage 
and support people to Lose 
Weight and Quit Smoking – 
Half of all smokers die from 
smoking-related diseases
2015
06 January 
Get Ireland Walking
08 January 
Know Your Numbers: 
Pharmacists team up with 
Operation Transformation 
28 January 
Seminar hears that 
pharmacists hold key to 
relieving pressures in GP 
surgeries
05 February 
IPU Crime Survey 
Confirms that Pharmacies 
Under Siege from 
Robberies and Raids
25 March  
Pharmacists warn parents 
of health risks when giving 
medicines to children
08 April 
Pharmacists warn parents 
not to give codeine-
containing medicines to 
children to treat coughs 
and colds 
15 April 
IPU Helps to Highlight that 
#littlethings can make a Big 
Difference to How We Feel
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